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FOREWORD 
 
  
 
 
 
 
 
 
 
 
Mr Francis Gurry                    Mr Roberto Azevêdo 
 
This volume is the sixth in a series of annual publications from the World Intellectual Property Organization (WIPO) 
and the World Trade Organization (WTO). Prepared by the WIPO-WTO Colloquium for Teachers of Intellectual 
Property, this collection of academic papers represents an important contribution to international scholarship in the 
field of intellectual property (IP). Today we witness ever increasing, more diverse forms of international interaction 
on IP, yet equally we see growing attention to differing national policy needs and social and developmental 
priorities in this field. The Colloquium Papers series highlights the importance of fostering scholarship in emerging IP 
jurisdictions, harvesting the insights from policy and academic debates from across the globe, and promoting 
mutual learning through the sharing of research and scholarship on a broader geographical base. 
For over a decade, the annual WIPO-WTO Colloquium itself has played a central role in the joint capacity building 
programmes of WIPO and the WTO. This cooperation seeks to enrich dialogue on IP issues and to address the 
developmental and wider policy considerations that form an integral part of IP law and policy today. The 
Colloquium responds to the recognition that developmental benefits from the IP system can only be reaped through 
skilled adaptation to national circumstances and judicious use by informed practitioners. Equally, effective policy 
development at the national level needs increasingly to draw upon skilled, informed and sophisticated policy 
analysis. The Colloquium bolsters the capacity of those best placed to ensure truly sustainable, long-term benefits 
from the adept use of the IP system – those who teach the IP practitioners of the future, and those who conduct 
research on IP law and policy. 
The programme has produced more than 300 alumni. This is a diverse and active network of highly engaged 
teachers and researchers, which reaches across the developing world.  Whilst this network is the principal focus of 
the programme, it also includes a number of developed countries. It is heartening to see the contributions of these 
scholars in many avenues – through their academic publications, through their active participation in national and 
international policy debates, through their own teaching and through their contribution to capacity building in the 
developing world.  
We see the Colloquium Papers – an edited, peer-reviewed academic journal – as epitomizing the trend towards 
more diverse and yet more rigorous capacity building in IP law and policy. The six publications issued since 2010 
draw together the participants' original insights into current IP issues in their countries, and give greater substance 
to the network of mutual learning and intellectual exchanges that characterize the Colloquium programme.  
The latest publication, a selection of papers from the 2015 Colloquium, covers an impressive range of IP subject 
matter, including patents, copyright and trademarks. The papers discuss policy issues, including IP protection of 
traditional knowledge and biodiversity, and IP and public health, all of which are vital to the development of IP 
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systems in developing countries. This publication series may now be presented as a significant academic journal 
with unique coverage of IP law and policy focussed on emerging IP jurisdictions.   
In today's changing global economy, IP significantly influences the everyday lives of all citizens around the world.  
An international IP system that can adjust to the shifting global economic landscape, while also stimulating 
innovation and furthering development, demands the understanding, participation and cooperation of all peoples 
across the societal spectrum. Initiatives such as the Colloquium play an important role in building capacity, raising 
awareness, and engaging all societies that are affected by the evolution of the international IP system. 
We congratulate the contributing scholars for their first rate research, and we thank the Editorial Board – a highly 
distinguished group of senior IP scholars – for their invaluable support and engagement, which has helped establish 
the Colloquium Papers as a credible academic publication. We should also record our appreciation for the work of 
our colleagues in the WIPO Academy and the WTO IP Division in organizing the Colloquium and facilitating the 
publication.  Finally, we commend the Colloquium Papers as an important source for academic research to what we 
trust will be a wide and ever more diverse readership. 
 
 
 
Francis Gurry 
Director General 
World Intellectual Property Organization 
Roberto Azevêdo 
Director-General 
World Trade Organization 
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PREFACE 
 
This volume is the sixth in the series of academic papers resulting from the WIPO-WTO Colloquium:  it serves as a 
tangible reminder of the vitality and richness of collaboration between the two organizations as they mark 20 years 
of cooperation following the conclusion of a bilateral agreement in 1995, shortly after the WTO was established.  
The content of this journal, representing emerging scholarship from across the developing world, encapsulates 
much that is challenging, significant and fascinating in the field of intellectual property (IP) today, and underscores 
why this bilateral cooperation is as valuable as ever.   
Always with a strong international dimension, the IP system is undergoing an unprecedented phase of globalization 
and a building of international institutions, bringing with it a deepened understanding of the centrality of a balanced 
and effective IP system in economic and social development. Yet this same period has precipitated an intensive, 
wide-ranging process of inquiry about how to adapt and apply IP principles to ensure economic growth, sound 
public policy, and sustainable development in diverse settings across the globe, recognizing the diversity of 
economic, social and technological settings, national developmental priorities, and legal and commercial systems. 
Intellectual property is seemingly ubiquitous in contemporary life, but its role and impact are both highly diverse 
and in need of careful analysis and informed debate. An IP dimension is present in many challenging public policy 
issues today. For instance, we see growing attention to its role in promoting public health, addressing climate 
change, and achieving food security, as well as its interaction with human rights and social and economic 
development. Intellectual property has been the subject of complex, multifaceted debates at the multilateral, 
regional and national levels over the rights of indigenous people, the conservation of biodiversity, the ethics and 
use of genetic resources, Internet governance, climate change technology, and access to education and medicine.  
And behind these debates lies an essential question:  how to come to grips with the significant responsibility of IP 
systems in the current world economy, in international trade, and in national policy environment: how should IP 
systems be designed or adapted to promote economic development, stimulate innovation, and disseminate 
knowledge in a manner that balances the rights of all stakeholders? 
The contemporary field of IP is therefore characterized by profound and searching debates on questions of essential 
public policy; an approach to policy-making that emphasizes empirical research, theoretical clarity, and achieves 
coherence with other areas of law; and the harvesting of practical experience from an ever widening base of 
national IP systems and participants in the policy and practice of IP. It is, therefore, a field in need of a deeper and 
wider research effort; sophisticated, informed and carefully tailored approaches to education and practical capacity 
building; and, above all, dialogue and debate founded on a richer base of information, theoretical understanding, 
practical experience, and knowledge of its implications in other areas of law and policy. 
Both WIPO and the WTO have been called upon to play a role in strengthening capacity to deal with the intellectual 
challenges of these policy debates. This increasing diversity of demand for capacity-building support has had a 
profound impact on programme design and delivery. The WIPO Academy has developed a wide range of specialist 
courses and training activities to respond to this evolving pattern of demand, and to reach out to and support an 
ever widening range of stakeholders. 
The WTO Intellectual Property, Government Procurement and Competition Division (IPD) continues to broaden and 
tailor its technical cooperation and policy support activities, developing a wider engagement with current 
international issues and with a broader base of stakeholders, exemplified by work on public health issues.  But none 
of these outcomes can be possible without partnerships – the sharing of ideas, pooling of resources, and 
coordination of practical activities – so that the necessary wide range of experience and expertise can be drawn on 
to meet diverse needs.  
Both the WIPO Academy and the WTO IPD therefore enjoy many valuable partnerships as a central strategy in 
ensuring programme delivery. The Colloquium has exemplified and promoted current trends in technical assistance 
and capacity building: it builds upon and extends an existing partnership between WIPO and the WTO; it responds 
to the need for stronger, broader dialogue and a greater involvement of voices from all perspectives in 
contemporary debates; it recognizes the central role of indigenous capacity building and of the key contribution of 
IP teachers and researchers as the mainstay of sustainable development of the necessary IP expertise in developing 
countries; it transcends traditional boundaries between regions and between 'north' and 'south' to allow fruitful 
discourse on the future of IP systems. Most importantly, it recognizes the importance of extending beyond an 
educational function to one of bringing together a diverse group with the aim of reviving and refreshing dialogues 
on IP and its cognate fields. 
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The Colloquium has, in particular, laid emphasis on the role of participants as active players, as informed, 
stimulating teachers and researchers who bring to the two-week dialogue as much as they take away from it. Past 
feedback from participants stressed the need to capture, in more permanent form, the many insights gleaned from 
these few days of intensive, vigorous discussion. Participating teachers and researchers expressed important new 
ideas and insights to global debates that could enrich and inform the exchange among policymakers, the academic 
community, and the public at large. 
These thoughts, guided very much by the participating teachers and researchers themselves, are what gave rise to 
the present publication, which is in a way a tribute to the intellectual energy and curiosity of the many alumni of the 
past Colloquia, with whom we continue to enjoy a range of partnerships and dialogue.  
WIPO and the WTO both host numerous meetings every year, in Geneva and in many locations elsewhere, and 
under numerous headings: committees, seminars, workshops, roundtables, symposia, and so on.  But amidst all this 
activity, the idea of a 'colloquium' has a special ring to it – for the WIPO-WTO Colloquium, it connotes a spirit of 
academic enquiry, a search for new ideas and new ways of analysing IP and related fields, through open debate, 
rigorous research, and new ways of communicating the complexities of IP law, practice and policy.  We trust that 
this publication will bring to a wider community of researchers, policymakers and teachers some of the colloquium 
spirit that we have valued so much in this unique programme. 
All of us who have participated in the Colloquium have benefited from the hard work and dedication of many 
colleagues within WIPO and the WTO Secretariat – notably, the WIPO Academy and the WTO IPD. All have 
contributed valuably to the design and delivery of this programme, and their spirit of collegiality makes a 
demanding programme also a pleasurable one. 
We owe a particular debt of gratitude to the Editorial Board and the editors of the Colloquium Papers:  they have 
been indispensable in ensuring that the Papers can be used as a trusted, academically sound and readable source of 
cutting edge IP scholarship from an impressive group of emerging scholars from across the developing world.  
Finally, we record our deep appreciation for the contributions made by individual scholars to this, and the 
preceding, volumes – we have come to know and respect their contributions to policy and legal scholarship, and we 
are sure that this active, informed and thoughtful participation in many of the key public policy debates of today will 
continue, exemplifying the important public service role performed by the scholarly community today. 
 
 
 
 
Mr Sherif Saadallah 
Executive Director 
WIPO Academy 
World Intellectual Property Organization 
 
 
Antony Taubman 
Director 
Intellectual Property, Government Procurement and 
Competition Division 
World Trade Organization 
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1 SPECIALIZED COURTS FOR INTELLECTUAL 
PROPERTY IN BRAZIL 
 
Márcia Maria Nunes de Barros 
 
 
ABSTRACT 
This article discusses the process of specialization of 
intellectual property courts within the Brazilian 
federal judicial system. The article starts by providing 
a brief overview of the functioning of the Brazilian 
federal justice system and how it evolved over time, 
including its bodies, its competence for trial, and its 
existing trial courts. It then describes the increasing 
number of intellectual property cases in the courts, 
and finally highlights several specific cases and 
recent developments in the jurisprudence. 
Keywords: judicial power, competences of Brazilian 
courts in IP matters, IPRs under Brazilian law  
I. INTRODUCTION 
This article aims to analyse the specialization of 
Brazil's justice systems, particularly at the federal 
justice level, with a focus on intellectual property, 
and highlights relevant cases that have occurred in 
recent years and recent developments in the 
jurisprudence. 
II. HISTORY 
A country of vast dimensions, Brazil is divided into 27 
units - 26 States and a Federal District, where the 
capital, Brasília, is located. A brief overview of 
Brazil's judicial system is critical to comprehending 
the intellectual property landscape in this country.  
On account of this geopolitical organization, 
traditionally there has always been a separation 
between the State Courts, also called regular courts, 
where judges preside over disputes between 
individuals, and the Federal Courts, whose 
jurisdiction is determined essentially by the person, 
i.e. any federal public entity concerned in the 
dispute.  
The Federal Justice Court was established after Brazil 
became a Republic in 1889. The first legislative 
document was Decree No. 848 of 1890, which 
regulated the organization and function of the Court 
prior to the establishment of the first Republican 
Constitution in 1891. The creation of the Federal 
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Justice was deemed necessary to consolidate 
national sovereignty and the justice system 
deployed, under which federal and state entities 
coexisted independently and harmoniously. This 
system was inspired by the jurisdiction models of the 
United States, Switzerland and Argentina, all newly 
established republics back then.  
During the period of military dictatorship, Brazil's 
Federal justice was temporarily dissolved under 
Institutional Act No. 2 of 27 October 1965. This act 
suspended the guarantees of life tenure and non-
removability of judges and recreated the first 
Instance at the Federal Court. At that time, judges 
were appointed by the President, based on a list 
drawn up by the Supreme Court. Furthermore, with 
Institutional Act No. 5 of 13 December 1968, the 
constitutional guarantees for judges, such as life 
tenure, non-removability, stability, and performance 
of functions for a defined period, were suspended 
and all measures taken under this Institutional Act 
were excluded from being reviewed by the Judiciary. 
On 17 October 1969, the Federal Court was 
reorganized under Constitutional Amendment No. 01 
and adopted its current form, marking the return of 
judiciary guarantees. 
The bodies of the Federal Justice are the Federal 
Judges and the Federal Regional Courts (Article 106 
of the Federal Constitution). 
The jurisdiction of the Federal Judges is defined in 
Article 109 of the Federal Constitution. Federal 
judges preside over Federal Courts in first instance 
and have jurisdiction to consider and judge the 
following matters: 
(i) Cases in which the Union, an autonomous 
government agency, or a federal public 
company, have an interest as plaintiffs, 
assistants or opponents, except cases of 
bankruptcy, workers' compensation, and the 
ones subject to the Electoral and Labour Courts; 
(ii) cases involving a foreign state, an international 
organization, a municipality or a person 
domiciled or residing in the country; 
(iii) cases based on a treaty or agreement between 
the Union and a foreign state or an 
international organization; 
(iv) political crimes and criminal offences 
committed against goods, services or interests 
of the Union or its autonomous agencies and 
public companies, excluding misdemeanours 
and excepting the competence of the Military 
Courts and Electoral Courts; 
Márcia Maria Nunes de Barros, Specialized Courts for Intellectual Property In Brazil 
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(v) crimes covered by an international treaty or 
convention when, once implemented in the 
country, the result has or should have taken 
place abroad, or conversely; v.A- cases 
regarding human rights referred to in § 5 of this 
article;  
(vi) crimes against a labour organization, and in 
cases determined by law, the ones against the 
financial system and the economic and financial 
order; 
(vii) habeas corpus, in criminal matters within their 
competence, or when the coercion is exercised 
by an authority whose acts are not directly 
subject to another jurisdiction; 
(viii) writs of mandamus and habeas data against an 
act of a federal authority, except for the cases 
of jurisdiction of federal courts of second 
instance; 
(ix) crimes committed aboard ships or aircrafts, 
excepting the competence of military courts; 
(x) crimes or illegal entry or stay of foreigners, 
execution of letters rogatory, after the 
'exequatur', and the foreign judgment, after 
homologation, and for cases related to 
nationality, including the respective option , and 
to naturalization; 
(xi) disputes over indigenous rights. 
All States and Federal District have judicial sections 
in their respective Capital, and courts of first 
instance are located where established by law 
(Article 110 of the Federal Constitution). 
Nowadays, Federal Courts have been established in 
the Federal Capital and in the capitals of the 
Member States, as well as in several other cities of 
large metropolitan centres and in the countryside, 
according to economic and population criteria. 
There are five Regional Federal Courts of Appeals, 
with powers defined under Article 108 of the Federal 
Constitution. They are responsible for:  
(i) processing and adjudicating, in the first 
instance:  
(a) federal judges in their area of jurisdiction, 
including military justice and the Labour 
Courts, in common and liability crimes, and 
the prosecutors of the Union, except for 
the competence of the Electoral Courts; 
(b) criminal reviews and severance actions 
against their decisions or those of the 
federal judges of the region; 
(c) writs of mandamus and habeas data 
against an act of the Court itself or of a 
federal judge; 
(d) habeas corpus, when the constraining 
authority is a federal judge; 
(e) conflicts of jurisdiction between federal 
judges that are subject to the Court; 
(ii) judging, on appeal, cases decided by federal 
judges and by state judges in the exercise of 
federal competence within the area of their 
jurisdiction. 
The dominant jurisprudential understanding with 
respect to industrial property shows that in actions 
involving concession or nullity of industrial property 
rights, even if there are two litigating companies, the 
Brazilian PTO (INPI – Instituto Nacional da 
Propriedade Industrial) should participate in the 
lawsuit as the defendant, because their role in the 
examination and granting is not limited to a formal 
or bureaucratic activity, but constitutes an effective 
verification of the legal requirements of 
registrability, seeking to preserve public interest. 
According to a rule of jurisdiction pursuant to 
Article 94 of Brazil's Code of Civil Procedure (CPC) 
(contained in Article 46 of the new CPC), the motion 
should be brought, as a rule, in the defendant's 
domicile headquarters. 
The PTO is an entity that has the authority to 
'execute, at a national level, the rules governing 
industrial property, with a view to its social, 
economic, legal and technical function' (Article 2 of 
Law No. 5648/1970) and has always had its 
headquarters in the city of Rio de Janeiro, the state 
capital of Rio de Janeiro. For this reason, most of the 
actions involving industrial property, such as 
trademarks, patents, utility model patents and 
industrial designs, are processed in Rio de Janeiro. 
These cases, however, were not prosecuted or tried 
sufficiently quickly to preserve the interests of 
industrial property right holders due to the excessive 
number of lawsuits in the Federal Court and the 
variety of subject matters involved. 
Accordingly, the new intellectual property law (IPL) 
constituted an important step by providing in 
Article 240 for the possibility of establishing 
specialized courts in this field. 
WIPO-WTO Colloquium Papers, 2015 
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This was followed by intense management of 
intellectual property operators, especially through 
their professional associations - ABPI (Associação 
Brasileira da Propriedade Intelectual) and ABAPI 
(Associação Brasileira dos Agentes da Propriedade 
Intelectual), with the Federal Court of Appeal, for the 
development of this expertise.  
In 2000, pursuant to a decision of the Plenary of the 
Federal Regional Court of the Second Circuit, the 
competence relating to intellectual property was 
added to the competence of the ten Courts which 
were specialized in social security matters, namely, 
the 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 
39th and 40th Federal Courts. 
In view of the urgent need for the establishment of 
Special Small Claims Federal Courts by the Regional 
Federal Courts, Law No. 10.259/2001 was enacted in 
2001. Five of these Specialized Courts oversaw 
intellectual property and social security matters. The 
31st, 32nd, 34th, 36th and 40th Federal Courts were 
transformed into specialized Special Small Claims 
Federal Courts, with lawsuits redistributed between 
the remaining specialized Federal Courts. 
In 2003, the 33rd Federal Court was also 
transformed into a Special Federal Court, and its 
lawsuits were redistributed among the other Courts. 
The 35th, 37th, 38th and 39th Federal Courts of Rio 
de Janeiro remained, specializing in intellectual 
property and were later renumbered respectively as 
the 25th, 13th, 31st and 9th Federal Courts - which 
remains to date. 
In 2005 the Federal Regional Court of the 2nd Circuit 
(Federal Court of Appeals) decided the specialization 
of the 1st and 2nd Panels, which constitute the 1st 
Specialized Section of the Tribunal in criminal, in 
social security and in intellectual property matters, 
consolidating the process of specialization within the 
2nd Circuit. 
Intellectual property is not a specific part of the 
curriculum of most law schools in Brazil. On that 
note, the initiative of specialized thematic trial 
sessions significantly contributes to the work 
undertaken by lawyers, the oral arguments, the 
organization of judicial departments, as well as 
concentrating the discussion of legal arguments. 
Indeed, specialization in intellectual property allows, 
both in the first and second instances, further study 
and training of judges and their assistants to be 
undertaken in this particular matter. This 
specialization also enhances the organization and 
standardization of procedures, leading to a 
significant improvement in the degrees of quality 
and reliability of jurisdictional provisions, as well as 
expeditious and effective decisions. 
Nowadays, the Federal Regional Court of the Second 
Circuit is the only Regional Federal Court with 
judges, in both first and second degrees, specialized 
in intellectual property. 
In addition, in the Superior Court of Justice (STJ – 
Superior Tribunal de Justiça), which focusses on the 
uniform application of federal law in the country, 
regardless of the vital public interest intrinsic in 
intellectual property matter – recognized widely in 
Federal Regional Court of the Second Circuit 
decisions –intellectual property cases are decided in 
Private Law Chambers - due to an understanding 
that it is a matter limited to the scope of business 
law. 
III. EVOLUTION 
Given the need for computerization and modification 
of the data system in the Federal Court in the 2nd 
Region, reliable statistics are only available from 
2006 onwards. 
In the table below, the statistics for the month of 
May on an annual basis since then show a rise in the 
number of lawsuits that were in progress in the four 
specialized Courts, as shown in the table below: 
 Total Social 
Security 
Intellectua
l Property 
Percentage 
May 2006 22,465 21,736 729 3.24% 
May 2007 20,833 20,043 790 3.79% 
May 2008 18,141 17,389 752 4.14% 
May 2009 17,751 16,871 880 4.95% 
May 2010 15,141 14,219 922 6.08% 
May 2011 12,132 11,172 960 7.91% 
May 2012 9,253 8,369 884 9.55% 
May 2013 9,214 8,187 1,027 11.14% 
May 2014 7,588 6,551 1,037 13.66% 
May 2015 6,519 5,608 911 13.7% 
 
The following table shows, on an annual basis, the 
number of new cases in the four specialized Courts, 
the number of new social security cases, the number 
of new intellectual property cases, and the 
percentage of new intellectual property cases in 
relation to the total number of new cases: 
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 Total Social 
Security 
Intellectual 
Property 
Percentage 
2006 1,847 1,762 85 4.60% 
2007 1,585 1,500 85 5.36% 
2008 1,557 1,467 90 5.78% 
2009 1,529 1,440 89 5.82% 
2010 1,238 1,167 71 5.73% 
2011 1,126 1,076 50 4.44% 
2012 1,209 1,121 88 7.27% 
2013 1,288 1,184 104 8.07% 
2014 1,109 1,039 70 6.31% 
2015 
(Jan-
May) 
439 400 39 8.88% 
 
 
IV. LANDMARK TRADEMARK CASES 
There are no reliable statistics on how many cases 
relate to each type of intellectual property rights, 
although the practice reveals that the largest 
number is related to trademarks, while fewer are 
related to industrial designs, utility model patents 
and patents. 
 
The main advantages of specialization for 
trademarks are the consolidation of understandings, 
the acceptance of new theses, and the possibility of 
studies with analysis of comparative law. 
 
There are numerous cases involving persons and also 
domestic and foreign companies of greater or lesser 
reputation. Some of the most notable are: 
 
A. CESAR CIELO X CIELO 
In Lawsuit No. 0031360-61.2012.4.02.510, the 
famous Brazilian swimmer and Olympic gold 
medallist, Cesar Augusto Cielo Filho, filed a lawsuit 
against Cielo S/A, a company that manages merchant 
payment options with credit and debit card 
machines. The company had contacted the athlete 
to use his likeness, but had not requested a special 
authorization to use his family name as a trademark. 
 
It was decided that the company could not use 
Cielo's family name without authorization, because it 
was a well-known surname associated with the 
swimmer, and also because when the company 
contracted him they wanted to associate his image 
with the persona of the newly branded business. 
B. APPLE FAMILY 
Apple Inc. filed Lawsuit No. 0490011-
84.2013.4.02.5101 against IGB Eletrônica S.A., 
another company dealing in electronic devices that 
had registered a trademark for GRADIENTE IPHONE 
in Brazil years before Apple. 
The decision considered that, undoubtedly, when 
consumers and the market itself think of IPHONE, 
they are thinking of an APPLE device. Allowing the 
defendant company to use the expression 'IPHONE' 
freely, without any restrictions, would cause 
considerable damage to the Plaintiff, for the 
product's fame and clientele stemmed from Apple's 
level of competence and excellence. Trademark 
spreading, at this moment, would be considered 
equivalent to a punishment for the company that 
developed the product and worked hard for its 
success. The reservation determined by the decision 
refers solely to the prohibition by the appellant 
company, IGB Eletrônica S.A., to use the term 
'IPHONE', in isolation, since it is closely linked, both 
in the domestic market and also internationally, to 
the products from the appellee, Apple Inc.  
Similarly, Apple Company almost lost the name 
'IPAD', as it was first registered for a defibrillator in 
Brazil called IPAD FAST, according to Lawsuit 
No. 0812089-04.2010.4.02.5101 - Apple Inc. and 
Apple Computer Brasil Ltda X Instituto Nacional Da 
Propriedade Industrial – INPI and the company 
Transform Tecnologia De Ponta Ltda, in which the 
plaintiff sought to nullify the registration of the 
trademark I-PAD FAST. 
The decision considered that the trademark I-PAD 
FAST conflicted with the trademark IPOD owned by 
the Plaintiff. The possibility of confusion or 
association between the signs in question is evident, 
and the extensive knowledge of the consumer 
population of Apple Company's 'I' products is 
undeniable. For this reason, the granting of the 
trademark's registration in question to designate 
computers and recorded computer programs was 
considered mistaken owing to an existing prior 
registration of the trademark IPOD in the same 
product class belonging to the Apple Company.  
The decision also stated that there was no obstacle 
to registration, in our country, of the term I-PAD 
FAST to designate medical products, given the fact 
that the term PAD is recognized, in English, to 
distinguish a defibrillator for public access, also 
known by the acronym AED. 
C. PRINCIPALITY OF MONACO X MÁRCIO 
MÔNACO 
In case No. 2002.51.01.523728-5, the Principality of 
Monaco's Government brought a lawsuit against the 
PTO and a company, Amonseg Insurance Broker S/C 
Ltda, for the annulment of the MONACO INSURANCE 
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trademark, created by a Brazilian citizen named 
Marcio Monaco, who used his last name with a small 
crown above the letter 'O' in its creation. The 
Principality claimed that the trademark induced false 
reference in relation to the royal family. 
The decision considered that the trademark fell 
under Article 181 of Brazil's IPL, as the geographical 
name MONACO was not an indication or a 
designation of origin for bank-related services. It also 
may serve as a characteristic element of the service 
developed by the defendant and/or its company, as 
any average consumer would assume any correlation 
with the Principality of Monaco, so there was no 
possibility of false source induction. 
In addition, the decision also argued that the mere 
fact that the defendant's trademark had a crown or 
mitre did not provide an immediate association with 
the royal family of Monaco for the average 
consumer, given that there were several other 
trademarks on the market that use such symbols, 
which translate the idea of excellence or quality of 
products or services. 
D. ALL STAR X ALL STAR 
In Case No. 2002.51.01.523832-0, the Converse Inc. 
company filed a lawsuit against a Brazilian company, 
All Star Sports Articles Ltda and against the PTO, 
seeking to invalidate the ALL STAR trademark, widely 
known in the international market, and obtained by 
the Brazilian company through the national patent 
office. 
The decision recognized the trademark's notoriety, 
considered a special object of protection pursuant to 
Article 6bis of the Paris Convention for the 
Protection of Industrial Property, and also the bad 
faith of the defendant company, which sought a 
business partnership with the plaintiff, and 
afterwards proceeded with the trademark 
registration as if it were its own creation. The 
registrations obtained by the defendant company for 
the ALL STAR trademark were thus decreed null, and 
the company was also ordered to abstain from any 
use of the ALL STAR trademark or other confusingly 
similar sign throughout the national territory. 
V. PATENTS 
There are also many cases involving patents. After 
TRIPS, the landmark cases have been in the field of 
pharmaceuticals and related areas. 
A. ARTICLE 40 OF BRAZIL'S PATENT LAW 
Prior to TRIPS, pharmaceutical products were not 
protected under Brazilian laws. Surprisingly, the 
transition periods provided in TRIPS were not used, 
and in 1996 a new IP law entered into force in 
accordance with the new agreement, which also 
included some TRIPS-plus provisions. One of them is 
the provision contained in Article 40.  
Article 40 provides that the validity of a patent will 
be 20 years from the application date. The sole 
paragraph states that, if the examinations take too 
long, the patent will then be guaranteed a minimum 
period of validity of ten years from the date the 
patent is granted. This provision is being questioned 
directly in Brazil's Supreme Court due to its 
unconstitutionality. However, there has been no 
decision so far. 
B. MAILBOX PATENTS 
Article 229, the sole paragraph of the IPL, provides 
that patent applications for pharmaceutical products 
and chemical products for agriculture, which were 
deposited between 1 January 1995 and 
14 May 1997, shall have the final date of validity as 
stated in the heading of Article 40 of the IPL, i.e. 20 
years from the filing date. These are the mailbox 
patents, which are referred to in TRIPS Article 70.8.  
In spite of the expressed legal provision, INPI, Brazil's 
patent office, fixed the period of validity of these 
patents incorrectly, based on the sole paragraph of 
Article 40 of the IPL, which provides for a period of 
ten years effective from the date of granting. 
After granting several mailbox patents with an 
incorrect validity term, the office realized its mistake 
and filed 48 lawsuits, of which 42 were brought 
before Federal Courts in Rio de Janeiro, seeking to 
modify the period of validity of these patents. 
Patent holders who questioned the merit of such 
lawsuits claimed the impossibility of the revision of 
the patents' validity term, arguing the principles of 
legitimate expectations, legal certainty and equality 
on the grounds that no single paragraph of the 
application of Article 40 of the IPL would consist of a 
discriminatory treatment of patents submitted to 
the mailbox. 
The decisions rendered by the Judge of the 13th 
Federal Court were made to determine the 
correctness of the term of 20 years from the filing 
date, as determined by law, since these patents 
dealt with material that was not permitted under the 
applicable law at the time of the deposit, and were 
subject to a special transition rule which allowed 
patenting during the validity of the current patent 
law. They also recognize the prevalence of the 
principles of legality, free competition and public 
interest in correcting the monopoly duration time. 
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The Court of Appeals confirmed the decisions in first 
instance, as seen in Lawsuits No. 0132265-
40.2013.4.02.5101 (INPI v. Janssen Pharmaceutica 
N.V.) and No. 0132265-40.2013.4.02.5101 (INPI v. 
Keiko Otsu and Louis V. Kirchhoff). 
C. TMC TEST OF OBVIOUSNESS – THE CREATIVE 
MOTIVATION TEST 
In case No. 0802461-54.2011.4.02.5101, the Brazilian 
Association of Generic Drugs Industry, Pró Genéricos, 
filed a lawsuit against Astrazeneca AB and against 
the PTO, seeking to invalidate patent PI 0003364-2, 
which refers to the drug marketed under the 
CRESTOR denomination for the treatment of high 
levels of blood fat, particularly cholesterol and 
triglycerides, claiming that it did not meet the legal 
requirements of novelty and inventive steps , being 
in fact a mere combination of state-of-the-art 
elements. 
As Brazilian law and the PTO had not yet developed 
an obviousness test for the determination of 
inventive step with objective criteria, such a test was 
developed in this decision and named Creative 
Motivation Test (Teste de Motivação Criativa ( TMC). 
This test was prepared after a study of comparative 
law had been undertaken, and adapted in the 
Brazilian system some of the criteria from American 
jurisprudence, such as in Graham v. John Deere and 
KSR v. Teleflex, and in the case law of the European 
Patent Office. 
With the application of the TMC in this case, it was 
found that the technical solution claimed in the 
patent in question was already suggested by the 
prior art (combination of two documents: 
WO 7/23200 and PT547000E). It was decided that 
the claimed subject matter was obvious to be 
attempted with reasonable and well-founded 
expectation of success, which is why the patent was 
void for lack of inventive step. 
The so-called TMC involves the following steps:  
(i) Determining the problem and the claimed 
technical solution;  
(ii) defining the prior art susceptible of knowledge 
for a skilled person in the art;  
(a) determining relevant prior art: verifying 
the similarities and differences between 
the claimed technical solution and the 
prior art; identifying those that are 
relevant to the analysis;  
(b) examining the creative motivation: 
examining whether a skilled person in the 
art would have been motivated to carry 
out the combination or the necessary 
modifications to reach the claimed 
technical solution, given the prior art 
information;  
(iii) Subsequently, verifying evidence of 
inventiveness and thus rejecting obviousness, 
such as:  
(a) the solution of a technical problem long-
 known but unsolved;  
(b) overcoming a bias or technical barriers;  
(c) obtaining commercial success if linked to 
the technical nature of the invention, and 
not for advertising; 
(d) the fact that the technical solution 
provided by the invention is contrary to 
prior art teachings, and producing 
unexpected technical effect;  
(iv) In concluding for obviousness, provide reasons 
according to objective reasoning based on the 
following non-exhaustive illustrative list:  
(a) the combination of prior art elements 
according to known methods, producing 
predictable results;  
(b) the mere substitution of one known 
element for another without 
demonstrating unexpected advantageous 
technical effect, producing predictable 
results;  
(c) using techniques generally known, 
neighbouring or suggested in the prior art 
in the area concerned, to enhance devices, 
methods, or similar products, producing 
predictable results;  
(d) choosing an 'obvious to try solution', from 
a finite number of identified predictable 
solutions, with a reasonable expectation of 
success that proved justified;  
(e) teaching, suggestion or motivation in the 
prior art, not necessarily explicit, that 
would have taken someone with average 
knowledge to modify the prior art 
reference or to combine the prior art 
reference teachings, to reach the claimed 
invention. 
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VI. CONCLUSION 
The Federal Courts in Brazil that are specialized in 
intellectual property matters are working extensively 
to deliver quick, effective and high-quality decisions. 
A balance between the public interest and the needs 
of the owners is being pursued. 
These Courts are essential entities to promote the 
enforcement of intellectual property rights in Brazil, 
without losing sight of important issues of concern, 
such as public health and access to medicines, issues 
that are especially crucial for developing countries. 
 
BIBLIOGRAPHY 
 
Almeida, José Maurício Pinto de, O Poder Judiciário 
brasileiro e sua organização, Curitiba: Juruá, 1992 
96 p 
Oliveira, Alexandre Vidigal de, Justiça Federal: 
evolução histórico-legislativa. Revista Ajufe. São 
Paulo, n 50, p 9-14, jun./jul. 1996 
Salles, M. Ferraz de Campos, Exposição de Motivos 
do Decreto n. 848, de 11/10/1890. In: BRASIL, 1993 
pp 13-18 
Velloso, Carlos Mário da Silva, Do Poder Judiciário: 
organização e competência. Revista de Direito 
Administrativo, Rio de Janeiro, v. 200, pp 1-19, 
abr./jun. 1995 
_______________ 
 
 9 
 
2 VALORIZATION OF INNOVATION AND 
RESEARCH RESULTS FOR SOCIAL AND ECONOMIC 
GROWTH IN BURKINA FASO 
 
Dr Mahamadi Tassembedo 
 
 
ABSTRACT 
 
The question of innovation and the utilization of 
scientific and technological research results has 
come to the forefront in recent years as a significant 
tool for socioeconomic development in African 
Countries. However, it could be argued that despite 
the multiplicity of works managed by different 
actors, research and innovation results in diverse 
areas remain unknown and unutilized, and are often 
unrecognized. This article examines the question of 
innovation and the valorization of research results in 
Burkina Faso. It also explores its inventory of 
research, together with the various constraints and 
opportunities associated with the utilization of 
research and innovation results. Finally, it proposes 
solutions to translate research and innovation into 
development tools for Burkina Faso. 
Keywords: valorization, research issues, innovation, 
intellectual property, development, Africa 
I. INTRODUCTION 
Ranked among the poorest countries in the world, 
the vast majority of African countries have relatively 
low human development indices and face many 
challenges, both at present and in the future. 
Nonetheless, thanks to the increased awareness of 
the role of research, coupled with the efforts of 
researchers, inventors and innovators, many results 
have been generated in Africa in various spheres 
such as agriculture, environment, technology, health, 
and traditional medicine that are likely to contribute 
to the development of the entire continent.
1
 Many 
of the results stemming from research and 
innovation have been published in scientific journals, 
papers and scientific meetings, as well as being the 
focus of topics in national, regional and international 
exhibitions. 
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1 Daniel P Kabore, Dissemination mechanisms Analysis 
improved agricultural technologies and innovations in the 
ECOWAS, (2011).  
However, it is clear that despite the willingness of 
various African leaders to consider scientific research 
and innovation as a tool for socioeconomic 
development, the general public is largely confused 
about research and innovation results. These results 
thus remain largely unknown, unprotected, unvalued 
and unutilized by the general public
2
. There is a 
significant gap in Africa between production results 
from research and innovation and their commercial 
value. Yet, there appears to be an increased focus on 
the utilization of research and innovation results in 
recent years in Africa with the involvement of 
several actors
3
. This paradoxical situation gives rise 
to many questions such as:  What is the current state 
of research and utilization of the results in Burkina 
Faso? What are the constraints and opportunities 
relating to the intensive use of research results and 
innovation? What are the solutions for the utilization 
of research and innovation results as development 
tools in Burkina Faso? 
II. GENERAL CONCEPTS 
Scientific research, inventions and innovation 
activities undertaken throughout the African 
Continent have generated several results that could 
contribute to its social, economic and cultural 
development. These diverse outcomes or endeavors 
are applicable to many sectors, yet there is general 
agreement that they lack valorization. In order to 
provide some clarity, it seems judicious to define 
certain concepts such as valorization, assignment 
and merchandizing, while discussing the rationale for 
the valorization of research and invention results.
4
   
A. VALORIZATION 
The term 'valorization' has many definitions and is 
commonly used, along with such terms as 
'merchandizing', 'utilization of research outcomes' 
and 'assignation'. However, these expressions imply 
unlike realities.
5
 
Indeed, valorization may be defined as a process that 
is essentially undertaken in universities for the 
purpose of adding value to research issues, to 
knowledge, to an invention or to an existing 
technology, so as to convert them into usable or 
marketable goods, processes and services. In other 
words, valorization signifies making knowledge and 
                                               
2 Michel P Sedogo, Research findings Development 
Programme and Innovations in Burkina Faso, 2009. 
3 OECD, Knowledge-based Economy, Paris, 1996.  
4 University of Strasbourg, Good Practice Guidance 
Valuation, Strasbourg, 2009. 
5 Souad Boussaid Valuation of Research and Funding 
Mechanisms of Innovation in Tunisia, 2013.  
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proficiency stemming from research and innovation 
usable and marketable.
6
 
'Assignment' refers to the transmission and receiving 
of flow of knowledge and ability between partners, 
especially in the private sector and research centres, 
for the purpose of enhancing knowledge and value 
of one of the partners. Its concrete expression is by 
the way of a technology transfer agreement 
between an institute or university and an enterprise, 
by granting an exploitation licence or by the transfer 
of intellectual property rights.  
Lastly, marketing refers to putting on the market 
products, processes, and services from the 
marketing exploitation of intellectual property rights, 
acquired from a university or institute. 
B. WHY RESEARCH AND INNOVATION RESULTS 
SHOULD BE VALORIZED? 
In the present-day context of the economy of 
knowledge, there are many reasons why States, 
institutes, research centres and universities are 
prioritizing the valorization of innovation and 
research results.
7
  
The transfer of research and innovation outcomes 
toward the productive sector enhances the 
competitiveness of enterprises and leads to job 
creation, while also helping to produce research and 
innovation outcomes, for instance, the development 
of drugs.  
Valorization avoids the use of results by another 
person without compensation; moreover, it also 
produces substantial incomes and helps to finance 
research in universities, institutes and research 
centres. 
The delivery of knowledge and know-how by 
researchers and innovators in the economics field is 
a source of recognition, notoriety and enrichment of 
research through the supply of professional 
contributions. 
Cooperation with the private sector encourages the 
professional integration of students in enterprises. 
Hence, research should help to respond to concerns 
from enterprises and people regarding issues 
relating to the utilization of results and investment 
feedback. 
                                               
6 Caudle, The Commercialization of University Research, 
(Quebec 1992). 
7 University of Strasbourg, Good Practice Guidance 
Valuation Good Practice Guidance Valuation (Strasbourg 
2009). 
III. STATUS OF RESEARCH 
The status of research in Burkina Faso and across the 
African continent in general is characterized at the 
political and institutional level by the existing 
political views, private and public research, 
valorization structures and lack of valorization and 
protection available for research.
8
 
As for financing of research and innovation, an 
inventory of fixtures shows a limited amount of state 
financing is channeled to this particular field; home 
research centres are subordinated towards foreign 
structures; and results are exported to foreign 
financing institutes.  
The sector of innovation and research results is 
characterized by some existing value structures, lack 
of reward for researchers, a low level of scientific 
publishing protection, a weak use of innovation and 
research issues and non-satisfied societal needs of 
the products brought into focus. 
Only less than 2 per cent of annual scientific 
publishing and 1 per cent of patents filed originate 
from Africa; despite numerous possibilities, only 
countries such as South Africa, Egypt, Tunisia, 
Nigeria, Algeria, and Morocco seem to be an 
exception, though there is no shortage of 
inventiveness and creativity within institutions, 
universities and research centres to meet the 
Continent's development priorities.
9
  
A. CONSTRAINTS AND OPPORTUNITIES OF 
INNOVATION AND RESEARCH RESULTS 
In African countries, there are numerous constraints 
and opportunities
10
 in relation to the valorization of 
research and innovation results: 
(i) CONSTRAINTS 
In this regard, African countries are confronted with 
a bewildering number of economic, political, 
institutional and sociocultural impediments: 
(a) Economic constraints 
There are considerable economic constraints, 
including
11
: 
                                               
8 OECD, Science, Technology and Industry Outlook (2012). 
9 Pan African Conference on the role and place of the 
University in the 21st century, Rabat (Morocco) Africa, 
November 21-23 2011. 
10 OECD, Science, Technology and Industry Outlook, 2012. 
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 Limited public funding granted to research 
and development, leading to dependence 
on investments abroad; 
 smallness of industries unable to absorb 
research results; 
 lack of training for industry and traders to 
provide an understanding of the research 
product and its application or use; 
 lack of issues between research and the 
national research system of production; 
 weak level of industrial property 
protection of the results; 
 Lack of researchers' knowledge about 
issues related to the private sector, 
precluding suitable technical solutions 
from being proposed. 
(b) Sociocultural and behavioral constraints 
The sociocultural and behavioral constraints can be 
summed up as follows
12
: 
 Brevity of training for researchers 
regarding the protection and valorization 
of results; 
 broadcasting of research results is 
predominantly limited to exhibitions, 
publishing, and participation in congresses, 
conferences and forums; 
 lack of a link between the private sector 
and socio-professional environments, 
institutions and research centres; 
 mismatch between research and 
enterprise needs and/or realities; 
 information withholding is still prevalent 
among inventors, innovators, and 
researchers; 
 inadequate social recognition of the 
researcher in the society; 
 researchers' lack of information concerning 
the necessity of filing a patent; 
                                                                
11Michel P Sedogo, Research Findings Development 
Programme and Innovations in Burkina Faso (2009). 
12 OECD, Science, Technology and Industry Outlook (2012). 
 lack of interest of certain researchers for 
market research products. 
(c) Political and institutional constraints 
The political and institutional constraints impeding 
the effective use of innovation and research results 
include
13
: 
 Lack of buildings and plants dedicated to 
research; 
 high school training is not geared towards 
current development needs; 
 mismatch between major development 
goals and research projects; 
 holding of intellectual property rights ( for 
example, patents) is not taken into account 
in researcher career value; 
 lack of legal texts governing the sharing, 
utilization and marketing of innovation and 
research result outcomes; 
 influential role of academics in the field of 
research; 
 research projects are conceived in order to 
respond to career enhancement without 
taking into account national priorities. 
(ii) OPPORTUNITIES 
Notwithstanding the foregoing constraints, it is 
hoped that Africa will eventually overcome these 
impediments. Several opportunities exist for more 
effective harnessing and leveraging of the results or 
findings stemming from inventions, innovation and 
research, which could translate into a source of a 
sustainable development and progress for African 
States.  
Indeed, it is now acknowledged that research at the 
national, regional and international levels is crucial 
from the perspective of the socioeconomic and 
cultural development of states. The recognition of 
the role of research in development across the 
African continent is reflected in the desire of 
authorities to support research and the valorization 
of research results. Since 2006, the Member States 
of the African Union have decided to earmark at 
least 1 per cent of their GDP for research. In the 
                                               
13 Aw Samba, Information and Optimization of the Results 
of Agricultural Research in West Africa, Information 
Librarian - Sciences (2002). 
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same vein as the New Partnership for Africa 
Development (NEPAD), the African Union plans to 
establish a sub-regional research pole throughout 
the Continent.
14
 
From the standpoint of natural and human 
resources, there are several African researchers and 
engineers working at present in foreign institutes 
and in large structured factories; students in well-
known international universities can also provide a 
valuable contribution to supply valorization and 
optimization. Consideration should also be given to 
the importance of the richness of the subsoil in 
certain regions of the African continent that are still 
not sufficiently explored and hold enormous 
potential in pharmacopoeia and in other spheres.  
Beyond the increase in the structures and actors 
involved in research and innovation, and the 
creation of several frameworks for the expression 
and broadcasting of research, invention and 
innovation results, it should be pointed out that 
Africans are looking more and more to 
entrepreneurship and becoming interested in 
innovation and intellectual property subject matters. 
IV. PROSPECTS 
Given the behavioral, sociocultural, institutional, 
political and economic constraints hampering 
research efforts and the development process of 
African countries, research and innovation results 
should be maximized at the political, institutional, 
social and economic levels.  
A. POLITICAL AND INSTITUTIONAL LEVELS 
(i) Reforming universities, institutions and 
research centres 
In the current economic context and the race for 
knowledge, universities, institutes and research 
centres are changing their structures to take into 
account current concerns. These changes may not 
only involve redefining relations with their 
economic, social and cultural environment, but also 
with their traditional mission of valorization.  
A new system for rewarding outcomes from the 
utilization of research results must be clearly 
established to serve as a stimulant for researchers. In 
order to promote the creation of enterprises through 
research results, researcher funding should be 
introduced, in order to assist contractors. Elsewhere, 
                                               
14 Pan African Conference on the role and place of the 
University in the 21st century Rabat (Morocco), Africa, 
21-23 November 2011.  
a linkage must be made between industrial property 
title handling and researchers' career system of 
valorization and appreciation. 
(ii) Universities, institutes and research centres 
must be provided with adequate structures 
To improve the management of marketing and 
industrial activities in universities, institutes and 
research centres, valorization units should be 
established. The focus of their work should be on:   
 Technical and marketing identification of 
issues relating to the valorization of 
various research outcomes so as to gauge 
potential for trade; 
 protection of research and innovation 
results and findings; 
 formulation of strategies for research issue 
valorization; 
 transaction, writing and management of 
research contracts and allowances; 
 development plan for setting up and 
financing these projects; and 
 management of intellectual property title 
security. 
Furthermore, in order to contribute to states' 
economic growth, universities, institutes and 
research centres must be allowed to undertake 
costly activities, create innovative enterprise 
incubators, exploit patents and licences and market 
their business products. 
(iii) Establishing a framework of incentives for 
research and innovation 
Establishing an innovation and research framework, 
which is subject to financial constraints, can help 
ease impediments to research, development and 
innovation, encouraging loans for the purpose of 
stimulating enterprises' research efforts.  
B. ECONOMIC LEVEL 
At the economic level, African countries must 
respect the agreement from 2006 to grant at least 1 
per cent of their GDP to research.
15
 Therefore 
                                               
15 Pan African Conference on the role and place of the 
University in the 21st century Rabat (Morocco), Africa, 
21-23 November 2011.  
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diversification of research financing sources can be 
achieved through the development of partnerships 
with the private sector, and international 
cooperation and economical research results 
generation for the private sector. In addition, 
cooperation and collaboration of efforts between 
intra-nation and inter-African partnerships would 
enable the optimization of existing infrastructures 
and plants.  
However, developing an appropriate loan system will 
be crucial to stimulating research efforts of 
enterprises through support processes.  
C. BEHAVIORAL AND SOCIOCULTURAL LEVEL 
At the behavioral and socio-cultural level, it is 
important to emphasize:  
 Ongoing training of employees in the area 
of research and innovation; 
 collaboration should be enforced between 
research units and enterprises to enhance 
comprehension of their research needs 
and issues; 
 private sector actors' awareness of new 
technologies; 
 promotion of mobility, exchange and inter-
African and international cooperation; 
 the valorization sector should be taken into 
account in the preparation of research 
plans; 
 innovators and researchers should be 
encouraged to share their findings and 
protect and value innovation and research 
outcomes; and 
 decision makers and partners should be 
made aware of the role and importance of 
research results and valorization in the 
development process. 
V. CONCLUSION 
The importance of research and development for 
enterprises and States' competitiveness is well 
known, especially in the current context of 
globalization, characterized by increased rivalry and 
competition and ever more demanding consumers. 
                                                                
 
In short, promoting research, development and 
innovation coupled with the valorization of 
innovation and research results is a real challenge for 
African countries. Meeting this challenge will lead to 
the creation of wealth and sustainable economic 
development in Africa.  
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3 A CONTEXTUAL FRAMEWORK FOR DESIGNING 
AND IMPLEMENTING LAWS AND POLICIES TO 
PROMOTE ACCESS TO MEDICINES 
IN CAMBODIA 
 
Dr Phin Sovath 
 
ABSTRACT 
This paper briefly reviews the TRIPS public health-
related flexibilities within the international legal 
framework, as well as Cambodia's national policies, laws 
and regulations, and then assesses to what extent such 
flexibilities have been incorporated and utilized under 
its intellectual property (IP) policies, laws and 
regulations. It concludes that Cambodia has failed to 
incorporate and utilize fully the TRIPS public health-
related flexibilities for three reasons. First, the Patent 
Law followed the WIPO Draft Industrial Property Act, 
which was developed many years ago and lacked these 
flexibilities. Second, since its adoption in 2003, the 
Cambodian Patent Law has never been reviewed and 
modified so as to take advantage of these flexibilities, in 
particular those envisaged in the Doha Declaration and 
put in place after its adoption, such as the transitional 
period for pharmaceutical products until 2033 and the 
special compulsory licensing system under the August 
30 Decision. Third and lastly, the draft Compulsory 
Licensing Law (CL), incorporating the flexibilities under 
the August 30 Decision, was finalized but has not been 
endorsed or adopted. These reasons also serve as 
lessons learned for other countries that need to address 
the same issue in relation to IP and public health. 
Keywords: Intellectual property, TRIPS Agreement, 
flexibilities, public health, compulsory licence, Doha 
Declaration, August 30 Decision, Paragraph 6 
I. INTRODUCTION 
As a least developed country (LDC), Cambodia is not 
obliged to comply with the Agreement on Trade-Related 
Aspects of Intellectual Property Rights (TRIPS 
Agreement) until the lapse of the transitional period in 
July 2021.
1
 In particular, Cambodia is not obliged to 
provide patent protection of pharmaceutical products 
under its patent law. Accordingly, at present Cambodia's 
patent law excludes pharmaceutical products from the 
subject matters of the patent protection. Although 
                                               
 Dr Phin Sovath (Cambodia) Professor of Law, Faculty of Law 
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1 In its draft working party report, Cambodia requested a 2009 
transition period. Finally, WTO Members pressed Cambodia to 
accept a 2007 transition period. However, due to the status of 
Cambodia as an LDC, it is entitled to the general transitional 
period agreed upon by all WTO Members. 
Cambodia does not provide patent protection for 
pharmaceutical products, it faces three main challenges 
in relation to intellectual property (IP) and public health.  
The first challenge is access to affordable medicines. 
Cambodia has so far made significant progress in 
promoting access to affordable medicines for the anti-
retroviral (ARV) treatment of persons living with HIV and 
for the treatment of both communicable and non-
communicable diseases, such as hepatitis C, heart and 
vascular diseases, diabetes and cancer.
2
 This 
achievement has been made possible owing to various 
global sources of funds and the increasing competition 
among generic versions of patent-protected medicines. 
However, Cambodia's access to affordable generic 
medicines is not guaranteed in the long term because 
the global fund resources on which Cambodia depends 
on to pay for the treatment are rapidly declining.
3
 
The second challenge is diminished competition among 
generic versions of patent-protected pharmaceutical 
products in developing countries which have largely 
supplied those pharmaceutical products to Cambodian 
patients. Countries that supply Cambodia with generic 
medicines such as India could soon or later enter into 
bilateral or regional free trade agreements that might 
restrict them from exporting cheap and affordable 
generic medicines to Cambodia
4
 and consequently 
restrict Cambodia's access to cheaper generic versions 
of essential drugs that are under patent protection. 
The third and last challenge is when Cambodia 
graduates from its LDC status due to its strong economic 
growth, an economic performance estimated by the 
Asia Development Bank and the World Bank to have 
shown solid growth in the previous three years. Such 
prolonged expansion has lifted Cambodia's gross 
national income per capita toward the $1,045 threshold 
for entry into lower-middle-income status.
5
 As part of its 
economic development strategy, Cambodia plans to 
graduate from a lower-middle income country to a 
                                               
2 See World Bank, Overview: Cambodia 
<http://www.worldbank.org/en/country/cambodia/overview#
2> accessed 17 January 2016. According to the World Bank, 
Cambodia has also been successful in combating HIV/AIDS, 
tuberculosis and malaria. HIV prevalence among adults aged 15 
to 49 decreased from 0.9 per cent in 2006 to 0.7 per cent in 
2012. In 2014, 89 per cent of active AIDS patients in Cambodia 
had access to antiretroviral treatment, a rate of coverage that 
is among the highest in the developing world.  
3 It is expected that there will be a decline in the total global 
fund of 55.3% for the next three years 2015, 2016 and 2017. 
See the National Aids Authority, Cambodia Country Progress 
Report (National Aids Authority 2015) 33. 
4 Those countries include India and other countries which are 
involved in bilateral and regional trade agreements such as TPP 
and the India-EU Trade Agreement. 
5 See May Kunmakara and Ananth Baliga, Nearing Lower-
Middle Income Phnom Penh Post (Phnom Penh 17 July 2015) 
<http://www.phnompenhpost.com/business/nearing-lower-
middle-income>   
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higher-middle income country in 2030.
6
 At that juncture, 
Cambodia will no longer be classified as an LDC and will 
be obliged to comply fully with the TRIPS Agreement, in 
particular regarding the protection of pharmaceutical 
products. 
In promoting access to affordable medicines, Cambodia 
recognizes this as a critical issue of public health and 
human rights, and ultimately of poverty reduction and 
human development. Cambodia has thus recently 
adopted the National Intellectual Property Strategy 
(NIPS), which addresses access to affordable medicines 
throughout the text. Cambodia is also in the process of 
drafting a law on compulsory licensing for public health, 
in order to address a public health crisis in the event of a 
national health emergency, extreme urgency or public 
non-commercial use.  
The NIPS was questionable, however, in respect of its 
assumption, information and evidence and failed to give 
adequate consideration to the public health implications 
of patented pharmaceutical products. The drafting of 
the law on compulsory licensing for public health has 
also met, both at the national and international levels, 
with various political and legal challenges. Even its 
future adoption and implementation cannot be precisely 
predicted. Moreover, several other existing related laws 
and policies, including a law on patents and a law on the 
management of pharmaceutical products, have not 
been reviewed to assess whether they are supportive of 
public health and to what extent they have incorporated 
and utilized flexibilities available under the TRIPS 
Agreement and the Doha Declaration on TRIPS and 
Public Health.
7
  
These challenges and failures raise three key questions: 
(1) how to promote access to affordable medicines, as a 
critical issue of public health and human rights, and 
ultimately of poverty reduction and human 
development; (2) how Cambodia's existing laws and 
policies should be reviewed and revised within the 
national and international context; and (3) how to 
balance public health interests and the interests 
protected by IP laws and policies.  
In order to address these three questions, this paper will 
briefly review the international legal framework of IP 
and public health in Part II, and the flexibilities provided 
to WTO Members in relation to public health. Part III of 
this Paper will review Cambodia's national laws and 
policies relating to IP and public health and assess 
whether they promote or obstruct access to affordable 
                                               
6 See National Strategic Development Plan 2014-2018 (RGC 
2014) 118. 
7 WTO, Doha Declaration on the TRIPS Agreement and Public 
Health, 14 November 2001 (the Doha Declaration)  
<https://www.wto.org/english/thewto_e/minist_e/min01_e/m
indecl_trips_e.htm> accessed 17 January 2016. 
medicines. Part IV will assess to what extent Cambodia 
has taken advantage of the IP and public health 
international legal framework and relevant flexibilities, 
and draw lessons learned and implications for other 
countries. Finally, after discussion, Part V will draw the 
relevant conclusions.  
II. THE INTERNATIONAL LEGAL FRAMEWORK OF IP 
AND PUBLIC HEALTH 
The TRIPS Agreement was adopted in 1994 and 
represents the most far-reaching international 
agreement that sets the global minimum substantive 
standard of protection for IPRs such as protectable 
subject matters, requirements and conditions for 
protection, protected rights, and minimum duration of 
protection, as well as enforcement obligations and 
dispute settlement mechanism.
8
 Regardless of its 
adoption, debates on the balance between the private 
interests of right holders and the public interests of 
users and governments for their development needs 
have started and continued both prior to and after the 
adoption of the TRIPS Agreement.  
After continuous debates among WTO State Members, a 
number of flexible provisions were incorporated under 
the TRIPS Agreement to promote public health and 
access to medicines, and a declaration and decision on 
the intersection between IP and public health was 
adopted. The following sections will provide an overview 
of the public health-related flexibilities contained in the 
TRIPS Agreement, along with the declaration and 
decision within the international legal framework of the 
TRIPS Agreement.
9
  
                                               
8 As a least developed country (LDC), Cambodia is granted an 
extension of the transition period up to 1 July 2021 to 
implement the TRIPS Agreement. 
9 Owing to the limited space of this Paper, this subject is not 
discussed in detail. For a detailed explanation and discussion, 
see UNDP, Good Practice Guide: Improving Access to Treatment 
by Utilizing Public Health Flexibilities in the WTO TRIPS 
Agreement (UNDP 2010) (the UNDP Good Practice Guide). 
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A. PUBLIC HEALTH - RELATED TRIPS FLEXIBILITIES 
Under the TRIPS Agreement, there are several 
provisions that relate to TRIPS flexibilities that can be 
utilized by WTO Members to promote public health. A 
good practice guide published by UNDP divides these 
public health-related TRIPS flexibilities into three types: 
preventive, remedial, and enforcement. The three types 
of public health-related TRIPS flexibilities are 
summarized in a table below. 
 
Among these public-health-related TRIPS flexibilities, 
certain flexibilities were incorporated into the Patent 
Law of Cambodia. Part III of this Paper will examine and 
review the Patent Law and identify which flexibilities 
were incorporated, as well as explain why they were not 
used to the fullest extent. 
 
B. DOHA DECLARATION AND DECISION ON IP AND 
PUBLIC HEALTH 
The debate on public health and access to medicines 
was initiated in 2001 in Doha, Qatar to clarify the 
ambiguities between the need for governments to 
implement the TRIPS Agreement and to protect the right 
to health.
10
 Developed countries, developing countries 
and LDCs took part in this discussion concerning IP and 
access to medicines, which led to the adoption by WTO 
Members of the 'Doha Declaration on the TRIPS 
Agreement and Public Health' (the Doha Declaration) in 
2001. The Doha Declaration affirms that the TRIPS 
Agreement 'does not and should not prevent Members 
from taking measure to protect public health' and that 
it: 
                                               
10 See UNDP Good Practice Guide 6-8. 
Public Health-Related TRIPS 
Flexibilities 
Examples and Relevant References 
Preventative: 
Policy options to ensure that patents do 
not hinder access to affordable 
medicines. 
Advantages: easier, faster, less 
politically sensitive compared to some 
remedial measures. 
Exclusion from Patentability: exclude new use of known substances, methods and processes 
(Articles 27.2 and 27.3) 
Patentability Criteria: develop and apply strict patentability criteria for examination of 
pharmaceutical patents. Mitigate frivolous patents and "evergreening" opportunities. 
(Articles 1 and 27.1). 
Patent Opposition: allow pre-grant and post-grant patent opposition in fast, accessible and 
cost-efficient manner. 
Waiver for LDCs: LDCs should utilize the waiver to provide patent protection for 
pharmaceuticals until 1 January 2016 (now 1 January 2033) (and possibly longer, if extended). 
Remedial: 
Preventative flexibilities cannot always 
be used to meet existing and emerging 
needs to secure access to affordable 
medicines. Therefore, series of remedial 
flexibilities are included in the TRIPS 
Agreement. 
Compulsory Licences and Government Use Orders 
(Article 31 (a)-(j)) 
Compulsory Licences for Export under the WTO 30 August, 2003 Decision. 
Exceptions: Bolar (early working) exception, research and experimental use exception, 
individual use (Article 30) 
Use of National Competition Laws to prevent IPR abuse and provide remedies (Articles 8.2, 
31(k) and 40) 
Parallel Importation (Article 6) 
Enforcement: 
Related to obligations under Part III of 
the TRIPS Agreement, which sets 
minimum standards for IPR 
enforcement. 
No border measures for suspected patent infringement (Article 51) 
No criminalization of patent infringement (Part III, Section 5) 
UNDP, Good Practice Guide: Improving Access to Treatment by Utilizing Public Health Flexibilities in the WTO TRIPS Agreement, 15 (2010) 
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can and should be interpreted and 
implemented in a manner supportive of WTO 
Members' right to promote public health and, 
in particular, to promote access to medicines 
for all.
11
 
In paragraph 4, the Doha Declaration formally affirms 
that WTO State Members should have the right 'to use, 
to the full, the provisions in the TRIPS Agreement, which 
provide flexibility for this purpose.'
12
 The Doha 
Declaration then spells out in paragraph 5 that, within 
the context of the TRIPS Agreement, these flexibilities 
include: 
 The right to grant compulsory licences and 
the freedom to determine the grounds upon 
which such licences are granted; and 
 the right to determine what constitutes a 
national emergency or other circumstances 
of extreme urgency, it being understood that 
public health crises, including those relating 
to HIV/AIDS, tuberculosis, malaria and other 
epidemics, can represent a national 
emergency or other circumstances of 
extreme urgency. 
The Doha Declaration, however, failed to address an 
issue under paragraph 6. Recognizing that:  
WTO Members with insufficient or no 
manufacturing capacities in the 
pharmaceutical sector could face difficulties in 
making effective use of compulsory licensing 
under the TRIPS Agreement. 
The Ministers charged the Council for TRIPS to find 'an 
expeditious solution' to the issue. For about two years, 
the Council for TRIPS implemented its mandate and 
finally presented the expeditious solution to WTO 
Members. In August 2003, a decision on the 
implementation of Paragraph 6 of the Doha Declaration 
was adopted by WTO Members, establishing a system 
under which a country can issue a compulsory licence 
for the purpose of exporting generic medicines to 
countries with insufficient or no manufacturing capacity 
(the August 30 Decision).  
The August 30 Decision introduced two important 
waivers to Article 31 of the TRIPS Agreement. The first 
waiver concerns the requirement of TRIPS Article 31(f) 
for predominant domestic use, which provides a 
mechanism that allows WTO Members to issue 
compulsory licences for the export of generic 
                                               
11 Ministerial Declaration on the TRIPS Agreement and Public 
Health, paragraph 4. 
12 ibid. 
equivalents of patented medicines to countries with no 
or insufficient pharmaceutical manufacturing capacity. 
The second waiver concerns the obligation of importing 
countries under the requirement of TRIPS Article 31(h). 
A number of conditions must be satisfied in order to 
implement the August 30 Decision.
13
  
The use and implementation of the August 30 Decision 
is optional, not mandatory and thus each WTO Member 
can decide whether or not to use and implement it. 
Among the WTO Members with express implementing 
laws or regulations, there are three categories of 
Members that have implemented the August 30 
Decision:  
 
 exclusively as exporters (41 Members);  
 exclusively as importers (three Members); or  
 both as exporters and importers (seven 
Members).
14
  
On 1 November 2011, Cambodia expressly submitted an 
Instrument of Acceptance of the amendment of the 
TRIPS Agreement that it will use and implement the 
August 30 Decision, both as exporter and importer.
15
 
However, Cambodia has not adopted any domestic law 
or regulation for such use and implementation. A law on 
compulsory licensing for public health is being drafted, 
but this process is lengthy and is proving challenging 
since the introduction of the first draft by experts and 
the Ministry of Health, who is in charge of this law. 
Section III below spells out the details of this draft law, 
while discussing some of the key challenges facing 
Cambodia. 
 
III. NATIONAL LEGAL AND POLICY FRAMEWORK FOR 
IP AND PUBLIC HEALTH 
Patents are the most relevant type of IP in the context 
of public health. In 2003 Cambodia adopted for the first 
time a Law on Patents, Utility Model Certificates, and 
Industrial Designs (the Patent Law). The Patent Law is 
supplemented by two important regulations on patents, 
utility models and industrial designs, namely the Prakas 
on Procedures for Granting Patents and Utility Model 
Certificates (2006) (the Patent Regulation), and the 
Prakas on Procedures for Registration of Industrial 
                                               
13 For a detailed explanation on these requirements, see 
Frederick M Abbot and Rudolf V Van Puymbroeck, Compulsory 
Licensing for Public Health: A Guide and Model Documents for 
Implementation of the Doha Declaration Paragraph 6 Decision, 
World Bank Working Paper No. 61 (World Bank 2005). 
14 See Roger Kampf, Special Compulsory Licences for Export of 
Medicines: Key Features of WTO Members' Implementing 
Legislation, Staff Working Paper ERSD-2015-07, 8 (Economic 
Research and Statistics Division, WTO 2015). 
15 See WTO, WT/Let/833. 
WIPO-WTO Colloquium Papers, 2015 
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Designs (2006). These two regulations provide 
guidelines both for the Patent Office and inventors, on 
how to grant patents and utility model certificates and 
how to register industrial designs. The Patent Law and 
the two regulations are fundamental legal frameworks 
for the protection of patents, utility models and 
industrial designs in Cambodia. 
 
The following sections will review the NIPS, the Patent 
Law and Patent Regulation in relation to public health.
16
 
 
A. NIPS IN THE CONTEXT OF PUBLIC HEALTH 
 
In line with objectives and challenges raised in the 
Second Health Sector Strategic Plan 2008-2015, the NIPS 
has identified five areas where the IP system should be 
managed to ensure that it contributes positively to 
public health in Cambodia: 
 
 Fostering the growth of the pharmaceutical 
industry in Cambodia; 
 controlling and reducing the price of 
pharmaceuticals by taking advantage of the 
flexibilities available under the TRIPS 
Agreement to access essential medicines; 
 providing tools to assist with enforcement 
action against providers of counterfeit 
pharmaceuticals; 
 facilitating collaboration with outside health 
organizations to share technologies, 
treatment methods and pharmaceuticals 
that otherwise may not be made available 
without adequate IP protection; 
 providing mechanisms for the control and 
protection of traditional medicines and 
traditional medicine practices, and 
opportunities for protection of innovations 
in this area.
17
 
In order to support these five areas, five initiatives were 
adopted in the NIPS in relation to IP and public health 
for implementation within short-, medium- and long-
term timelines.
18
 Some of the initiatives have been 
launched and implemented by the relevant ministries in 
charge, while others have yet to start or be developed. 
Hence, an evaluation of what needs to be done and 
what has not been done by the relevant ministries 
should be undertaken to identify and share both the 
                                               
16 Owing to space limitation, this Paper will not discuss the laws 
and regulations on the management of pharmaceutical 
products, which also have a potential impact on the access to 
medicines in Cambodia. 
17 ibid., 43. 
18 ibid., 43-48. 
success stories and the challenges facing the relevant 
ministries in their implementation. 
B. PATENT LAWS AND REGULATIONS IN THE 
CONTEXT OF PUBLIC HEALTH 
In addition to the NIPS, Cambodia has the Patent Law, 
which does not grant patent protection to 
pharmaceutical products until 1 January 2016. 
Pharmaceutical products were clearly excluded from the 
subject matters of patent protection
19
 and will be 
granted accordingly from 1 January 2016.
20
 
Although the Patent Law does not provide patent 
protection to pharmaceutical products, the Patent 
Office has, however, accepted patent applications for 
pharmaceutical products since 2007 under the Patent 
Regulation.
21
 Thus Cambodia has practiced a mailbox 
system, although it is not obliged under the TRIPS 
Agreement to have this system in place. The mailbox 
would be opened starting in January 2016, at which time 
Cambodia would need to grant patent protection in 
accordance with the Patent Law as from the grant of the 
patent and for the remainder of the patent term, 
counted from the filing date.
22
 Following the granting of 
patent protection, access to generic medicines would be 
potentially restricted because the medicines are 
patented.  
Even though a patent is granted to pharmaceutical 
products, there are some situations in which a 
government agency or a designated third party can 
exploit the invention without the agreement of the 
patent holder
23
, in particular when the public interest, 
including national security, nutrition, health or the 
development of other vital sectors of the national 
economy so requires; when the exploitation by an 
owner is anti-competitive;
24
 when the patented 
invention is not worked or worked but not sufficiently;
25
 
or when there is an interdependent patent.
26
 This is 
called a 'compulsory licensing' or 'a non-voluntary 
licensing' system. In such situations, however, a 
compulsory licence must be issued in compliance with 
the following requirements and conditions: 
 Adequate remuneration (Article 47); 
 an authorization may be obtained only if 
efforts have been made to obtain a 
contractual licence and have failed with 
exceptions (Article 52);  
                                               
19 The Patent Law, Article 4. 
20 The Patent Law, Article 136. 
21 The Patent Regulation, Rule 45. 
22 ibid. 
23 The Patent Law, Articles 11 and 12. 
24 The Patent Law, Article 47. 
25 The Patent Law, Article 56. 
26 The Patent Law, Article 59. 
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 non-exclusive (Article 51); 
 limited transfer of the authorization (Article 
50); 
 predominantly used for the supply of the 
domestic market (Article 53);  
 variation of decision (Article 48); 
 termination of decision (Article 49); 
 subject to appeal (Article 55). 
Under the Patent Law, condition No. 2 above will not 
apply when the compulsory licence is issued for the 
purpose of national emergency, extreme urgency and 
public non-commercial use.
27
 Conditions No. 4 and No. 
5, however, are the same as Article 31 of the TRIPS 
Agreement and have not been modified since its 
adoption in 2003, even though these conditions are 
partially or fully waived by the August 30 Decision of the 
Council for TRIPS. These conditions will be spelt out in 
more detail in Part IV.  
C. DRAFT LAW ON COMPULSORY LICENSING FOR 
PUBLIC HEALTH 
Since 2004, with assistance and support from 
development partners such as UNDP, UNAIDS and WHO, 
the Ministry of Health of Cambodia has started the 
discussion about IP and public health and the process of 
drafting the law on compulsory licensing for public 
health (the CL Law) has already been initiated since that 
time. Until now, however, the draft CL Law has not yet 
been adopted. The current version of the draft CL Law 
has already been discussed and finalized by the 
technical working group of the Ministry of Health and 
other relevant ministries. The next step in the process 
will be the endorsement of the Council of Ministers, the 
submission to the National Assembly and the Senate, 
and then the promulgation of the CL Law by the King. 
The draft CL Law is a standalone law, separate from the 
Patent Law. It intends to incorporate flexibilities under 
the Doha Declaration and the August 30 Decision, in 
order to promote access to affordable medicines 
through the use and implementation of the special 
compulsory licensing system, that is, the import and 
export of medicines through this system. As long as the 
CL Law has not been adopted, however, the use and 
implementation of the August 30 Decision have yet to 
be realized. Consequently, it will potentially impact the 
access to medicines for patients in Cambodia. 
                                               
27 The Patent Law, Article 52, para 2. 
IV. LESSONS LEARNED AND IMPLICATIONS FOR 
OTHER COUNTRIES 
After reviewing and discussing the international and 
national legal framework in Part II and Part III, some 
lessons can be learned from Cambodia's experience, 
together with implications for other countries when 
they seek to address the balance between IP and public 
health. The following sections will spell out those 
lessons and implications in more detail. 
A. NO FULL USES OF PUBLIC HEALTH-RELATED TRIPS 
FLEXIBILITIES 
The Cambodian Patent Law was adopted in 2003 and 
since then it has never been modified or amended. The 
drafting of the Patent Law followed a WIPO Model Law 
called 'Draft Industrial Property Act for [Country] and 
Commentary on Its Main Provisions'. Consequently, the 
Patent Law incorporated certain flexibilities and left 
other flexibilities unstipulated. The following table 
summarizes what flexibilities were incorporated and 
which flexibilities were not incorporated by using the 
three types of flexibilities developed by the UNDP Good 
Practice Guide.  
WIPO-WTO Colloquium Papers, 2015 
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As set out in the above table, the Cambodian Patent Law 
has failed to incorporate fully the key TRIPS public 
health-related flexibilities. There are three main reasons 
for this failure:  First, the Patent Law followed the WIPO 
Draft Industrial Property Act, which was developed 
several years ago and did not contain all of these 
flexibilities. Second, since its adoption in 2003, the 
Cambodian Patent Law has never been reviewed or 
modified to take advantage of these flexibilities, in 
particular those envisaged in the Doha Declaration and 
put in place after its adoption, such as the transitional 
period for pharmaceutical products until 2033 and the 
special compulsory licensing system under the 
August 30 Decision. Third and last, the draft CL Law, 
incorporating the flexibilities under the August 30 
Decision, was finalized, but has not been endorsed or 
adopted. 
In addition to the above findings, the Patent Regulation 
is also problematic since the Patent Office had adopted 
and implemented the mailbox system since 2007. In 
light of the recent development with regard to this 
issue, Cambodia as a LDC is not required to establish 
such a mailbox system.
28
 Therefore, the Cambodian 
Government needs to address two issues urgently.   The 
first issue concerns the current version of the Patent 
Regulation, which should be amended to abolish the 
current mailbox system. The second issue concerns the 
applications which have been filed with the Patent 
Office since 2007 and particularly whether those 
applications should be opened from 1 January 2016 or 
they should not be opened until the lapse of the new 
transitional period (2033). 
                                               
28 See WTO Decision on Obligations under Article 70.8 and 
Article 70.9 of the TRIPS Agreement with respect to 
Pharmaceutical Products, dated 30 November 2015, WT/L/971. 
Type of Flexibilities Incorporated Not Incorporated 
Preventative 
 
Waiver for LDCs: 
Patent protection for 
pharmaceuticals until 1 January 2016 
(Article 136 of the Patent Law). 
Exclusion from Patentability: exclude new use of known 
substances, methods and processes (Articles 27.2 and 27.3) 
Patentability Criteria: develop and apply strict patentability 
criteria for examination of pharmaceutical patents. Mitigate 
frivolous patents and "evergreening" opportunities. (Articles 1 
and 27.1). 
Patent Opposition: allow pre-grant and post-grant patent 
opposition in fast, accessible and cost-efficient manner. 
Waiver for LDCs: Cambodia has not yet amended its Patent Law to 
the exception for patent protection for pharmaceuticals until 1 
January 2033 (and possibly longer, if extended). 
Remedial 
 
Government Use and Non-Voluntary 
Licence 
(Article 47-64 of the Patent Law) 
International Exhaustion (Article 44(i) 
of the Patent Law) 
Exceptions: Research and 
experimental use exception, 
individual use (Article  (iii)(iv) of the 
Patent Law) 
Compulsory Licences for Import and Export under the August 30 
Decision. 
Exceptions: Bolar (early working) exception (Article 30) 
Use of National Competition Laws to prevent IPR abuse and 
provide remedies (Articles 8.2, 31(k) and 40) 
Enforcement 
 
No border measures for suspected 
patent infringement  
No criminalization of patent infringement (Part III, Section 5) 
Dr Phin Sovath, A Contextual Framework for Designing and Implementing Laws and Policies to Promote Access 
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B. CHALLENGES OF DRAFTING THE LAW ON 
COMPULSORY LICENSING FOR PUBLIC HEALTH 
In the process of drafting the CL Law, Cambodia has 
faced many challenges and four of them can be 
summarized as follows
29
: 
 Overlapping Jurisdiction: there has been a 
lengthy debate over whether or not MIH 
should be in charge of implementing the 
Patent Law or MOH in charge of public health 
should be the institution in charge of issuing 
compulsory licences for public health.  
 Reasonable Royalty: the stakeholders had little 
understanding about the standard reasonable 
royalty, which continues to be debated, or of 
other countries' experience.  
 Penalty: a question has also been raised as to 
how to stipulate those provisions in the draft 
CL Law, without limiting the public health 
protection offered by the compulsory licence.  
 Implementing Regulations: the draft CL Law 
sets forth only basic principles and 
procedures, but does not contain detailed 
provisions, which need to be provided for in 
subsequent implementing regulation.    
The reasons for these challenges are threefold. First of 
all, there is a very limited human resource that can 
understand the intersection of IP and public health. 
Second, although there are some model provisions and 
guides available for drafting the compulsory licensing 
system
30
, they are purported to be incorporated into the 
patent law, but not in a standalone law such as in 
Cambodia. Third, limited human resource and capacity 
have prevented Cambodia from using and taking 
advantage of those model provisions and guides, which 
are available mostly in English. The actual use and 
implementation of the August 30 Decision will take 
place within the context of each country's existing 
legislative and regulatory framework, practice and 
                                               
29 See Lim Ratanak, Cambodia's Draft Law on Compulsory 
Licensing and Public Health, Presented at the Workshop on 
Trade and Access to Medicines in Cambodia, 
11-12 November 2013, Siem Reap, Cambodia. 
30 Those model provisions and guides include Frederick M 
Abbot and Rudolf V Van Puymbroeck, Compulsory Licensing for 
Public Health: A Guide and Model Documents for 
Implementation of the Doha Declaration Paragraph 6 Decision, 
World Bank Working Paper No. 61 (World Bank 2005), and 
Correa M Carlos, Compulsory Licensing: How to Gain Access to 
Patented Technology, in Intellectual Property Management in 
Health and Agricultural Innovation: A Handbook of Best 
Practices (eds A Krattiger, RT Mahoney, L Nelsen, et al), 
available online at <http://www.ipHandbook.org>  
jurisprudence. Therefore, the Government of Cambodia 
should work closely with its own experts to draft and 
adopt the CL Law appropriate for Cambodia's unique 
situation.  
V. CONCLUSION 
Cambodia is a LDC Member of the WTO since October 
2004. It has adopted all key laws and regulations related 
to IP rights, and at the same time it has made efforts to 
introduce new laws and policies to address public health 
issues. The opportunities and challenges facing 
Cambodia are interesting and are helpful lessons which 
should be shared with other policy makers and 
researchers from other countries or regions, in 
particular its experience and lessons on how the existing 
laws and policies should be reviewed and revised within 
the national and international context to balance public 
health interests and the interests protected by IP laws 
and policies. 
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4 INTELLECTUAL PROPERTY PROTECTION 
OF CLINICAL TRIAL DATA 
 
Dr Doaa Abdelrahman 
 
ABSTRACT 
Researchers who conduct clinical research with human 
subjects face a profound problem related to the 
protection of their work throughout the study and 
before reaching the final result. Clinical trial processes 
are one of the most important and perilous scientific 
processes, particularly from the legal perspective. There 
are various legal instruments embodying the legal and 
ethical principles, rights and obligations of research 
subjects and investigators, and procedures relating to 
the clinical trial process. 
Current protection under intellectual property rights 
(IPRs) does not provide appropriate legal coverage of 
the clinical trial process. In order to ensure a suitable 
degree of protection, a new form of IPR is required that 
would be compatible with the nature of the data and 
information collected. The form of IPR proposed in this 
Paper will be known as the Clinical Trials Right (CTR). 
The CTR would protect all data and information 
stemming from the drug development process. It would 
also cover the work carried out by investigators before 
and during the trial. 
Creating a new form of clinical trial data and information 
protection would encourage investments in the field of 
pharmaceutical inventions and provide an effective 
process for the circulation of information. In addition to 
enhancing pharmaceutical research and industries, it 
would also ensure a balance of benefits between the 
sponsor and investigators on the one hand, and the 
competitors on the other. 
Keywords: Clinical trials, works of investigators, new 
form of intellectual property rights, data protection 
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I. INTRODUCTION 
The clinical trial process is one of the most important 
and perilous medical and scientific processes, 
particularly from the legal perspective. There are several 
reasons for this. First, it is a vital step in the drug 
development process since no drug or medicine can 
enter the markets without undergoing a clinical trial. 
Second, if they have not been provided with a proper 
degree of legal protection, this process could infringe 
the safety, security and welfare of the individuals who 
are subject to it. Hence, the process should be governed 
by precise laws and legislations to ensure a suitable 
degree of protection for research subjects. 
There are several international legal instruments dealing 
with the clinical trial process. These legal instruments 
deal with legal and ethical principles, the rights and 
obligations of both research subjects and investigators, 
and the procedures to be followed during the clinical 
trial process. The most important instruments are the 
Nuremberg Code and the Declaration of Helsinki. 
Both of these international legal instruments, as well as 
others, are silent, whether explicitly or tacitly, as to the 
method of data and information collection during the 
clinical trial process. In fact, the clinical trials process is 
costly in most cases in the long run
1
, and thus 
necessitates a proper degree of legal protection.
2
 
The author's suggestion that the work undertaken by 
investigators during the clinical trial process should be 
protected is based on reviewing the different forms of 
legal protection available for intellectual property rights 
(IPRs), analysing the possibility and scope of application, 
and selecting the best form of protection and how it 
might be useful. This article will cover the following 
topics: a brief overview of clinical trials, the various 
types of protection for the IPR and finally, it will 
determine the best form of protection for clinical trial 
data and information.  
II. WHAT ARE CLINICAL TRIALS? 
It seems difficult to imagine our life without clinical trials 
because medicines and drug inventions have been 
developed as a result.
3
 A clinical trial is a process carried 
out in scientific fields to test and study the effects of a 
new medicine by experimenting it on human subjects. 
The aim of the clinical trial is to test the safety and 
                                               
1 Joseph A DiMasi, Ronald W Hansen and Henry G Grabowski, 
'The Price of Innovation: New Estimates of Drug Development 
Costs', (2003) 22 Journal of Health Economics 151. 
2 Tomi Suryo Utomo, 'Pharmaceutical Patent Protection and the 
Introduction of Generic Drugs in Indonesia in the Post-TRIPS Era 
-- Is Patent Law the Only Factor Affecting the Introduction of 
Generic Drugs?', (2011) 42 International Review of Intellectual 
Property and Competition Law, 767. 
3 Sara Fovargue, '"Oh Pick Me, Pick Me"--Selecting Participants 
for Xenotransplant Clinical Trials' (2007) 15 Medical Law Review 
176. 
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medical efficacy of the new drug, and establish it 
advantages and drawbacks, as well as its side effects and 
use.
4
 The European Union Council defines clinical trials 
as: 
any investigation in human subjects intended 
to discover or verify the clinical, pharmacology 
and/or pharmacodynamics effects of one or 
more investigational medicinal products, 
and/or to identify any adverse reactions to 
one or more investigational medicinal 
products and/or to study the absorption, 
distribution, metabolism and excretion of one 
or more investigational medicinal products 
with the object of ascertaining the safety 
and/or efficacy thereof.
5
 
Likewise, the Medicine for Human Use Regulations 2004 
(UK) defines clinical trials as: 
any investigation in human subjects, other 
than a non-interventional trial, intended: (1) to 
discover or verify the clinical, pharmacological 
or other pharmacodynamics effects of one or 
more medicinal products; (2) to identify any 
adverse reactions to one or more such 
products; or (3) to study absorption, 
distribution, metabolism and excretion of one 
or more such products, with the object of 
ascertaining the safety or efficacy of those 
products.
6
 
At the international community level, there are 
numerous legal documents that deal expressly with the 
clinical trial process. The most important one and the 
oldest is the Nuremberg Code, which dates back to the 
Nuremberg trials, when Nazi physicians and researchers 
had been found to conduct medical experiments on 
prisoners and hostages without their consent and 
without any means of compensation or recovery. This 
Code sets out the principles that were embodied in the 
judgement of the Court that decided this case in August 
1947, and these principles were subsequently approved 
by the United Nations in 1948.
7
 
In addition, the Declaration of Helsinki enacted by the 
World Medical Association in June 1964 sets out the 
ethical principles relating to medical research that 
                                               
4Pamela R Ferguson, 'Clinical Trials and Healthy Volunteers' 
(2008) 16; Medical Law Review 24 
5 European Union Directive 2001\20\EC, Part 2 
 – Definitions - (a). 
6 Medicines for Human Use Regulation 2004, Article2(1), clinical 
trials. 
7 Code of Nuremberg 1947, available at: 
<http://history.nih.gov/research/downloads/nuremberg.pdf> 
should be adopted in every clinical research involving 
human subjects.
8
 
Moreover, the European Union Council has adopted 
several directives for member States to manage all 
aspects of clinical trials, including EU Directive 
2001\20\EC and EU Directive 2005/28/EC. 
On the national level, not all countries have adopted 
laws or regulations on organizing and managing the 
clinical trial process. Indeed, there are no legal 
instruments or regulations in some countries governing 
clinical trial-related matters, except largely broad 
provisions in their constitutions or in their national civil 
codes and other related legislations. By contrast, other 
countries, such as the United States of America
9
 and the 
United Kingdom
10
, have a well-organized legal system 
dealing with the clinical trial process. 
Indeed, it is crucial to ensure the legal and medical 
protection of human subjects in medical and scientific 
research, because in a few cases this process may lead 
to death or severe injuries and reactions being 
sustained. Recent examples of clinical trials ending in 
catastrophic results are TGN1412
11
 and Abdullahi v. 
Pfizer.
12
 
                                               
8 Declaration of Helsinki 1964, available at: 
<http://www.wma.net/en/30publications/10policies/b3/17c.p
df> 
9 Mainly, the clinical trials process is governed in the United 
States by the Code of Federal Regulation, Title 21 (Food and 
Drug) and Title 45 (Public Welfare). 
10 The clinical trials' process is governed by the Medicines for 
Human Use regulations 2004 and its amendments. 
11 In 2006, a scientific research centre called 'Parexel' was 
tasked to operate and manage the clinical trials of a new drug 
called 'TGN1412' for a German company for the 
industrialization of medical instruments called 'TeGenero'. The 
new drug was developed for the treatment of rheumatoid 
arthritis and leukaemia. In March 2006, phase I of the clinical 
trial took place involving six of the healthy volunteers in order 
to examine the safety of this drug. After the first dosage, all the 
subjects experienced severe reactions, including multiple organ 
disfunction, and they were then hospitalized in critical care in 
Northwick Park Hospital in London. In June 2006, five of the 
volunteers recovered and left the hospital, while the sixth 
volunteer was in a coma for three weeks and after awakening, 
discovered that he might lose parts of his fingers and toes, 
which had turned black because of the reaction to the drug. For 
more details about this case, see Pamela R Ferguson, 'Clinical 
Trials and Healthy Volunteers' (2008) 16; Medical Law Review 
23; Sara Fovargue, '"Oh Pick Me, Pick Me"--Selecting 
Participants for Xenotransplant Clinical Trials', (2007) 15 
Medical Law Review, 176; MJH Kenter and AF Cohen, 
'Establishing Risk of Human Experimentation with Drugs: 
Lessons from TGN1412' (2006) 368 The Lancet 1387:91. 
12 In this case, a new medicine called 'Trovan' invented in 2002 
by Pfizer, one of the largest pharmaceutical companies in the 
United States, which applied to experiment this drug on 
children in Nigeria. The investigation team selected 200 
children as subjects in this clinical trial, and divided them into 
WIPO-WTO Colloquium Papers, 2015 
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The clinical trials process involves the following steps:  
 Preclinical Testing I: scientists in their 
laboratories predict that certain chemical 
components may be effective in the treatment 
of a certain disease. A series of scientific 
experiments is then conducted in a laboratory 
to understand how those components work 
and what the most suitable chemical form is. 
The resulting information may or may not be 
proved to be useful for the treatment of the 
illness in the subsequent steps. 
 Preclinical Testing II: in this step, scientists and 
researchers test the new components, which 
may be deemed to be useful or not, on 
animals in the laboratories. The aim is to 
examine the safety and medical effects of 
these components on animals that may have 
certain medical features similar to those of 
human beings. If scientists find that the new 
chemical entity could be useful to treat a 
certain disease, they can move to the next 
step and apply for the 'New drug investigation' 
process through the competent administrative 
authority.
13
 
 Clinical trial Phase I: this is considered the first 
step in the clinical trial process. In phase I of 
the clinical trial process, the investigators 
select a limited number of human research 
subjects. The purpose of this phase is to test 
the safety of the new components when used 
on individuals and whether or not they may 
cause severe problems. In this phase, the 
number of research subjects is limited to 
                                                                    
two groups. The investigators used the new drug with the first 
group, while the second used a placebo. As a result, eleven 
children died, six from the first group and five from the second 
one. In addition, a large number of children from the two 
groups experienced severe reactions, including paralysis, 
amnesia, deafness and blindness. The guardians of those 
children brought a case before the US District Court, Southern 
District of New York, requesting legal protection, because Pfizer 
did not abide by the legal rules governing clinical trials 
regarding the necessity of informed consent of the research 
subjects. 
For more details about Abdullahi v. Pfizer, see Dennis M Coyne, 
'International Pharmaceutical Mistrials: Existing Law for The 
Protection of Foreign Human Subjects and a Proposal for 
Reform', (2011) 29 Boston University International Law Journal 
427; Finnuala Kelleher, 'The Pharmaceutical Industry's 
Responsibility for Protecting Human Subjects of Clinical Trials in 
Developing Nations' [2004] Columbia Journal of Law and Social 
Problems 67. 
13 'Understanding the Clinical Research Process and Principles 
of Clinical Research' (HIV/AID Network Coordination), p.9, 
available at: 
<http://www.hptn.org/web%20documents/CIPDocs/CABTraini
ngMaterials/Participant's%20Guide.pdf> 
between five to ten, and they usually receive a 
small dosage of the new drug. 
In most clinical trials, the subjects in this phase are 
healthy volunteers, who agree to participate in the 
study and provide informed consent to this end.
14
 Owing 
to the inherent danger of this step, the investigator and 
his or her team collect detailed data and an up-to-date 
description of the research subjects, in order to 
determine whether to continue with the study or not, 
based on the results obtained during this phase.
15
 
 Clinical trial phase II: if the investigators of the 
clinical trial are satisfied with the results of the 
previous phase, they then move to Phase II of 
the study. In this step the purpose of the trial 
is to examine the medical effects of the drug, 
to determine the proper dosage for treatment 
and to ascertain its side-effects. In this phase, 
the number of research subjects is increased 
to between 50 and 100 subjects.
16
 Selected 
volunteers may be patients or a mix of healthy 
and patient volunteers. The testing method is 
the control group technique, in which the 
volunteers are divided into two groups: the 
first group are given the new drug, while the 
second group are given the placebo. The aim 
of this phase is to test the medical effects of 
the new drug when compared with the 
placebo or the old medicine. If this step is 
completed successfully, the investigators can 
proceed to the next one.
17
 
 Clinical trial Phase III: in this phase, a large 
number of patient volunteers are used to 
establish the safety degree of the drug and its 
medical effect, as well as its side-effects.
18
 The 
number of research subjects that participate in 
this phase may be around 200 patients.
19
 
During all these phases of the trial, the 
progress of all the subjects and the interaction 
of the new drug with their medical situation 
                                               
14 Sara Fovargue, '"Oh Pick Me, Pick Me"--Selecting Participants 
for Xenotransplant Clinical Trials', (2007) 15 Medical Law 
Review,177. 
15 David B Resnik, 'Compensation for Research-Related Injuries: 
Ethical and Legal Issues' (2006) 27 Journal of Legal Medicine, 
265. 
16 Pamela R Ferguson, 'Clinical Trials and Healthy Volunteers' 
(2008) 16 Medical Law Review, 25. 
17 Richard M Cooper, '"Response", a Response to an Article 
Published in the Harvard Law Review", (2008) 121 Harvard Law 
Review Forum, 36; Joseph A DiMasi, Ronald W Hansen and 
Henry G Grabowski, 'The Price of Innovation: New Estimates of 
Drug Development Costs', (2003) 22 Journal of Health 
Economics, 157. 
18 Emma Cave, 'Seen but Not Heard? Children in Clinical Trial' 
(2010) 18 Medical Law Review, 3. 
19 Pamela R Ferguson, 'Clinical Trials and Healthy Volunteers' 
(2008) 16 Medical Law Review, 25. 
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are recorded by the investigators and 
assistance team. All these data must then be 
submitted to the competent authorities, who 
review all the phases of the study and decide 
whether to approve, require revision or reject 
it.
20
 
During these phases, all the collected data and 
information is recorded and analysed by the 
investigators and the team of researchers, who have 
undertaken the clinical research, so as to decide 
whether to continue with the process or not. This critical 
data and information is of high commercial value and 
will be used in subsequent steps of the process and in 
the licencing of the new drug (New Drug Application 
process (NDA)). When deciding to grant a licence for the 
new drug, licencing authorities are required to review 
the clinical trial's protocol and the outcomes of the 
clinical trial phases. 
There is a need to protect all such data for a reasonable 
period of time during and after the clinical trials, and 
during the application of a licence and after it has been 
granted. However, neither the Nuremberg Code nor the 
Declaration of Helsinki expressly provide for protection 
of such data. Similarly, the Food and Drug 
Administration or the Medicines for Human Use 
Regulation are silent on the protection of work 
undertaken by researchers during the clinical trial 
process. 
The often conflicting interests of stakeholders and the 
possible forms of protection for data and information 
collected before, during and after the clinical trial 
process will be discussed below.  
III. CONFLICT OF INTERESTS WITHIN THE CLINICAL 
TRIAL PROCESS 
The clinical trial process embodies a wide range of 
rights, advantages and interests for stakeholders. All 
those involved stand to gain from this process with 
different degrees of interest, including the 
pharmaceutical companies that fund the trial, the 
researchers and investigators that conduct the research, 
the research subjects and the public itself. However, 
these benefits and interests potentially conflict with one 
other.  
The desire to protect data collected during the clinical 
trial process is a clear example of how stakeholders' 
interests might often conflict. Indeed, all the individuals 
                                               
20 Richard M Cooper, '"Response", a Response to an Article 
Published in the Harvard Law Review', (2008) 121 Harvard Law 
Review Forum, 36; Joseph A. DiMasi, Ronald W Hansen and 
Henry G Grabowski, 'The Price of Innovation: New Estimates of 
Drug Development Costs', (2003) 22 Journal of Health 
Economics, 157. 
involved in the clinical trial process have differing 
interests in the data and information collected.  
First, the pharmaceutical companies that sponsor and 
fund the research from its early moments until the 
marketing stage want the protection of all the trial data 
and information to be used exclusively for an extensive 
period of time.
21
 This interest may be understood given 
the economic value of the clinical trial information, 
which gives the sponsor a chance to maximize profit 
from marketing the new drug. 
The process of developing new drugs costs millions of 
dollars
22
 and lasts for a sustained period of time.
23
 In 
order for this process to be profitable, all these 
expenditures need to be protected during the 
development process and for a reasonable period of 
time. Although this point of view somewhat 
contradictory to the strategies adopted in most 
countries, some scholars consider that in order to 
ensure profitability, all data and information from the 
development process should be obscured and kept 
undercover, so as to prevent others from knowing, 
utilizing or exploiting them.
24
 
Second, the researchers and investigators involved in 
the development of the new drug have a scientific 
interest in the clinical trial data and information. The 
work undertaken in laboratories and in research centres 
includes formulating a new chemical entity; 
investigating the new chemical entity in preclinical 
phases on animals; investigating the new chemical 
entity in the phases of the clinical trial on human 
subjects; and observing its medical effect and safety 
after marketing.
25
 The interest of the researchers and 
investigators is reflected in their desire to declare any 
progress achieved in their research and studies, to make 
it public in academic conferences or by publication in 
scientific journals and reviews.
26
 Researchers stand to 
                                               
21 Pamela Andanda, 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
Public Health', (2013) 44 International Review of Intellectual 
Property and Competition Law, 140. 
22 A study in 2010 estimated the values of developing new 
drugs to exceed $1.8 Billion. Steven M Paul and others, 'How to 
Improve R&D Productivity: The Pharmaceutical Industry's 
Grand Change', (2010) 9 Nature Reviews: Drug Discovery, 
supplementary information box2. 
23 The drug development process takes about ten to fifteen 
years to formulate a new chemical entity, to examine its safety 
and efficiency through clinical trials and to apply for the 
necessary licensing and marketing approvals. 
24 Pamela Andanda 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
Public Health' (2013) 44 International Review of Intellectual 
Property and Competition Law, 140. 
25 Carl H Coleman, 'Duties to Subjects in Clinical Research' 
(2005) 58 Vanderbilt Law Review, 387. 
26 Pamela Andanda, 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
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gain from the announcement of the clinical research 
results in terms of their academic and scientific 
careers.
27
 
Third, research subjects have a personal interest not to 
reveal research data and information as the publication 
and announcement of the research results constitute an 
infringement of their confidentiality and privacy, as well 
as exploitation of their personal data for the sake of 
economic profit and scientific reputation. Yet, some 
potential research subjects ask to be clearly aware of 
previous studies in deciding whether to participate in 
the research.
28
 The double standards methodology 
makes it difficult for research subjects to decide 
whether to support or oppose the protection of clinical 
trial data. 
Furthermore, it is in the interest of the public to have 
updated knowledge and access to all data and 
information related to health-care and medicines 
sectors. The principle of access and benefit sharing (ABS) 
with respect to public health means that all studies and 
research in the medical field should be available and 
accessible to the public.
29
 The goal of applying this 
principle is to enhance the ability of workers in the 
medical sector to deal with diseases and to ensure a 
proper degree of welfare for the public. In this regard,  
[…] the struggle to combat human disease and 
to promote health is inherently international 
in character and is recognized as an element of 
maintaining international peace and security.
30
 
As a result of the conflict of interests inherent in the 
clinical trial process and especially when dealing with 
clinical data and information, it could be argued that 
these opposing interests make it difficult to adopt one 
point of view over the other. At the same time, these 
opposing interests pose considerable challenges in 
creating a unified system to address the issue of clinical 
trial data on an equal footing of profit for all 
stakeholders. 
                                                                    
Public Health' (2013) 44 International Review of Intellectual 
Property and Competition Law, 140. 
27 Rachel Kreppel, 'Clinical Trials: A New Form of Intellectual 
Property?'4, available at: 
<http://www.kentlaw.iit.edu/Documents/Academic%20Progra
ms/Honors%20Scholars/2002/Rachel-Kreppel-paper.pdf> 
28 Pamela Andanda, 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
Public Health' (2013) 44 International Review of Intellectual 
Property and Competition Law, 141. 
29 Pamela Andanda, 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
Public Health', (2013) 44 International Review of Intellectual 
Property and Competition Law. 
30 Antony Taubman, 'The International Patent System and 
Biomedical Research: Reconciling Aspiration, Policy and 
Practice' (2008) 10 The American Association of Pharmaceutical 
Scientists Journal, 526. 
IV. WHAT KIND OF DATA SHOULD BE PROTECTED? 
Before and during the clinical trial process, a vast 
amount of data is collected during every phase and 
submitted for the licensing process. Broadly speaking, 
the clinical trial data, which are intended to be 
protected, include
31
: 
 Chemical formulas; 
 clinical trial protocols; 
 files of information provided to potential 
volunteers to clarify their knowledge; 
 data and statistics collected during the various 
phases of the clinical trial; and  
 final research results. 
It should be noted that these are the minimum amounts 
of data which require legal protection. The exact set of 
data differs from case to case according to the type of 
study and its scientific value.
32
 
A. POTENTIAL WAYS TO PROTECT CLINICAL TRIAL 
DATA 
In order to ensure a suitable degree of protection for 
clinical trial data, it is important to determine, firstly, the 
nature of the data and information. Essentially, all the 
data and information collected should be considered a 
form of intellectual property resulting from the mental 
work and efforts undertaken by the researchers and 
investigators involved in the process. Accordingly, the 
best method to protect these data and information 
would be recourse to the legal protection provided for 
IPRs in international conventions and national 
legislations. 
Generally speaking, the different types of IPRs are
33
: 
copyright and related rights; trademarks; geographical 
indications; industrial designs; patents; layout-designs 
(topographies) of integrated circuits; and undisclosed 
information. The TRIPS Agreement and other 
international conventions dealing with IPRs fail to 
                                               
31 Pamela Andanda, 'Managing Intellectual Property Rights Over 
Clinical Trial Data to Promote Access and Benefit Sharing in 
Public Health', (2013) 44 International Review of Intellectual 
Property and Competition Law, 145. 
32 Rachel Kreppel, 'Clinical Trials: A New Form of Intellectual 
Property?' 4, available at: 
<http://www.kentlaw.iit.edu/Documents/Academic%20Progra
ms/Honors%20Scholars/2002/Rachel-Kreppel-paper.pdf> 
33 As stated in the Agreement on Trade Related Aspects of 
Intellectual Property Rights (TRIPS), administrated by the World 
Trade Organization (WTO) 1994. 
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address the protection of clinical trial data.
34
 Hence the 
focus will be on already established IPRs, especially 
those that lend themselves to ensuring suitable 
protection of clinical trial data and information. A 
detailed explanation will follow on the applicability of 
copyrights, patents and undisclosed information to 
clinical trial data. 
Copyright: From the standpoint of the clinical trial 
process, copyright could be used to protect the broad 
range of work undertaken by both researchers and 
investigators, including written reports and statistics, 
published papers on the study's results, and any files 
and documents submitted to the administrative 
authorities as a condition for the application of a licence 
or for marketing approval.
35
 
As stated, protection under copyright could be 
applicable to the work undertaken by investigators in 
the clinical trial process. However, because 
copyrightable works need to be published or made 
available for the public to benefit from copyright 
protection, this type of protection is unsuitable in the 
clinical trial arena. In other words, this work cannot be 
covered by copyright since the goal is to protect the 
work undertaken by investigators during the clinical trial 
process and before arriving at the final results or 
publishing them in conferences or scientific reviews. It is 
well known that in order to protect the data and 
information gathered during the clinical trial process, 
the work must be announced to the public.
36 
Patents: When patent rules are applied to clinical trial 
data, the patent protection may include the new 
chemical entity, the formulation of the new drug, and 
the final results of the study and the manufacturing 
method of this new drug. All these inventions are 
patentable as provided for in the TRIPS Agreement. 
 
In the pharmaceutical industry, both the pharmaceutical 
product itself and the manufacturing process can be 
patented. The application for a patent should therefore 
clearly state the subject matter of the patent 
application, and whether it concerns a new drug or the 
manufacturing process or both, the patent protection 
being restricted to the subject matter of the patent 
application.
37 
 
                                               
34 Jeremy de Beer, 'Applying Best Practice Principles to 
International Intellectual Property Law-making' (2013) 44 
International Review of Intellectual Property and Competition 
Law, 885. 
35 Rachel Kreppel, 'Clinical Trials: A New Form of Intellectual 
Property?' 4, available at: 
<http://www.kentlaw.iit.edu/Documents/Academic%20Progra
ms/Honors%20Scholars/2002/Rachel-Kreppel-paper.pdf> 
36 Article 9/2 of the TRIPS Agreement. 
37 Daiichi Sankyo Co Ltd and Another v. DEMO Anonimos 
Viomikhaniki kai Emporiki Etairia Farmakon [2013] Court of 
By contrast, the following are not patentable: the clinical 
trial's protocol; any data and statistics collected during 
the various phases of the clinical trial; and data and files 
submitted to the authorized licencing agencies.
38
 This is 
normal, because the previous types of clinical trial data 
do not satisfy patent requirements, especially the 
condition of capability of industrial application.
39
 From 
this perspective, sponsors and investigators do not have 
the right, either to have exclusive use of these data 
during the trial, or to prevent others from using, 
exploiting, selling or offering such data for sale. 
In short, patent rights may be used to protect certain 
forms of clinical trial data, but are not applicable to 
other forms due to the absence of patent conditions and 
requirements. 
Undisclosed Information: When the rules of 
Undisclosed Information (UI) are applied to clinical trial 
data, one can say that there is a wide range of data and 
information that may be protected by the UI, including 
the clinical trial's protocol; files and documents made 
available to potential research subjects; files and 
documents submitted to administrative authorities; data 
and statistics on the progress of research subjects; final 
results of the research; and any other information that 
may be useful during the research. 
As this protection, according to UI rules, neither requires 
any administrative procedures nor must last for a 
certain period of time, this valuable information is 
protected as long as it is kept secret. Even when this 
information is submitted to administrative bodies for 
approval and the granting of a licence, it is still 
protected pursuant to paragraph 3 of TRIPS Article 39, 
which provides that:  
Members, when requiring, as a condition of 
approving the marketing of pharmaceutical or 
of agricultural chemical products which utilize 
new chemical entities, the submission of 
undisclosed test or other data, the origination 
of which involves a considerable effort, shall 
protect such data against unfair commercial 
use. In addition, Members shall protect such 
data against disclosure, except where 
necessary to protect the public or unless steps 
are taken to ensure that the data are 
protected against unfair commercial use. 
                                                                    
Justice of the European Union [2013] All ER (D) 262 (Jul), All 
England Reporter, paragraph 84.3. 
38 Rachel Kreppel, 'Clinical Trials: A New Form of Intellectual 
Property?' 4, available at: 
<http://www.kentlaw.iit.edu/Documents/Academic%20Progra
ms/Honors%20Scholars/2002/Rachel-Kreppel-paper.pdf> , 12. 
39 Rachel Kreppel, 'Clinical Trials: A New Form of Intellectual 
Property?' 4, available at: 
<http://www.kentlaw.iit.edu/Documents/Academic%20Progra
ms/Honors%20Scholars/2002/Rachel-Kreppel-paper.pdf>, 12. 
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Pursuant to this article, Member States have a duty to 
maintain and guarantee the confidentiality of the 
information submitted to administrative agencies upon 
application for a licence.
40
 This rule applies where the 
information submitted includes details about a new 
chemical entity, test data or any other secret 
information, if related to a pharmaceutical or 
agricultural licence.
41
 This article provides that, 
administrative bodies, which are authorized to receive 
such data, are obliged to protect the confidentiality of 
this data during the licensing process and after granting 
the licence for the stated period of time.
42
 
The interpretation of this article of the TRIPS Agreement 
raises many legal issues.
43
 Developed Member States 
explain it in their national legislations as it grants the 
right of the exclusive use of the protected data and 
information for the stated period of time. On the other 
hand, developing Member States interpret it as it only 
protects the submitted data from being undisclosed, 
used or exploited by the competitors in a manner which 
is inconsistent with fair competition.
44
 
Another issue related to the application of this article 
concerns the impact on national legislations. This issue is 
related to the second application for the similar 
chemical entity. As a result of protecting the UI of the 
first registration of the new chemical entity, any other 
application for registering a similar entity must submit 
new data and information and cannot rely on the data 
of the previous application. This is the rule adopted by 
developed countries, which aim to control competition 
in the markets of the pharmaceutical industry. On the 
other hand, developed countries will permit the 
registration of the similar chemical entity, which relied 
on the data and information of the previously registered 
chemical entity. This is the rule even when the second 
                                               
40 Jonathan de Ridder, 'Data Exclusivity: Further Protection for 
Pharmaceuticals', available at: 
<http://www.findlaw.com.au/articles/1576/data-exclusivity-
further-protection-for-pharmaceut.aspx> 
41 Sam Ricketson, 'The Future of the Traditional Intellectual 
Property Conventions in the Brave New World of Trade-Related 
Intellectual Property Rights' (1995) 26 International Review of 
Intellectual Property and Competition Law, 890. 
42 Public Citizen Health Research Group v. Food and Drug 
Administration [1997] United States District Court for the 
District of Columbia 
43 Karin Timmermans and Togi Hutadjulu, 'The TRIPS Agreement 
and Pharmaceuticals - Report of an ASEAN Workshop on the 
TRIPs Agreement and Its Impact on Pharmaceuticals' (World 
Health Organization 2000), 39. 
44 Tomi Suryo Utomo, 'Pharmaceutical Patent Protection and 
the Introduction of Generic Drugs in Indonesia in the Post-TRIPS 
Era -- Is Patent Law the Only Factor Affecting the Introduction 
of Generic Drugs?' (2011) 42 International Review of 
Intellectual Property and Competition Law, 768. 
application is made during the period of the protection, 
as long as the first chemical entity was patented.
45
 
The variation in the application of Article 39.3 of the 
TRIPS Agreement among Member States raises many 
practical issues. For instance, Argentinian Courts adopt 
the second point of view to allow other companies to 
use the data and information of chemical entities 
already registered.
46
 
In short, the protection provided for UI under the TRIPS 
Agreement affords protection, first, for valuable secret 
information, as long as it is kept secret; and second, for 
information provided to administrative agencies under 
the licence procedures. 
Consequently, it is apparent from this overview that 
among the potential forms of legal protection for clinical 
trial data and information, not all the types of protection 
are applicable to the various forms of clinical trial 
process data. Consequently, stakeholders need to resort 
to more than one track protection for their work, as 
follows: 
 Chemical formula: patent; 
 clinical protocol: undisclosed information; 
 informed consent files: undisclosed 
information; 
 clinical data and statistics: undisclosed 
information; 
 final results: patent; and 
 published papers and researches: copyright 
Although UI seems to be the best technique, it only 
covers two types of data, namely, (1) secret data and 
statistics collected during the trial itself, and (2) data 
and statistics provided to administrative agencies for 
licence and approval.
47
 
                                               
45 Karin Timmermans and Togi Hutadjulu, 'The TRIPS Agreement 
and Pharmaceuticals - Report of an ASEAN Workshop on the 
TRIPs Agreement and its Impact on Pharmaceuticals' (World 
Health Organization 2000), 39. 
46 Novartis Pharma AG v. Monte Verde SA and Varios Propiedad 
industrial e intellectual, the Federal Civil and Commercial Court 
of Appeals in Argentina, Case No. 5.619/05. See text below to n 
55. 
47 Undisclosed information is considered the best technique to 
protect researchers' work during the clinical trials' process as a 
result of the express protection provided by Article 39.3 of the 
TRIPS Agreement. See Jonathan de Ridder, 'Data Exclusivity: 
Further Protection for Pharmaceuticals', available at: 
<http://www.findlaw.com.au/articles/1576/data-exclusivity-
further-protection-for-pharmaceut.aspx>(n 39). 
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Therefore, the UI remains for information already 
registered such as a chemical formula or published 
information such as final research results, which should 
be covered by other forms of IPRs. In addition, the UI is 
inapplicable in cases related to the approval of similar 
pharmaceutical products. 
In Novartis Pharma AG v. Monte Verde SA & Varios 
Propiedad industrial e intellectual, under Argentine 
Confidentiality Act No. 24,766, the right of 
confidentiality is granted to the first pharmaceutical 
product applied for only and the information from any 
subsequent application containing similar ingredients is 
made available for public use. The Argentine Law 
provides that such data is not required to be protected 
where similar products have been approved in one of 
the other countries.
48
 Hence, even in the case of 
applying Article 39.3 of the TRIPS Agreement regarding 
the protection of data submitted to licenced authorities, 
the UI remains a problematic issue. 
The proposed solution in this case is the creation of a 
new form of protection under the umbrella of IPRs, in 
order to cover the mental work undertaken by 
researchers and investigators during the clinical trial 
process from A to Z. The proposed form of protection 
called Clinical Trials Rights (CTR) would provide the 
following set of rights for stakeholders in the clinical trial 
process: 
B. PROPOSED FORM OF PROTECTION: THE CLINICAL 
TRIAL RIGHT  
As stated, this Paper proposes the CTR as a form of IPR 
that would protect the work undertaken by investigators 
and researchers during clinical trials. The CTR would 
provide stakeholders with the following rights: 
 The right to protect all data and information 
used, submitted or resulting from the clinical 
trials process against unfair competition: 
according to this right, the government 
would be responsible for providing a wide 
range of protection for work performed by 
investigators against any form of exploitation 
or misuse by other competitors in the field of 
drug development. Governments, in this 
regard, would be required to impose criminal 
sanctions i.e. fines and imprisonments, for 
violators of the protected CTR. 
 The right to maintain the confidentiality of 
the registered data for a certain period of 
                                               
48 Jorge Otamendi, 'Confidential Data in the Approval of a 
"Similar" Pharmaceutical Product' No. 19, July 2011, available 
at: 
<https://www.aippi.org/enews/2011/edition19/Pharmaceutica
l_Product.html> 
time: the government administrative 
agencies responsible for receiving requests 
for licensing of the new drugs are obliged to 
maintain the confidentiality of the submitted 
data and information. This obligation lasts for 
a certain period of time to be expressly 
determined by national legislations. 
Accordingly, in case of negligent infringement 
to this right by the administrative agency, a 
remediable compensation would be paid to 
the owner of the CTR. Nevertheless, in case 
of intentional infringement by the 
responsible officials at the administrative 
agency or by other competitors, a criminal 
sanction would be imposed.
49
 The aim of this 
right is to ensure a suitable degree of 
protection for data and information 
submitted to the licencing body, in order to 
guarantee effective protection against unfair 
competition in the drug development 
market. 
 The right to exclusive use of the registered 
data for a certain period of time: as a result 
of granting the CTR to the sponsor of the new 
drug, both the latter and the investigators 
should have the right to exclusive use of the 
clinical trial data and information. This 
exclusive right includes using the data before, 
during and after the trial, as long as the 
period of the protection is still running. The 
duration of the protection should cover the 
various phases of the trial, as long as it did 
not exceed ten years. Such protection 
terminates after the declaration of the final 
results or after a lapse of ten (10) years, 
whichever is shorter. In case of intentional 
infringement of this right, a remediable 
compensation and a criminal sanction should 
be imposed. 
 The right to prevent others from using or 
exploiting the registered data or for applying 
for a licence for a certain period of time. The 
foregoing right of exclusive use of the clinical 
trial data entails the right of the owner to 
prevent others from using or exploiting this 
data and to apply the required procedures in 
case of any infringement. This right also 
prevents others from applying to conduct 
clinical trials for the new drug as long as it is 
proved that the data utilized were obtained 
                                               
49 The intentional infringement of the CTR takes the form of 
disclosing, acquiring, using or exploiting such information by 
other competitors without the consent of the owner in a 
manner contrary to honest commercial practices. It may also 
take the form of facilitating the disclosure, use or exploitation 
of the information by the employee, who is responsible for its 
confidentiality. 
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by illegal means. The governmental body that 
grants the CTR should provide the CTR owner 
with all the necessary means to benefit from 
this right and to prevent others from 
minimizing or limiting such benefit. 
The advantages of the CTR as a form of IPR are that it 
would provide a wide range of protection for clinical 
data before, during and after the trials. This protection 
would cover all forms of data and information used and 
resulting from the trials. This right would also be granted 
by a specialized governmental agency, which reviews 
the request for protection, grants the CTR and protects 
it against any unauthorized use by other competitors. 
With regard to the governmental body which grants the 
CTR, a specialized agency should be established to deal 
with all matters related to this new right. This agency 
would have the authority to: 
 Revise the request to obtain the CTR; 
 register the protected data and information; 
 grant the CTR to the sponsor of the drug 
development process; 
 grant the licence for exclusive use of the registered 
data and information; 
 create a registry of all protected drug development 
processes and protected data from each process; 
 follow precautionary procedures to ensure the 
required protection of registered data and 
information; and 
 apply the procedures for prosecution of violators of 
the CTR. 
All details relating to the authorities and structure of the 
granting agency should be clearly mentioned in national 
legislations, according to the administrative system of 
each country.  
Concerning the protection of data and information from 
failed clinical trials, the CTR aims to protect the work 
performed by investigators during clinical trials in order 
to allow them to benefit from their efforts after 
declaration of the final results. However, what is the aim 
of such protection if the clinical trial failed and the 
sponsor has declared its termination? In other words, 
what is the effect of declaration of the failure of the 
clinical trial on the conferred CTR? 
Declaration of the failure of a clinical trial leads to the 
termination of the CTR granted and results in the 
possibility of registration of new trials to benefit from 
the protection under the CTR. However, what is the 
legal situation of the ex-protected data and 
information? Are they still covered by the CTR or do 
they lose such protection and become available for 
public use? 
Dealing with ex-protected data results in a conflict of 
interest between the owner of such data and other 
competitors who stand to gain from the protection 
under the CTR. On the one hand, the owner of the ex-
protected data would clearly like to maintain protection 
as long as possible to preserve the efforts of the 
investigators during the period that preceded the clinical 
trial's declaration of failure. On the other hand, other 
competitors would like to have the ex-protected data 
made available for public use, in order to improve the 
work undertaken previously and benefit from any flaws. 
Clearly, it would be unfair if the ex-protected data are 
disclosed and made available for public use, as the 
sponsor and the investigators would not benefit from all 
their efforts. It would also be unfair to provide 
protection for failed clinical trials and prevent other 
competitors from benefiting from such protection, 
signifying that the failed trial is still protected. 
To resolve these conflicting interests, a special mode of 
protection should be adopted. In fact, the ex-protected 
data should be covered by the CTR, even after the 
declaration of the clinical trial's failure, however, this 
protection should last for three (3) years only from the 
date of the declaration. During this period, it should be 
prohibited to disclose, sell, use or exploit the ex-
protected data without the consent of the owner. Other 
competitors would then have the right to register new 
clinical trials (of the same type) to be protected by the 
CTR as long as the submitted data and information stem 
from personal efforts of the investigators of the new 
trial. 
After the expiry of the three-year period, the ex-
protected data would be disclosed and made available 
for public use. 
At the end of the clinical trials and after the final result is 
declared, the CTR would terminate and all the protected 
data and information should be disclosed to the public. 
Such a disclosure is part of the procedures for protecting 
new drugs through the patent system. 
V. CONCLUSION 
The clinical trial process differs from other types of 
mental works, since more than one form of IPR is 
required to ensure a suitable degree of protection. The 
CTR is a proposed as a form of protection covering any 
data and information provided or used during the drug 
development process or resulting from it. The CTR 
would cover any work performed by investigators 
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before and during the trial. After the termination of the 
clinical trial and declaration of the final results, the CTR 
would to an end and the new drug would be protected 
by patent rights, if applicable. The CTR would last for a 
specific period of time or for the completion of the trial, 
whichever is shorter. 
Ultimately, this new form of protection for clinical trial 
data and information would encourage investments in 
the field of pharmaceutical inventions, while ensuring an 
effective process for the circulation of information. It 
would also ensure a balance of benefits between the 
sponsor and the investigators on the one hand, and 
other competitors on the other, as well as, enhancing 
pharmaceutical research and industries. 
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5 ENFORCEMENT OF INTELLECTUAL PROPERTY 
LAW: SOME ASPECTS OF TRADE IN COUNTERFEIT 
GOODS IN THE FORMER YUGOSLAV REPUBLIC OF 
MACEDONIA 
 
Dr Katerina Tosevska-Trpcevska 
ABSTRACT 
This paper examines the enforcement of the 
customs law of the Former Yugoslav Republic of 
Macedonia on the protection of intellectual property 
rights (IPRs). The Customs Administration has the 
main role in the enforcement of intellectual property 
rights and in hampering the trade of counterfeit 
goods in the country. In order to step up the fight 
against trade in counterfeit goods and the protection 
of intellectual property rights in 2015, a new Law on 
Customs Measures for the Protection of Intellectual 
Property Rights was enacted. In addition, the 
number of registered customs officers that use the 
World Customs Organization (WCO) Interface Public-
Members Platform has steadily risen. As a result of 
the increased involvement of the customs 
community in the protection of intellectual property 
rights, more goods have been temporarily retained 
under suspicion of violating intellectual property 
rights. This paper also highlights the rise in the sale 
of counterfeit products on the Internet, and the 
need for enhanced international cooperation in this 
area.  
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I. INTRODUCTION 
Counterfeit and pirated goods are being produced 
and consumed in virtually all economies in the 
world. In recent years there has been an alarming 
expansion of the types of products being infringed, 
from luxury items, such as watches and designer 
clothes, to personal health and safety items, such as 
pharmaceutical products, food and drinks, medical 
equipment, personal care items, toys, tobacco and 
automotive spare parts. 
 
It might not be such an issue if this increase 
represented a small portion of world trade. Although 
it is difficult to quantify the volume of counterfeit 
products, and the data obtained from customs 
seizures of infringing products does not reflect the 
overall number of counterfeit products in the world, 
it is still possible to obtain a general overview based 
on available data. An OECD study on trade in 
counterfeit and pirated goods in 2007 concluded 
that this trade might have accounted for as much as 
US$ 200 billion in 2005.
1
 The updated estimates 
based on the growth and changing composition of 
trade between 2005 and 2007, suggest that 
counterfeit and pirated goods in international trade 
grew steadily over the period 2000 to 2007 and 
could have attained US$ 250 billion in 2007. The 
share of counterfeit and pirated goods in world 
trade is estimated to have raised from 1.85 per cent 
in 2000 to 1.95 per cent in 2007.
2
 For the sake of 
clarity, the data regarding counterfeit and pirated 
products do not include domestically produced and 
consumed products or non-tangible pirated digital 
products. 
 
The latest report on illicit trade by the World 
Customs Organization also indicates that there is a 
significant increase in the number of cases of goods 
suspected of infringing intellectual property rights or 
failing to meet national standards.
3
 Among the 
countries that have reported the highest number of 
cases are the United States in first place with 33.63% 
of all cases, followed by Saudi Arabia, Italy, Germany 
and Japan. An analysis of the countries which 
reported the highest number of intercepted pieces, 
shows a drastic change, with Angola ranked first, 
followed by the Democratic Republic of Congo, Togo, 
Saudi Arabia and Madagascar. 
4
 
                                               
1 OECD, The Economic Impact of Counterfeiting and Piracy: 
Executive Summary (OECD 2007).  
2 OECD, Magnitude of Counterfeiting and Piracy of Tangible 
Products: An Update (OECD 2009). 
3 WCO, Illicit Trade Report 2013 (World Customs 
Organization 2014). 
4 WCO, Illicit Trade Report 2013 (World Customs 
Organization 2014). 
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A snapshot of the structure of intercepted 
commodities reveals that more than half of the 
reported intercepted goods were illicit 
pharmaceutical products, followed by counterfeit 
electronic appliances and illicit foodstuff – all of 
which threaten consumer health and safety.
5
 This 
sharp increase in counterfeit products that endanger 
health and safety of consumers highlights the 
importance of the fight against counterfeit products 
and underlines the need for customs organizations 
to demonstrate their preparedness and dedication.  
 
The aim of this paper is to provide an overview of 
the enforcement of intellectual property law in the 
Former Yugoslav Republic of Macedonia with a focus 
on trade in counterfeit goods. To this end, it is 
important to elaborate on the provisions of the Law 
on Customs Measures for Implementing Protection 
of Intellectual Property Rights. This law was enacted 
in 2015 for the purpose of replacing the Law on 
Customs Measures for the Protection of Intellectual 
Property Rights first enacted in 2005 and amended 
in 2007, 2011 and in 2013. There is also a Manual 
(Book of Rules) for implementation of the Law on 
Customs Measures for Protection of Intellectual 
Property Rights from 2013. 
 
II. PROTECTION OF INTELLECTUAL PROPERTY 
RIGHTS IN THE FORMER YUGOSLAV 
REPUBLIC OF MACEDONIA  
 
After its independence in 1991, the Former Yugoslav 
Republic of Macedonia became a member of the 
World Intellectual Property Organization (WIPO) the 
same year. Some laws concerning the protection of 
intellectual property were enacted afterwards, but, 
after becoming a Member of the World Trade 
Organization (WTO) in 2003, the country was obliged 
to abide by the rules of the TRIPS Agreement. Since 
then, the country has enacted its main intellectual 
property laws on industrial property, on copyright 
and related rights, on breeder's rights and on 
protection of topographies of integrated circuits, 
along with several implementing rules and 
regulations. Besides those, a few IP-related laws 
have been enforced, including the Law on Customs 
Measures for Implementing Protection of 
Intellectual Property Rights (replacing the Law on 
Customs Measures for the Protection of Intellectual 
Property Rights), the Customs code with its 
amendments, the Code of Criminal Procedure, the 
Penal Code and the Law on Administrative Fees. 
 
                                               
5 WCO, Illicit Trade Report 2013 (World Customs 
Organization 2014). 
III. LAW ON CUSTOMS MEASURES FOR 
IMPLEMENTING THE PROTECTION OF 
INTELLECTUAL PROPERTY RIGHTS 
 
The enacting of the new Law on Customs Measures 
for Implementing Protection of Intellectual Property 
Rights is in line with the new European Union 
Regulation No. 608/2013. The previous Law on 
Customs Measures for Protection of Intellectual 
Property Rights was in line with the old EU 
Regulative No. 1383/2003. Moreover, the new law 
on implementing protection of intellectual property 
rights is harmonized with the new system for 
processing customs declarations and excises 
documents (CDEPS) of the Customs Administration. 
6
 
 
The Law on Customs Measures for Implementing 
Protection of Intellectual Property Rights regulates 
the customs procedures for taking action when there 
is reasonable suspicion that certain goods are 
violating intellectual property rights. According to 
this Law, goods that are under suspicion for violating 
intellectual property rights are defined as goods 
that: 
 
(a) Are the subject of actions that violate 
intellectual property rights; 
 
(b) represent devices, products or 
components which are primarily made for 
or adapted in order to allow avoidance of 
any technology, device or components 
which in their ordinary activities prevent or 
limit the activity not authorized by the 
holder of certain copyright or related right 
and which is connected to activity that 
violates those rights; 
 
(c) Represent any mould or matrix specially 
designed or adjusted for the production of 
goods that violate intellectual property 
rights, if the usage of those moulds or 
matrixes violates intellectual property 
rights.
7
  
 
The Law also defines counterfeit and pirated goods. 
'Counterfeit goods' are defined as:  
 
(a) goods that violate the right of the 
trademark when, without the consent of 
the holder of the right, the goods bearing 
an identical trademark sign with a certain 
registered trademark sign, or the goods 
                                               
6 Customs Administration, Report: Second Quartile 2015 
(CARM 2015). 
7 Law on customs measures for implementing protection of 
intellectual property rights 2015 art 4. 
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cannot be differentiated according to the 
essential features of that trademark;  
(b) goods violating the right of geographical 
indication when bearing or being described 
with a name or term protected in the 
sense of geographical indications; and  
(c) the shape of the goods or packaging, 
labels, brochures, instruction manuals, 
warranty documents or similar elements, 
even though separated from the goods, is 
subject to violation of the right of 
trademark or geographical indication, and 
when containing a sign (including: logo, 
words, letters, numbers, pictures, 
drawings, combination of colours, three 
dimensional forms and their 
combinations), name or term identical to 
the valid and registered trademark or 
protected geographical indication, or 
whose essential characteristics cannot be 
differentiated from that of the 
geographical indication.
8
  
'Pirated goods' are goods that violate copyright or 
related rights or design right and are made or 
contain copies made without the consent of the 
owner of copyright or related right or design right of 
the person authorized by the owner of the right in 
the country of production.
9
 
According to the new Law on Customs Measures for 
Implementing Protection of Intellectual Property 
Rights, the Customs authorities may postpone the 
clearance of the goods or may retain the goods after 
accepting the claim by the holders of intellectual 
property rights or when they have reasonable doubt 
that certain goods may violate IP rights acting 'ex 
officio'.  
 
The Law first acknowledges a situation where 
holders of an intellectual property right file a claim 
with the customs authorities to undertake 
appropriate customs measures to deal with certain 
goods. The customs authorities may accept or deny 
the claim for undertaking customs measures with 
respect to the goods. If they accept the claim they 
may postpone the clearance of the goods or may 
retain the goods.
10
  
 
The customs authorities may postpone the clearance 
or retain the goods before accepting the claim from 
                                               
8 Law on customs measures for implementing protection of 
intellectual property rights 2015 Article 4. 
9 Law on customs measures for implementing protection of 
intellectual property rights 2015 Article 4. 
10 Law on customs measures for implementing protection 
of intellectual property rights 2015 Articles 11 and 12. 
the holders of the rights if they identify goods under 
suspicion as violating intellectual property rights. 
When acting 'ex officio', Customs authorities should 
inform the holder of the intellectual property right of 
the possible infringement and await the official filing 
of complaint by the holder. If the holder of the 
intellectual property right does not file a complaint 
for IP infringement within four working days, the 
Customs authorities may release the retained 
goods.
11
  
 
The holder of the intellectual property right should 
inform the Customs authorities within ten working 
days if the goods retained violate intellectual 
property rights. If the holder of the intellectual 
property right confirms violation, the goods may be 
destroyed under customs supervision.
12
 
 
The Law prescribes fees for persons and legal 
entities that violate certain provisions of the law, 
among which the highest are the fees of 2,500 to 
5,000 euros for the legal entity and fees of 500 to 
1000 euros for persons that seek to import or export 
goods that violate the right of the same trademark 
as the goods previously seized from them.
13
 
 
IV. CUSTOMS ENFORCEMENT OF THE PROTECTION 
OF INTELLECTUAL PROPERTY RIGHTS  
 
Customs administration has the main role in 
enforcing intellectual property rights and in 
hampering trade in counterfeit goods in the Former 
Yugoslav Republic of Macedonia. The Law on 
Customs Measures for Implementing Protection of 
Intellectual Property Rights prescribes a fast and 
efficient procedure for enforcement of the 
protection of intellectual property rights, and there 
are also several applicable tools. 
 
In 2013, in order to improve the fight against trade 
in counterfeit goods and the protection of 
intellectual property rights, the Customs 
administration provided a manual for electronic 
evidence to be used in the process for protection of 
intellectual property rights. The aim of this evidence 
is to obtain a systematized and structured database 
to enable access to goods temporarily retained 
under suspicion of violating intellectual property 
rights and a detailed control of the registered 
trademarks.
14
  
 
                                               
11 Law on customs measures for implementing protection 
of intellectual property rights 2015 Articles 7 and 20. 
12 Law on customs measures for implementing protection 
of intellectual property rights 2015 Article 26. 
13 Law on customs measures for implementing protection 
of intellectual property rights 2015 Articles 37-39. 
14 Customs Administration, Annual Report 2013 (CARM 
2014). 
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The Customs administration has also provided a 
User's manual for working with the World Customs 
Organization platform for the protection of 
trademarks and intellectual property rights. This so-
called Interface Public Members (IPM) platform is an 
effective online anti-counterfeiting tool that enables 
crucial information to be exchanged in real time in 
order to intercept counterfeited goods. Increasingly 
attracting more countries, Interface Public Members 
now hosts customs officers from more than 85 
member countries.
15
 
 
From the basic functionality of a database for 
genuine and fake products, featuring pictures and 
basic descriptions of products, the IPM has 
developed into a more complex system offering 
additional options, including the ability to send alerts 
to customs officers, an e-learning feature and a 
mobile application launched in 2014. Today the IPM 
tool has been redesigned and the two versions of the 
web and mobile platforms were made available in 
September 2015.
16
 The number of right holders to 
join IPM is also encouraging with over 700 brands 
covering a wide range of industry sectors from 
pharmaceutical, foodstuffs and pesticides to fast-
moving goods and luxury items.  
 
The number of registered customs officers that use 
the IPM platform in the Former Yugoslav Republic of 
Macedonia has steadily grown. The latest report 
shows that 530 customs officers have been 
registered of which 328 have been active users of 
the database.
17
  
 
Besides the increased awareness among customs 
officers in the country of the importance of 
protecting intellectual property rights, the 
awareness of the business community has been 
growing, alongside the trust in the activities of the 
customs organization. The number of registered 
applications for customs protection of trademarks 
has been steadily growing. At the end of 2012, 222 
applications were registered with the Customs 
administration for the protection of intellectual 
property rights. In 2013 334 applications were filed, 
in 2014 there were 345 and in the first six months of 
2015 308 applications were filed for the protection 
of intellectual property rights.
18
  
                                               
15 WCO launches the new IPM platform 
<www.wcoipm.org/news/wco-launches-the-new-ipm-
platform/> assessed 27 October 2015. 
16 WCO launches the new IPM platform 
<www.wcoipm.org/news/wco-launches-the-new-ipm-
platform/> assessed 27 October 2015. 
17 Customs Administration, Report: second quartile 2015 
(CARM 2015). 
18 Customs Administration, Annual Report 2013 (CARM 
2014) and Customs Administration, Report: second quartile 
2015 (CARM 2015). 
As a result of the increased involvement of the 
customs community in the protection of intellectual 
property rights, there is a rise in the number of 
pieces of goods that have been temporarily retained 
under suspicion of violating intellectual property 
rights. In 2013 the Customs administration retained 
333,799 pieces of goods; in 2014 in 157 actions 
Customs authorities retained 945,302 pieces and 
768 kg of goods; and in the first six months of 2015 
587,455 pieces and 350 kg of goods were retained 
under suspicion of violating intellectual property 
rights.  
Table 1. Goods retained temporarily in 2013, 2014 
and from January to June 2015 
 Type of 
products 
unit 2013 2014 Jan-June 
2015 
1 Apparel, 
accessories 
and related 
materials 
pieces 17,960 200,864 9,769 
2 Footwear and 
accessories 
pieces 36,321 32,419 2,019 
3 Perfumes, 
deodorants, 
cosmetics 
pieces         
kg 
19,041 546,317,           
768 
77,224              
350 
4 Telephones, 
IT, audio, 
video, parts 
and 
equipment 
pieces 10,745 7,876 742 
5 Spare parts 
and 
equipment 
pieces 18,662 1,208 1,861 
6 Medicines pieces 80   
7 Other pieces 23,0990 156,618 495,840 
 Total pieces         
kg 
333,799 945,302             
768 
587,455              
350 
Source: Customs Administration, Report: second quartile 2015 
(CARM 2015) and Customs Administration, Annual Report 2013 
(CARM 2014). 
From the structure of the seized goods it is obvious 
that textile products and apparel usually dominated, 
except in 2014, when cosmetic products with 58 per 
cent of the goods were temporarily retained. These 
products were followed by shoes, phones, IT 
equipment and car accessories. 
If we analyse the origin of the goods that have been 
temporary retained, it should be acknowledged that 
until 2014 the counterfeited goods usually originated 
from China. By contrast, in 2014, 63 per cent of the 
goods temporarily retained originated from Turkey. 
The trend continued in the first six months of 2015, 
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when 68 per cent of the goods also originating from 
Turkey.
19
  
 
According to analyses undertaken by the Customs 
administration, the counterfeit goods retained in the 
country were directed to the domestic market or 
were transiting to Kosovo and the Republic of 
Serbia.
20
  
 
Every year the Customs administration organizes 
actions for destroying counterfeit goods or, in 
coordination with the representatives of trademark 
holders, donates seized goods to socially vulnerable 
families.  
 
The Customs administration of the country is 
constantly involved in international activities, 
projects and operations under the auspices of the 
World Customs Organization and shares information 
about trade in counterfeit and pirated goods with 
other customs administrations and international 
organizations.  
 
The efforts of the Customs administration aimed at 
protecting intellectual property rights were 
recognized in 2009 by the Yolanda Benitez Trophy 
awarded by the World Customs Organization as the 
best customs organization in the world in combating 
counterfeiting and piracy.  
 
In 2014 the Customs administration developed an 
action plan for the protection of intellectual property 
rights for the period from 2014 to 2016. The new 
action plan involves several measures aimed at 
enhancing the protection of intellectual property 
rights, namely: enhancement of the regulatory 
framework in line with the new regulation of the 
European Union; enhancement of the risk 
management system; enhancement of the customs 
controls and surveillance of border crossing points 
and inside the country; enhancement of the customs 
intelligence system; enhancement of the training 
system employees; enhancement of the cooperation 
with domestic and international institutions and with 
the business community; further enhancement of 
transparency for the protection of intellectual 
property rights; and continued application of the 
WCO IPM platform.
21
  
 
 
                                               
19 Customs Administration, Report: second quartile 2015 
(CARM 2015). 
20 Achievements of the Customs Administration of the 
Former Yugoslav Republic of Macedonia in combating 
counterfeiting and piracy (presentation from the Customs 
Administration 2014). 
21 Customs Administration, Action Plan for Protection of 
Intellectual Property Rights for the period 2014-2016 
(CARM 2014). 
V. ONLINE SALE OF COUNTERFEIT GOODS 
 
Distribution channels for counterfeit and pirated 
products are expanding. Previously, counterfeit and 
pirated goods were largely distributed through 
informal markets, but nowadays these products are 
infiltrating legitimate supply chains. Additionally, the 
Internet has provided counterfeiters and pirates 
with a new and powerful means to sell their 
products through auction sites, stand-alone 
commercial websites and email solicitations. The 
online environment is attractive to counterfeiters 
and pirates for a number of reasons, including the 
relative ease of deceiving consumers and the market 
reach.
22
  
 
There are several factors that are driving the usage 
of Internet by counterfeiters and pirates. Anonymity 
or the ease with which counterfeiters and pirates 
can conceal their true identity and limit the risk of 
detection is one of the driving factors. Another 
factor is the flexibility or possibility to establish, take 
down or move online sites quickly and to 
jurisdictions where legislations and enforcement of 
intellectual property rights are weak. An important 
factor that enables the use of the Internet by 
counterfeiters and pirates is the size of the market 
or the huge number of e-commerce sites and 
volume of listings that makes it difficult for right 
holders and enforcement agencies to identify and 
respond to their actions. The Internet provides 
sellers with a means to reach a global audience at 
low cost and offers an opportunity to expand sales 
and market reach. Another important factor that 
drives the use of the Internet by forgers is the ability 
to use readily available software and images that can 
facilitate deception of consumers by creating a false 
sense of security.
23
 The evasive role of the Internet 
has flooded new channels that drive the use by 
counterfeiters and pirates, amongst which are the 
increasingly used apps and social media platforms. 
 
The Former Yugoslav Republic of Macedonia hosts 
the premises of the Internet Monitoring Team of 
REACT, a non-for-profit organization with over 20 
years of experience in the fight against counterfeit 
trade with 200 members in more than 65 countries 
in the world. The REACT Internet Monitoring 
Programme is designed specifically to meet the 
needs of intellectual property right holders. The 
programme is founded on six pillars: monitoring and 
removal of advertisements from some 200 auction 
platforms worldwide; worldwide search and removal 
of web shops (B2B exchanges, e-commerce sites and 
search engines); monitoring and removal on social 
                                               
22 OECD, The Economic Impact of Counterfeiting and Piracy: 
Executive Summary (OECD 2007). 
23 OECD, The Economic Impact of Counterfeiting and Piracy: 
Executive Summary (OECD 2007). 
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media platforms like Facebook, Instagram, YouTube, 
Weibo and Twitter; monitoring and removal of 
infringing apps, including in ITunes store and Google 
play; monitoring and removal of unauthorized use of 
trademark keywords; and monitoring and removal of 
unauthorized use of trademarks in (sub)domain.
24
  
 
The REACT Internet Monitoring Programme offers 
advantages such that after identification of an 
Internet case follow up can take place through 
practical and law enforcement actions such as 
making test purchases; investigating registrants or 
any other connected addresses; initiating raids; 
blocking payments (PayPal, Master card, Visa); 
providing cluster analysis; localizing big traders and 
finding links to their Internet shops; initiating legal 
action through local lawyers and investigators; 
removal of search results from search engines; and 
domain dispute procedures.
25
 
Table 2. Number of auction pages removed in the 
period 2006-2014 
 
Source: REACT (data are obtained directly through e-mail) 
The dedication of the REACT Internet Monitoring 
Programme in the fight against global trade in 
counterfeit goods has resulted in success as 
reflected in Tables 2 and 3. Table 2 above gives the 
results from the number of auction pages that have 
been removed from the Internet during the period 
observed from 2006 to 2014. It shows that in the 
beginning, in 2006, 32,807 auction pages were 
removed from the Internet. There has been a steady 
rise in the number of pages removed as reflected in 
the sharp increase in 2011 when 448,508 pages were 
removed and especially in 2014 when 1,125,711 
auction pages were removed from the Internet by 
the REACT Internet Monitoring Team. The data 
might appear to be encouraging, but also indicate 
there has been a sharp rise in the usage of the 
Internet to sell counterfeit products. 
                                               
24 React, Service Guide 2015-2016 (SNB-REACT 2015/2016). 
25 React, Service Guide 2015-2016 (SNB-REACT 2015/2016). 
Table 3 below shows the number of commercial 
pages that have been reported as infringing 
intellectual property rights and the number of 
commercial pages that have been successfully been 
removed from the Internet because of IPR 
infringement in the period from 2009 to 2014. The 
data reflects the success of the team in the 
prevention of the online sale of counterfeit products, 
as exemplified by the fact that in 2014 more than 
20,000 webpages were removed from the Internet 
because of infringement of intellectual property 
rights. But again it must be stressed that these 
results are relative since it is expected that there will 
be an even sharper increase in the usage of 
commercial pages for the sale of counterfeit 
products and other deception practices with regard 
to consumers. 
Table 3. Number of commercial pages removed in 
the period 2009-2014 
 
Source: REACT (data are obtained directly through e-mail) 
 
From data obtained from REACT, two main 
conclusions can be formulated. First of all, it should 
be recognized that REACT is waging a serious, 
dedicated and successful fight against traders of 
counterfeit products as reflected by these results. By 
contrast, it should be recognized that the online sale 
of counterfeit products is flourishing throughout the 
world and different counterfeit products can reach 
consumers at every single point in the world. 
Although some may put into perspective the 
importance of the fight against the online sale of 
counterfeit products because such sales are usually 
via postal packages and for personal usage, the 
importance of this fight must be stressed because of 
the allegations of the representatives of 
pharmaceutical companies. At the last national 
seminar organized in the Former Yugoslav Republic 
of Macedonia on the fight against counterfeiting and 
piracy, under the auspices of the World Customs 
Organization and the Customs Administration of the 
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country, according to the representative of one 
pharmaceutical company, about 90 per cent of the 
medicines that were sold online were counterfeit.  
 
Based on these declarations and the results of the 
report of the World Customs Organization that more 
than half of the seized goods were illicit 
pharmaceuticals, it should be noted that there has 
been a sharp rise in commodities endangering the 
health and safety of consumers. The report confirms 
the seriousness of the issue relating to the online 
sale of counterfeit products and acknowledges the 
pressing need to undertake proactive action. 
 
In this respect, the organizations dealing with the 
online sale of counterfeit products offer 
standardized services such as removing commercial 
and auction pages; locating big sellers; comparing 
data and defining clusters; and creating local cases 
and investigations, but they also face serious 
problems. Some of the problems include fraudulent 
identifies, protected personal data or simply dealing 
with uncooperative Internet service providers. This 
has led these organizations to provide additional 
services such as local research, buying samples, 
blocking the payment systems, and performing 
additional investigations.
26
  
 
In short, it is crucial that those involved in the fight 
against the online sale of counterfeit products be 
provided with the appropriate means and tools to 
deal with abuses, supported by international 
cooperation. 
 
VI. CONCLUSION 
 
Based on the presentation of certain aspects of the 
enforcement of intellectual property rights and the 
customs measures applied in the fight against trade 
in counterfeit products, it can be concluded that the  
Customs administration is serious and dedicated to 
enforcing protection of intellectual property rights in 
the country. Protection of intellectual property rights 
has been one of the highest priorities of the Customs 
administration. The administration has constantly 
been working towards improving the legal 
procedures and regulations resulting in the 
enactment of a new Law on Customs Measures for 
Implementing Protection of Intellectual Property 
Rights in line with the new Regulation of the 
European Union. 
 
The protection of intellectual property rights should 
be enforced through fast and efficient procedures 
prescribed by the Law on Customs Measures for 
Implementing Protection of Intellectual Property 
Rights and by the usage of several applicable tools. 
                                               
26 Mufisovski, E, React – Association for the Fight against 
Counterfeit Products, presentation in Skopje, 2015 
Among the tools that are used, the Interface Public-
Members platform designed by the World Customs 
Organization to ease the global fight against 
counterfeit products deserves special attention. The 
number of registered customs officers that use the 
Interface Public-Members platform in the country 
has been steadily growing. As a result of the 
increased involvement of the customs community in 
the protection of intellectual property rights, an ever 
increasing number of goods have been temporary 
retained under suspicion of violating intellectual 
property rights in the country. 
 
Besides the increased awareness among customs 
officers of the importance of the protection of 
intellectual property rights, the awareness of the 
business community has been growing alongside the 
trust in the activities undertaken by customs 
organisations. The number of registered applications 
for customs protection of trademarks has been 
steadily growing. 
 
It should also be stressed that the significant 
increase in the online sale of counterfeit products is 
becoming a central issue and international 
cooperation in this field should be encouraged. 
Moreover, more than 90 per cent of the drugs sold 
on the Internet are alleged to be counterfeit 
medicines. Online infringement of intellectual 
property is a global problem and adopting 
appropriate measures is crucial when dealing with 
this type of crime.  
 
One of the most important aspects in the prevention 
of online counterfeiting is developing people's 
consciousness and raising political awareness and 
the will to deal with this issue. Several means are 
available to the organizations dealing with online 
sale of counterfeit products: cooperation with 
various auction pages and Internet service providers 
should be enhanced; civil investigations should be 
established; cooperation should be encouraged with 
other state organs responsible for the proper 
implementation of legal acts; cooperation with 
Google, Facebook and financial institutions like Visa, 
Master Card, PayPal should be encouraged; and 
additional and special measures should be 
undertaken.  
Katerina Tosevska-Trpcevska, Enforcement of Intellectual Property Law: Some Aspects of Trade in 
Counterfeit Goods in the Former Yugoslav Republic of Macedonia 
_____________________________________________________________________________________ 
 
44 
 
BIBLIOGRAPHY 
Achievements of the Customs Administration of the 
Former Yugoslav Republic of Macedonia in 
combating counterfeiting and piracy (presentation 
from the Customs Administration 2014) 
Customs Administration, Action Plan for Protection 
of Intellectual Property Rights for the period 2014-
2016 (CARM 2014) 
Customs Administration, Annual Report 2013 (CARM 
2014) 
Customs Administration, Annual Report 2014 (CARM 
2015) 
Customs Administration, Report: second quartile 
2015 (CARM 2015) 
Harms LTC, The Enforcement of Intellectual Property 
Rights: A Case Book (3
rd
 edition, WIPO 2013)  
Law on customs measures for implementing 
protection of intellectual property rights 2015 
Law for ratification of the Singapore Treaty on the 
Law of Trademarks, 2010 
Law for ratification of the Vienna Agreement 
Establishing an International Classification of the 
Figurative Elements of Marks, 2010 
Law for ratification of the Protocol for Madrid 
Agreement Concerning the International Registration 
of Marks, 2002 
Mufisovski E, React – Association for the fight 
against counterfeit products, presentation in Skopje, 
2015 
OECD, Magnitude of Counterfeiting and Piracy of 
Tangible Products: An Update (OECD 2009) 
OECD, The Economic Impact of Counterfeiting and 
Piracy: Executive Summary (OECD 2007) 
Olsen K, Counterfeiting and Piracy: Measurement 
Issues (Background report for the WIPO/OECD 
Expert Meeting on Measurement and Statistical 
Issues, OECD 2005) 
React, Service Guide 2015-2016 (SNB-REACT 
2015/2016) 
WCO, Illicit Trade Report 2013 (World Customs 
Organization 2014) 
WCO launches the new IPM platform 
<www.wcoipm.org/news/wco-launches-the-new-
ipm-platform/> accessed 27 October 2015 
_______________ 
 
 45 
 
6 MANAGING COPYRIGHT IN MOOCS: THE 
VIABILITY OF THE TEACHING EXCEPTION 
 
Dr Ratnaria Wahid 
ABSTRACT 
 
Massive Open Online Courses (MOOCs) are 
becoming a new trend in the international 
development of education. MOOCs offer various 
resources online across the globe with the 
expectation that this will help towards reducing 
costs, widening access and increasing productivity. 
The scope of teaching is thus expanded since 
technological development enables easy access to 
information, to publishing, and to reusing and to 
sharing resources. Hence, it is important for policy 
makers, legal authorities and legal scholars to 
rethink the copyright exceptions that are currently 
available for teaching purposes, and whether they 
support teaching practices in the context of MOOCs. 
This paper first provides a brief overview of MOOCs. 
It then outlines some concerns and challenges 
concerning copyright and MOOCs. It analyses 
whether the teaching exceptions under Article 10(2) 
of the Berne Convention apply in the context of 
MOOCs. It also look examines the relation between 
the teaching exception and the three-step test. 
Finally, it discusses the relation between copyright 
protection and public interest and argues that 
flexibilities in interpreting the copyright exception 
are pertinent to serving the public interest. 
 
Keywords: MOOC, copyright; online courses; three- 
step test, teaching exceptions.  
 
I. INTRODUCTION 
 
Massive Open Online Courseware essentially refers 
to the capacity to enrol a large number of course 
participants with adequate Internet connection in a 
different variety of courses, where open content for 
all to use and learn from is provided. While most 
MOOCs are free of charge at present, some do 
impose minimal fees either with or without any 
academic credit. The open content normally offers a 
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coherent set of resources and follows a sequence of 
activities organized by an instructor in order to 
address specific learning objectives or goals bounded 
within a certain time period.
1
 Further activities 
involve registration; a learning environment based 
on a set of curriculum and assessment; and 
communication, including interaction, collaboration, 
and sharing.
2
 Access to materials, mainly scholarly 
publications on the Internet, will be in such a way 
that the materials are free for all to read, use, and 
reuse to a certain extent.  
 
Since then emergence of MOOCs in 2012, this latest 
trend in online learning is well accepted by various 
universities around the world and outsourcing 
companies have been launched to provide the 
infrastructure for it. Malaysia, for instance was the 
first country in the world to implement a nationwide 
strategy that integrates MOOCs with its public on-
campus university classes. Through the deployment 
of the Digital Malaysia 354 Roadmap in 2013, 
Malaysia focuses on MOOCs as one of the ways to 
transform the country into a digital economy by 
2020. Through MOOCs, it is hoped that institutions 
will enhance the quality of graduates, enable more 
customized and remote learning opportunities, 
reduce costs for higher education, raise productivity 
and provide a holistic approach to the public.  
 
Despite such aims, Malaysia, however, does not 
have a proper copyright licensing system like 
Australia, the United Kingdom or the United States. 
Some students still photocopy textbooks in order to 
save their limited educational loans to support their 
studies. Most lecturers are still vague about the issue 
of copyright in an educational setting. When using a 
traditional method of teaching, these problems may 
not be easily transparent but in MOOCs, where the 
courses will be offered globally, universities may 
leave themselves open to copyright infringement 
claims. Teaching is becoming more transparent and 
will be subject to criticism and copyright claims if 
proper copyright management is not put into place. 
 
II. STUDIES ON MASSIVE OPEN ONLINE COURSES 
(MOOCS) 
While MOOCs seem to offer free access to 
information and resources at present, MOOCs are 
ultimately meant to earn revenue within the formal 
higher education system as content licensed for use 
                                               
1 Fiona M Hollands and Devayani Tirthali, 'MOOCs: 
Expectations and Reality' (Center for Benefit-Costs Studies 
of Education, 2014) <https://oerknowledgecloud.org/ 
sites/oerknowledgecloud.org/files/MOOCs_Expectations_a
nd_Reality.pdf> accessed 27 October 2015. 
2 Xin Chen, Deborah R Barnett and Casheena Stephens, 'Fad 
or Future: The Advantages and Challenges of Massive Open 
Online Courses (MOOCs)', Research-to Practice Conference 
in Adult and Higher Education (2013) 
<https://www.lindenwood.edu/r2p/docs/ChenBarnettStep
hens.pdf> accessed 27 October 2015. 
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by institutions awarding degrees. Open educational 
resources have become 'try before you buy' 
marketing tools that provide a way of leveraging 
scale in a new, potentially highly profitable 
educational industry.
3
 Some have even found that 
MOOCs are creating heavy debts for students.
4
 The 
educational industry is leaning more towards 
privatization leading to the question of whether such 
teaching is for profit or for non-profit purposes. 
While reusable educational resources are being 
created and disseminated, development in 
technology has managed to expand the scope of 
teaching by facilitating access to information, to 
publishing and to sharing.
5
  
Various studies have shown that MOOCs present 
various complex copyright issues that can challenge 
the relationship between a higher education 
institution, its faculty, learners and MOOC 
providers.
6
 Dames questioned the situation when 
MOOC' participants contributed copyrighted 
materials, either with or without any licence to do 
so.
7
 Thomson
8
 discussed the challenge of copyright 
compliance in MOOCs, stating that the global nature 
of MOOCs makes copyright difficult. Arnold viewed 
copyright as a challenge for MOOCs, especially with 
the commercialization of open resources that is 
underway.
9
 Some viewed it as being unlikely that the 
teaching exception or the fair use exception in the 
context of classroom teaching can be applied in the 
MOOC environment.
10
 The fair use defence may not 
apply on the basis that most MOOC providers are 
for-profit companies, MOOC are open to the mass
11
 
                                               
3 Richard Wellen, 'Open Access, Megajournals, and MOOCs: 
On the Political Economy of Academic Unbundling' (2013) 3 
SAGE Open 
<http://sgo.sagepub.com/lookup/doi/10.1177/2158244013
507271> accessed 4 June 2014. 
4 Helen Hu, 'MOOC Migration' (2013) 30 Diverse: Issues in 
Higher Education 10 
<http://search.ebscohost.com/login.aspx?direct=true&db=
aph&AN=86441058&site=ehost-live> accessed 27 October 
2015 
5 ibid. 
6 Educause, 'Copyright Challenges in a MOOC Environment' 
(2013) 
<https://net.educause.edu/ir/library/pdf/PUB9014.pdf> 
accessed 27 October 2015 
7 K Matthew Dames, 'Copyright Norms Clash With MOOCs 
Learning by Example' (2013) 30 Intellectual Property 24. 
8 Helen Thomson, 'Copyright , Compliance , and the Big 
Wide World of MOOCS' (2013) 34 Incite 30. 
9 Stephen E Arnold, 'GADZOOKS, It's MOOCs.' (2013) 37 
Online Searcher 10. 
10 Meredith Schwartz, 'Massive Open Opportunity: 
Supporting MOOCs in Public and Academic Libraries' 
(Library Journal, 2013) 
<http://lj.libraryjournal.com/2013/05/library-services/ 
massive-open-opportunity-supporting-moocs/#_> accessed 
27 October 2015. 
11 Derek Whitehead and Luke Padgett, 'The Myth of 
MOOCs', The Higher Education Technology Agenda (THETA 
and not confined to certain group of students
12
, and 
that some students access the content from 
jurisdictions where fair use or fair dealing principles 
are either weaker or entirely absent.
13
 It was viewed 
impossible for MOOCs to pass the three-step test 
elements.
14
  
It is a concern that MOOCs lack the rich and vast 
resources necessary for true learning if resources 
and materials continue to be in the hands of 
publishers.
15
 In 2013, there was a call in Australia to 
reform the Copyright Act 1968 in order to allow 
more Australian university competence in world 
online education.
16
 Courtney
17
 focusses on different 
strategies to deal with copyright and access 
problems associated with MOOCs materials. 
However, it is arguable whether other institutions 
that might have lesser expertise and fewer resources 
can easily adopt the same strategies. Courtney's 
view is that the difficulties in creating MOOCs 
contents have led faculty authors to understand the 
pitfalls that a particular contract may involve, 
copyright issues, licence bounded restrictions and 
how this can impact education.
18
 In short, with 
MOOCs it is crucial for policy makers to begin 
rewriting rules about copyright and its impact on 
scholarship. 
A normal course of teaching in MOOCs may include 
different acts of exploitation of copyright works. 
Different works such as journal, articles and books, 
sound recording of lectures, visual recordings, news 
or broadcasts may be made available online; 
sometimes translations of works may be necessary 
in certain circumstances. This article will examine to 
what extent the teaching exceptions provided by 
international conventions, particularly Article 10(2) 
of the Berne Convention, permit exploitations of 
copyright works in these different acts. 
 
                                                                
2013) (2013) 
<https://www.caudit.edu.au/system/files/Media library/ 
Resources and Files/Presentations/THETA 2013 - The Myth 
of MOOCs - D Whitehead L Padgett - Presentation.pdf> 
accessed 1 November 2015. 
12 ibid. 
13 ibid. 
14 Charis Palmer, 'Universities Seek Copyright Law Reform 
to Enable MOOCs' (The Conversation, 2013) 6 
<http://theconversation.com/universities-seek-copyright-
law-reform-to-enable-moocs-11524> accessed 1 November 
2015, p6. 
15 Kyle K Courtney, 'The MOOC Syllabus Blues Strategies for 
MOOCs and Syllabus Materials' (2013) 74 College and 
Research Libraries News 514 
<http://crln.acrl.org/content/74/10/514\nhttp://crln.acrl.o
rg/content/74/10/514.full.pdf> accessed 27 October 2015. 
16 ibid. 
17 ibid. 
18 ibid. 
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III. RELATED INTERNATIONAL CONVENTIONS 
 
As one of the 14 multilateral trade agreements in the 
World Trade Organization (WTO), the Agreement on 
Trade-Related Aspects of Intellectual Property Rights 
Agreement (TRIPS) is considered a comprehensive 
international Agreement on copyright and 
intellectual property that is binding on all WTO 
Members.
19
 Under TRIPS, Contracting States are 
required to comply with most of the provisions of 
the Berne Convention, irrespective of whether the 
country is a signatory to that Convention, by virtue 
of TRIPS Article 9, which provides that all Members 
shall comply with Articles 1 to 21 of the Berne 
Convention 1971. In other words, the Berne 
Convention is a source of rights and obligations for 
all WTO Members. Some commentators even 
conclude that the Berne Convention, to the extent 
incorporated, is a source of law.
20
  
 
The Berne Convention, before the revision of its 
substantive copyright provisions (Articles 1 to 20) at 
the Stockholm Conference 1967 has only provided 
for special copyright exceptions, as contained in 
Articles 10, 10bis, 11bis(3) and 13(1). Back then, 
different copyright exceptions in favour of various 
public and cultural interests were widespread and 
available in domestic laws. Recognition of the need 
for information and knowledge appears to constitute 
one of the most frequent exceptions recognized in 
various domestic laws; for instance those related to 
works used in public speeches, quotations, school 
books and chrestomathies, newspaper articles, 
reporting of current events, as well as reproduction 
by photocopying in libraries.
21
 
 
IV. SPECIFIC COPYRIGHT EXCEPTION FOR 
TEACHING PURPOSES 
Article 10(2) of the Berne Convention specifically 
permits utilizing copyright work for the purpose of 
teaching, by stating: 
It shall be a matter for legislation in the 
countries of the Union, and for special 
agreements existing or to be concluded 
between them, to permit the utilization, to 
the extent justified by the purpose, of 
literary or artistic works by way of 
illustration in publications, broadcasts or 
                                               
19 Adrian Sterling, World Copyright Law (Sweet and Maxwell 
2003). 
20 Mitsuo Matsushita, Thomas J Schoenbaum and Petros C 
Mavroidis, The World Trade Organization: Law, Practice 
and Policy (Second Edition, Oxford University Press 2006) 
58. 
21 WIPO, 'Records of the Intellectual Property Conference of 
Stockholm' (1971) 112. 
sound or visual recordings for teaching, 
provided such utilization is compatible 
with fair practice. 
Article 10(2) of the Berne Convention is not 
mandatory in nature since it left the matter for 
national legislation or for bilateral agreements 
between Union members to decide on
22
 by using the 
words 'it shall be a matter for legislation'.
23
 
Nevertheless, should a country opt to use the 
specific teaching exception, it must do so within the 
ambit of Article 10(2) of the Berne Convention and 
this can be analysed as follows:  
 
A. 'TO PERMIT THE UTILIZATION' 
 
Article 10(2) uses a general term, namely it permits 
the 'utilization' instead of the term 'borrowing' used 
in the Brussels Act 1948. By using a general term, it 
covers a broad range of utilization.
24
 It was viewed 
that Article 10(2) is an 'open, flexible and 
technology-neutral exception.'
25
 The word is 
considered neutral enough to cover not only 
reproduction, but also other kinds of economic 
rights granted under the Berne Convention, namely 
the right of adaptation, translation, distribution or 
communication to the public, making available to 
the public and even extendable to the use of digital 
means in teaching.
26
 Ultimately, it is left for each 
national legislation to determine what 'utilization' 
means
27
 and this includes all the exploitation acts 
                                               
22 Sam Ricketson and Jane C Ginsburg, 'International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond' (Second, Oxford University Press 2006) 791. 
23 Samuel Ricketson, 'WIPO Study on Limitations and 
Exceptions of Copyright and Related Rights in the Digital 
Environment' (World Intellectual Property Organization 
2003) 14. 
24 Ruth L Okediji, 'The International Copyright System: 
Limitations, Exceptions and Public Interest Considerations 
to Developing Countries' (UNCTAD-ICTSD 2006) 13. 
25 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), 'Copyright Law: A Handbook of Contemporary 
Research' (Edward Elgar Publishing 2007) 379. 
26 Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' (World 
Intellectual Property Organization 2009)1 15 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. 
27 Samuel Ricketson, 'WIPO Study on Limitations and 
Exceptions of Copyright and Related Rights in the Digital 
Environment' (World Intellectual Property Organization 
2003) 14; Raquel Xalabarder, 'Study on Copyright 
Limitations and Exceptions for Educational Activities in 
North America, Europe, Caucasus, Central Asia and Israel' 
(World Intellectual Property Organization 2009) 15 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015 
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envisaged under the Berne Convention, TRIPS and 
later, by the WIPO Copyright Treaty (WCT).  
 
B. 'OF LITERARY OR ARTISTIC WORKS' 
 
Article 10(2) also specifies that only 'literary or 
artistic works' may be used under the copyright 
exception for the purpose of teaching. A very wide 
and broad definition of the term 'literary and artistic 
works' is found in Article 2(1) of the Berne 
Convention, where it includes 'every production in 
the literary, scientific and artistic domain, whatever 
may be the mode or form of its expression'.  
Although digital technology may pose greater risks 
to authors' interests compared to works used in 
face-to-face teaching
28
, it has been well accepted 
that digital technologies are also covered under the 
exception.
29
 The reason behind all the subsequent 
Berne Convention revisions
30
 show that such 
wording was to enable educators 'to take full 
advantage of the new means of dissemination 
provided by modern technology'
31
, and that it should 
extend to digital fixations of works.
32
 Acceptance for 
the exceptions to be applied to digital technology 
can also be seen in the Agreed Statement concerning 
Article 10 of the WCT, where member states may '… 
appropriately extend into the digital environment 
limitations and exceptions in their national laws … 
[and] devise new exceptions and limitations that are 
appropriate in the digital networked environment.'
33
 
Thus, the law made it clear that whatever mode of 
literary, scientific and artistic works that may be 
used in MOOCs, it will still be covered under the 
specific exceptions for teaching purposes.  
 
                                               
28 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 794. 
29 Raquel Xalabarder, 'The Liability of Internet Service 
Providers (ISP) for the Infringements Committed by Their 
Clients and Users' [2006] IDP. Internet, Law and Politics E-
Journal 378–379 
<http://journals.uoc.edu/index.php/idp/article/view/n2-
xalabarder> accessed 27 October 2015.  
30 That provides for 'publications destined for educational 
or scientific purposes' as in the Berne Act 1886, 
'educational or scientific publications' as in the Brussels Act 
1948, 'publications intended for teaching or having a 
scientific character or in chrestomathies' as proposed in the 
Programme for the Stockholm Conference 1967, and the 
current text which added 'recordings and broadcasts'. 
31 Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' (World 
Intellectual Property Organization 2009) 14 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015 
32 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 793. 
33 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 112. 
C. 'BY WAY OF ILLUSTRATION' 
 
Article 10(2) uses the phrase 'by way of illustration', 
whose ordinary meaning refers to: 
 
The action or fact of illustrating, 
(1) Lighting up, illumination, 
enlightenment; (2) The action of making or 
fact of being made illustrious, brilliant, or 
distinguished; distinction. Also, an 
example, means or cause of distinction; 
(3)(a) The action or fact of making clear or 
evident to the mind; setting forth clearly or 
pictorially; elucidation; explanation; 
exemplification; (b) That which serves to 
illustrate or make clear, evident, etc.; an 
elucidation, explanation; an example, 
instance; (4)(a) The pictorial elucidation of 
any subject; the elucidation or 
embellishment of a literary or scientific 
article, book, etc., by pictorial 
representations; (b) An illustrative picture; 
a drawing, plate, engraving, cut, or the like, 
illustrating or embellishing a literary 
article, a book, etc.
34
 
Based on the Proposal of the Working Group on 
Excerpts from Protected Works, 'by way of 
illustration,' was to be understood 'in the sense of 
subsidiary reproduction'.
35
 On this basis the 
exception only applies when the copyright work is 
used for supplementing other work and is only 
regarded as secondary or of lesser importance.
36
 For 
instance, a short video used in a MOOC to illustrate 
the conflict happening in Syria for its International 
Law students may fall under the Article 10(2) 
exception since the video is simply reproduced to 
support or demonstrate the lesson. Similarly, a 
journal article is reproduced for students' further 
reading so as to provide further clarification in the 
lesson.  
The word 'illustration' refers to works that could 
make things clearer or evident to the mind, not just 
by giving a mere example, but also including setting 
forth clearly or pictorially, elucidating or explaining a 
matter in question, which can commonly be done by 
posting journal articles or chapters that better 
define, clarify or explain the subject matter in detail. 
Moreover, the Working Group dealing with Article 
10(2) describes 'by way of illustration' to be 
understood only 'in the sense of subsidiary 
                                               
34 Oxford English Dictionary (Second, University Press 
1989). 
35 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 885.  
36 Ratnaria Wahid, 'Exploring Flexibilities within the 
International Copyright System for Teaching, Research and 
Study'  (DPhil thesis, University of East Anglia 2011).  
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reproduction', which means that the copyright work 
is used to assist or supplement the main teaching 
material, which is normally the lecturer's notes.
37
  
Moreover, the phrase 'by way of illustration' was not 
intended to restrict the term 'educational purposes' 
previously used in the earlier version of the Berne 
Convention, but to ensure that the reproductions 
used are indeed 'illustrating' the teaching.
38
 
However, when a journal article is reproduced for 
students to analyse and comment in a MOOCs' 
online forum, this may arguably not constitute mere 
'illustration'. However, such argument is not valid 
because the work will be at the centre of discussion 
and thus becomes primary in ensuring success of the 
teaching activities, and  therefore would not surpass 
the requirement of 'by way of illustration' under 
Article 10(2).  
 
It was also accepted at the Stockholm Conference 
that the words 'by way of illustration' do impose 
some limitation on the size of the borrowing, but 
would not exclude the use of the whole of a work in 
appropriate circumstances.
39
 For example, it may be 
necessary to reproduce a short literary work or 
artistic work such as case summaries or photographs 
in order for it to be properly utilized for teaching 
purposes.  
 
D. 'PUBLICATIONS, BROADCASTS OR SOUND OR 
VISUAL RECORDINGS' 
Article 10(2) further specifies that utilization is 
permitted by way of illustration 'in publications, 
broadcasts or sound or visual recordings for 
teaching'. These expressions were not meant to 
exhaust the full range of permissible utilizations, but 
instead to accommodate new technology.
40 
Hence, 
                                               
37 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 885. 
38 Raquel Xalabarder, Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel (World 
Intellectual Property Organization 2009) 15 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015. 
39 Lucie Guibault, The Nature and Scope of Limitations and 
Exceptions to Copyright and Neighbouring Rights with 
Regard to General Interest Missions for the Transmission of 
Knowledge: Prospects for their Adaptation to the Digital 
Environment' [2003] e-Copyright Bulletin 1, 15; Sam 
Ricketson and Jane C Ginsburg, International Copyright and 
Neighbouring Rights: The Berne Convention and Beyond 
(Second, Oxford University Press 2006) 791. 
40 Raquel Xalabarder, 'The Liability of Internet Service 
Providers (ISP) for the Infringements Committed by Their 
Clients and Users' [2006] IDP. Internet, Law and Politics E-
Journal 378 
<http://journals.uoc.edu/index.php/idp/article/view/n2-
xalabarder>. accessed 27 October 2015 
'distance learning', correspondence courses, 
'teaching on demand' or 'broadcasting'
41 
or any kind 
of teaching and learning conducted online
42
, which 
are very common in MOOCs environment, are all 
covered under the Article 10(2) provision. By 
including the term 'broadcasts' it also shows that 
Article 10(2) includes wire transmission. Based on 
the records of the Brussels Conference, the 
delegates have accepted that broadcast was one 
means of wireless communication to the public, as 
interpreted in the Rome Convention Article 3(f) to be 
'the wireless transmission for public reception of 
sounds or images and sounds of the 
representations'.
43 
 
 
When utilizing copyright works in broadcast, it may 
be difficult to ensure that the utilization is used for 
teaching purposes only, since it is not easy to control 
the destination when a work is broadcasted. Hence, 
an educational broadcast may be made to a larger 
group of people other than those for whom the 
instruction is intended. This approach is acceptable 
when the Study Group rejected a proposal that seeks 
to limit the scope of the teaching exception to only 
educational broadcasts carried out within teaching 
establishments or inside schools.
44
 Moreover, Article 
10(2) encompasses not only the making of 
broadcasts but also the performances of broadcasts 
in schoolrooms or lecture theatres.
45
 The phrase 'by 
way of illustration in publications, broadcasts or 
sound or visual recordings for teaching' does not 
constitute an exhaustive list.
46
 Based on these 
                                               
41 Daniel Seng, WIPO Study on the Copyright Exceptions for 
the Benefit of Educational Actitivities for Asia and Australia  
(World Intellectual Property Organization 2009) 10 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130249> accessed 27 October 2015 
42 Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' (World 
Intellectual Property Organization 2009) 14 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393> accessed 27 October 2015. 
43 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 732; 
Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' 
(World Intellectual Property Organization 2009) 9 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015. 
44 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 886. 
45 Claude Masouye, Guide to the Berne Convention for the 
Protection of Literary and Artistic Works (Paris Act 1971) 
(World Intellectual Property Organization 1978) 60. 
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Intellectual Property Organization 2009) 14 
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arguments, wireless transmission of works to public 
as adopted in MOOCs is covered under the teaching 
exception of Article 10(2).  
 
It is debatable whether Article 10(2) facilitates the 
use of teaching compilations under the exception. 
Digital educational compilations, which are 
fundamental in online teaching, consisting part of 
the instruction itself compiled on a web page, may 
pose far greater risks against the legitimate interests 
of authors compared to non-digital educational 
compilations.
47
 The application of Article 10(2) to 
teaching compilations was derived from its reference 
to 'publication' as well as the express reference to 
'chrestomathies'
48
 which might be rendered as 
'educational compilations'
49
 in the earlier version of 
the Berne Convention. This is particularly provided 
for in Article 8 of the Berne Act of 1886, which was 
later reorganized into Article 10(2) of the Brussels 
Act 1948.
50
 The Working Group, however, 
recommended deleting the word 'chrestomathies' 
on the ground that it was no longer necessary due to 
the number of exceptions to the right of 
reproduction already available in the Convention.
51
  
 
Ricketson in his early edition rationalizes that 
chrestomathies and anthologies, in many instances, 
would naturally fall within the scope of publications 
for teaching purposes under Article 10(2).
52
 This 
position was later altered, stating that it is unlikely 
that chrestomathies and anthologies would fall 
within the scope of publications intended for 
teaching purposes under Article 10(2), as 'it will be a 
distortion of language to describe an anthology of 
poetry (with the complete texts of the poems) or a 
'course pack' consisting of chapters taken from 
various books about the subject to be covered in the 
course, as being used 'by way of illustration […] for 
                                                                
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015. 
47 ibid. 
48 According to the Oxford English Dictionary, the term 
'chrestomathy' refers to 'a collection of choice passages 
from an author or authors, esp. one compiled to assist in 
the acquirement of a language'. 
49 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 784. 
50 Article 10(2) of the Brussels Act 1948 provides as follows: 
'The right to include excerpts from literary or artistic works 
in educational or scientific publications or in 
chrestomathies, in so far as this inclusion is justified by its 
purpose, shall be a matter for legislation in the countries of 
the Union, and for special Arrangements existing or to be 
concluded between them.' 
51 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 885. 
52 Samuel Ricketson, 'The Berne Convention for the 
Protection of Literary and Artistic Works: 1886-1986' 
(Kluwer 1987) 499. 
teaching' '.
53
 Australia, for instance, has subjected its 
compilation of copyright materials to voluntary 
licensing arrangement or compulsory licensing 
schemes.
54
 
 
Others, however, contended that Article 10(2) did 
refer to 'publications' (as well as the original 
reference to 'chrestomathies' in the Berne Act), 
which favours the acceptance of teaching 
compilations provided that it fulfils further 
conditions i.e. 'to the extent justified by the purpose' 
and that 'such utilization is compatible with fair 
practice'.
55
 Hence, it is not a straightforward case 
but should be decided on a case-by-case basis. 
 
E. 'FOR TEACHING' 
 
Article 10(2) specifically allows copyright exceptions 
for 'teaching', which includes 'teaching at all levels - 
in educational institutions and universities, 
municipal and State schools and private schools.'
56
 
The Stockholm Report however excludes education 
outside these institutions, for instance, general 
teaching available to the general public.
57
 Thus, 
Article 10(2) only refers to formal education at 
elementary, intermediate and tertiary institutions of 
learning, or something that is of an 'official' degree.
58
  
Nevertheless it could be argued that such a view 
may be disadvantageous to informal educational 
setting, since the development of technology has 
opened up the opportunities for anyone to pursue 
distance learning. Applying this to the context of 
MOOCs, teaching can still be considered as 
classroom-based since it will comprise the same 
registered students, studying a subject matter 
provided by trained lecturers, guided by a specified 
curriculum that lasts for a certain period of time. 
MOOC students still need to register, follow a certain 
syllabus within a certain time frame, complete 
certain activities and are also expected to participate 
and contribute to forums and online discussions. 
Thus, MOOCs should also be considered as falling 
                                               
53 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 794. 
54 ibid. 
55 Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' (World 
Intellectual Property Organization 2009) 14 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393>. accessed 27 October 2015 
56 WIPO, 'Records of the Intellectual Property Conference of 
Stockholm' (1971) 293. 
57 ibid. 
58 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), Copyright Law: A Handbook of Contemporary 
Research (Edward Elgar Publishing 2007) 378. 
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under the scope of formal education that could 
benefit from the teaching exceptions.  
 
The word 'teaching' should not be interpreted 
restrictively
59
, since it will exclude adult education 
programmes
60
 which are beneficial for a country's 
development. In interpreting the scope of 'teaching', 
the focus should be on the nature of the instruction, 
not just on the award itself.
61
 It is important that in 
this information technology era different modes of 
teaching and learning are acknowledged and 
recognized. There is no reason to limit the scope of 
'teaching' to the classroom only for the purposes of 
Article 10(2), and the word 'teaching' should extend 
to correspondence courses or Web-based courses 
where students receive no face-to-face instruction 
from a teacher.
62
  
 
F. 'TO THE EXTENT JUSTIFIED BY THE PURPOSE' 
AND 'UTILIZATION IS COMPATIBLE WITH 
FAIR PRACTICE' 
 
Article 10(2) requires that the use of copyright works 
under the teaching exception must be justified and 
compatible with fair practice. At this point, 
commentators differ as to whether Article 10(2) as a 
special rule, which comes much earlier, should exist 
in an unqualified form or need to be applied 
cumulatively with the three-step test
63
, which 
specifies three conditions that need to be fulfilled in 
order to qualify as exceptions to the reproduction 
right, namely that: (a) it must be a certain special 
                                               
59 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 886. 
60  Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 792; 
Raquel Xalabarder, 'Study on Copyright Limitations and 
Exceptions for Educational Activities in North America, 
Europe, Caucasus, Central Asia and Israel' 
(World Intellectual Property Organization 2009) 14 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130393> accessed 27 October 2015. 
61 Daniel Seng, 'WIPO Study on the Copyright Exceptions for 
the Benefit of Educational Actitivities for Asia and Australia' 
(World Intellectual Property Organization 2009) 8 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130249> accessed 27 October 2015. 
62 Sam Ricketson and Jane C Ginsburg, International 
Copyright and Neighbouring Rights: The Berne Convention 
and Beyond (Second, Oxford University Press 2006) 793. 
63 The three-step test is provided for in Article 9(2) of the 
Berne Convention and Article 13 of the TRIPS Agreement, 
which bears the same three conditions. Article 9(2) of the 
Berne Convention provides that: 'It shall be a matter for 
legislation in the countries of the [Berne] Union to permit 
the reproduction of such works in certain special cases, 
provided that such reproduction does not conflict with a 
normal exploitation of the work and does not unreasonably 
prejudice the legitimate interests of the author.'  
case; (b) that it does not conflict with a normal 
exploitation of the work; and (c) that it does not 
unreasonably prejudice the legitimate interest of the 
author. 
 
The first possibility is that the three-step test does 
not need to be applied to the exception for teaching 
purposes. In interpreting the text of the Berne 
Convention, the Main Committee I
64
 remarked as 
follows:  
 
The Drafting Committee was unanimous 
in adopting, in the drafting of new texts, 
as well as in the revision of the wording of 
certain provisions, the principle lex 
specialis legi generali derogat: special 
texts are applicable, in their restricted 
domain, exclusive of texts that are 
universal in scope. For instance, it was 
considered superfluous to insert in Article 
9, dealing with some general exceptions 
affecting authors' rights, express 
references to Articles 10, 10bis, 11bis and 
13 establishing special exceptions. 
 
This line of interpretation demonstrates that the 
operation of the specific teaching exception within 
its specific sphere is unaffected by the more general 
provision contained in Article 9(2).
65
 The uses 
allowed under the teaching exception are thus not 
bound by the requirement of the three-step test.
66
 
Applying the principle of lex specialis legi generali 
derogat, which means that specialized law prevails 
over general law, the teaching exception continues 
to exist in an unqualified form because it provides, in 
effect, a special rule, where the three-step test 
would not be applicable.
67
  
 
Thus, although the three-step test appears to apply 
to all types of exceptions, there is a general rule of 
interpretation that where there is a specific rule in 
an earlier treaty, then that earlier treaty continues 
and is not replaced by the general provision of a 
later treaty. Moreover, in discussing Article 9(2) of 
the Berne Convention, the study group pointed out 
that 'the provisions already existing for certain 
special purposes (Articles 10, 10bis and 11bis, 
paragraph (3) must be regarded as rules exercising 
                                               
64 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 1134. 
65 Richard K Gardiner, Treaty Interpretation (Oxford 
University Press 2008) 297–298. 
66 Samuel Ricketson, 'WIPO Study on Limitations and 
Exceptions of Copyright and Related Rights in the Digital 
Environment' (World Intellectual Property Organization 
2003) 21. 
67 Richard K Gardiner, Treaty Interpretation (Oxford 
University Press 2008) 297–298. 
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limits on the questions with which they deal'.
68
 On 
this basis, the teaching purposes exception 
continues to exist in an unqualified form because it 
provides, in effect, a special rule, and thus the three-
step test does not need to be applied in this 
particular situation.  
 
Based on this structure of the Berne Convention, 
states may freely enact legislation on subjects 
covered under the specific exceptions without the 
restrictions of the three- step test.
69
 Hence, it is up 
to member countries to consider what is regarded as 
'fair practice' and 'justified by the underlying 
purpose.
70
 The expression 'fair practice' implies that 
'the uses in question can only be accepted after an 
objective appreciation'.
71
 The requirement of 'fair 
practice' is essentially a question for national 
tribunals to determine in each particular instance. 
Using copyright works without permission or not 
paying compensation for work used for the purpose 
of teaching in a private university, may not be 
considered 'justified by the purpose'. Similarly, 
utilizing a substantial amount of copyright works, 
even for the purpose of teaching, may not be 
considered as fulfilling the condition of 'compatible 
with fair practice'.  
 
Despite these two conditions, an analysis of the 
specific teaching exception provision in the Berne 
Convention shows that it is quite an open, flexible 
and technology-neutral exception, in the sense that 
it does not limit copying to any specific quantitative 
or qualitative restrictions on exempted uses.
72
 The 
provision also does not require any payment of 
remuneration; it is up to member states to 
implement it either as a free exception or limitation, 
as a remunerated legal licence, or as a combination 
of both.
73
 Such flexibilities certainly provide an 
opportunity for member countries to find the right 
balance between the public interest (education) and 
that of the author, according to their different 
circumstances.  
                                               
68 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 112.  
69 Ruth L Okediji, The International Copyright System: 
Limitations, Exceptions and Public Interest Considerations 
to Developing Countries (UNCTAD-ICTSD 2006) 14. 
70 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), Copyright Law: A Handbook of Contemporary 
Research (Edward Elgar Publishing 2007)  380. 
71 WIPO, Records of the Intellectual Property Conference of 
Stockholm (1971) 117. 
72 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), Copyright Law: A Handbook of Contemporary 
Research (Edward Elgar Publishing 2007) 378. 
73 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), Copyright Law: A Handbook of Contemporary 
Research (Edward Elgar Publishing 2007) 380 
The second possibility is where Article 13 of the 
TRIPS Agreement applies the three-step test to all 
exceptions to exclusive rights, as it is clearly 
expressed, and thus should be applied in addition to 
the exception for teaching purposes. It was viewed 
that the specific exceptions are supported by the 
open-formulated three-step test, which acts as an 
additional safeguard.
74
  
 
Thus, a national legislature that wants to exempt the 
utilization of a work by way of illustration for 
teaching must fulfil not only the conditions under 
Article 10(2) of the Berne Convention, but also the 
abstract criteria of the three-step test. The exception 
must also be limited to certain special cases, not 
conflict with the normal exploitation of a work, and 
not unreasonably prejudice the legitimate interests 
of the right holder. All specific limitations provided 
under the Berne Convention, including teaching 
exceptions, can automatically be regarded as a 
'special case'.
75
 In terms of the application of the two 
conditions to MOOCs, it depends on the facts and 
circumstances of the case.  
 
Without clear interpretation and in the context of 
the TRIPS Agreement, WCT and WPPT, it was viewed 
as advisable to employ the proportionality test 
inherent in the three-step test in determining 
whether the use of certain copyright work is 'fair'.
76
 
To this extent, one may need to consider the kind 
and amount of work used, the quantity of copies 
made, and the specific implications of the 
technology, in order to find the right balance 
between the copyright owners' and the users' 
interest.  
 
It may well be that when a person applies the three-
step test in addition to the teaching purposes 
exception, he may find himself going through the 
same exercise twice because he is only considering 
the same factors in relation to the teaching purposes 
exception and the three-step test, but in a different 
                                               
74 Martin Senftleben, 'Copyright, Limitations and the Three-
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International and EC Copyright Law' (Kluwer Law 
International 2004) 155. 
75 ibid. 157. 
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language.
77
 Bringing the teaching purposes 
exception and the three-step test together, it can be 
seen that although the two exceptions are not 
identical, there are compromises between those.
78
 
Article 10(2) reiterates factors that are similar to the 
three-step test, which are thus not likely to yield a 
different outcome in normal circumstances; both 
exceptions seem to have similar philosophies.  
 
When the three-step test and the inherent 
requirement of the teaching purposes exceptions are 
applied cumulatively, in effect the TRIPS Agreement 
may conceivably narrow the scope of the teaching 
purposes exception under the Berne Convention. 
This may occur based on a narrow reading of TRIPS 
on the assumption that Article 10(2) of the Berne 
Convention does not oblige States to comply, but 
leaves it to countries to decide as a matter of 
national legislation.
79
  
 
G. ACKNOWLEDGEMENT 
 
Article 10(2) is further subject to the requirement in 
Article 10(3) of the Berne Convention which requires 
that the source and the name of the author be 
mentioned when copyright works are used for 
teaching purposes. The attribution of the source and 
authorship is consistent with common practice in 
educational scholarship.
80
 
 
However, there are inconsistent views regarding the 
question of whether the right of integrity or moral 
rights as referred in Article 6bis of the Berne 
Convention also applies.
81
 Ricketson initially viewed 
                                               
77 Ratnaria Wahid, 'Exploring Flexibilities within the 
International Copyright System for Teaching, Research and 
Study' (DPhil thesis, University of East Anglia 2011) . 
78 ibid. 
79 ibid. 
80 Daniel Seng, 'WIPO Study on the Copyright Exceptions for 
the Benefit of Educational Actitivities for Asia and Australia' 
(World Intellectual Property Organization 2009) 11 
<http://www.wipo.int/meetings/en/doc_details.jsp?doc_id
=130249>. accessed 27 October 2015. 
81 Article 6bis of the Berne Convention reads: 
(1) Independently of the author's economic 
rights, and even after the transfer of the said 
rights, the author shall have the right to claim 
authorship of the work and to object to any 
distortion, mutilation or other modification of, 
or other derogatory action in relation to, the 
said work, which would be prejudicial to his 
honor or reputation.  
(2) The rights granted to the author in 
accordance with the preceding paragraph shall, 
after his death, be maintained, at least until the 
expiry of the economic rights, and shall be 
exercisable by the persons or institutions 
authorized by the legislation of the country 
where protection is claimed. However, those 
that the moral right under Article 6bis does not apply 
in respect of Article 10, as for practical reasons, 
there is a need for flexibility to modify and alter a 
work where necessary when it is quoted or utilized 
for teaching purposes.
82
  However, on the basis of 
the report of the Main Committee I, which notes 
that delegates generally agreed that Article 6bis 
applied in respect of exceptions authorized by the 
Convention, including Article 10
83
, it was later 
viewed that 'while modifications within reason may 
be required when works are utilized for teaching 
purposes, this should not give carte blanche to 
educators to make deleterious, reputation-damaging 
alterations'.
84
  
 
V. CONCLUSION 
 
In short, Article 10(2) of the Berne Convention can 
facilitate the teaching of courses in universities via 
MOOCs provided that it is flexibly interpreted. The 
wording under Article 10(2) is purposely couched to 
be open and flexible, so as to allow national 
lawmakers to take advantage of its flexibility and to 
apply the scope of the teaching exception according 
to their circumstances. The rights cover a broad use 
of works for teaching exceptions. Based on a flexible 
interpretation, the exception may apply when a 
work is copied, reproduced, translated, adapted or 
performed for the purpose of teaching. The 
exception may also apply when the copyright work is 
communicated or made available to the public. Thus, 
flexibly interpreted, Article 10(2) seems to support 
various activities conducted on copyright works, 
which are commonly undertaken by lecturers when 
teaching their students and this includes MOOC as a 
new form of delivery in teaching and learning.  
 
The phrase 'justified by the purpose' and 'compatible 
with fair practice' under Article 10(2) was also 
worded in general terms and necessitates further 
                                                                
countries whose legislation, at the moment of 
their ratification of or accession to this Act, does 
not provide for the protection after the death of 
the author of all the rights set out in the 
preceding paragraph may provide that some of 
these rights may, after his death, cease to be 
maintained.  
(3) The means of redress for safeguarding the 
rights granted by this Article shall be governed 
by the legislation of the country where 
protection is claimed. 
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interpretation by the courts. Hence, the provision 
still allows for national law to take advantage of the 
inherent flexibilities. Arguably, the three-step test 
may or may not necessarily be employed. It is for the 
national law to determine the exempted use of 
works for teaching purposes, within the limits of 
Article 10(2).
85
 The exceptions provided under 
international agreements are purposely couched in 
general terms, so as to pose as guidance and as a 
yardstick for member countries to make laws that 
suit their needs and circumstances.  
 
The teaching exception is important since it is based 
on major public interest considerations, such as the 
promotion of education and culture.
86
 Copyright 
exceptions also prevent monopoly control
87
 and 
exploitation not just by authors or inventors, whose 
creativity are supposed to be rewarded, but by large 
information-based corporations.
88
 In rapid 
technological development, various works can easily 
be made available, benefiting the public by way of 
reducing costs for innovation, encouraging the 
exchange of ideas as well as enhancing networking, 
public funding and support.
89
 Often, it is in the 
interest of authors to disseminate and make known 
his or her creations. Copyright exceptions play an 
important role as a mechanism of access and  
 
contribute to the dissemination of 
knowledge, which in turn is essential for a 
variety of human activities and values, 
including liberty, the exercise of political 
power, and economic, social and personal 
advancement … open up rapid advances in 
information and communication 
technologies that are fundamentally 
transforming the processes of production, 
dissemination and storage of 
information.
90
 
 
                                               
85 Raquel Xalabarder, 'On-Line Teaching and Copyright: Any 
Hopes for an EU Harmonized Playground?' in P Torremans 
(ed), Copyright Law: A Handbook of Contemporary 
Research (Edward Elgar Publishing 2007) 380. 
86 Lucie Guibault, 'Contracts and Copyright Exemptions' in 
PB Hugenholtz (ed), Copyright and Electronic Commerce: 
Legal Aspects of Electronic Copyright Management (Kluwer 
Law International 2000) 137.  
87 Adrian Sterling, World Copyright Law (Sweet & Maxwell 
2003). 
88 S Picciotto, 'Defending the Public Interest in TRIPS and 
the WTO' in Peter Drahos and R Mayne (eds), Global 
Intellectual Property Rights: Knowledge, Access and 
Development (Palgrave 2002) 1–2. 
89 ibid. 1. 
90 PB Hugenholtz and Ruth L Okediji, 'Conceiving 
an International Instrument on Limitations and 
Exceptions to Copyright'(2008)10–11. 
<https://www.opensocietyfoundations.org/reports/conceiv
ing-international-instrument-limitations-and-exceptions-
copyright> accessed 27 October 2015. 
A successful implementation of MOOCs will only 
materialize through sufficient understanding of the 
role of copyright law and utilizing the flexibilities 
permitted under the copyright exceptions, taking 
into consideration the need of the people. It is 
important for every country to address the issue of 
access and sharing of information for the purpose of 
education that considers the interests of both 
copyright owners and users. However, public 
interest in education should be given more weight, 
as education is not a luxury, nor a mortgage nor a 
business, but a right to be upheld. In a time when 
education could be delivered across borders 
instantly with minimal costs, copyright law should 
not be seen as posing a risk or a hindrance. While 
some aim to profit from education by means of 
technology, one should not take for granted the 
shared responsibility in supporting education, which 
is considered a basic human right for all.  
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7 ESTABLISHMENT OF SPECIALIZED IP COURTS 
IN PAKISTAN FOR THE EFFICIENT ENFORCEMENT 
OF INTELLECTUAL PROPERTY RIGHTS 
 
Saad Nusrullah 
ABSTRACT 
In the last few years intellectual property has been 
gaining ever increasing recognition in Pakistan. The 
Government of Pakistan is concerned about the 
impact of infringement, counterfeiting and piracy on 
Pakistan’s economy, and is taking steps to curb 
infringing activities and ensure effective 
enforcement of intellectual property rights in the 
country. One such step is the establishment of 
separate intellectual property courts, as required 
under the Intellectual Property Organization of 
Pakistan Act, 2012. This paper examines the previous 
judicial regime for the enforcement of intellectual 
property rights in Pakistan, and highlights issues 
relating to the present system and the need for 
improvement. In addition, it considers the 
advantages and drawbacks of establishing separate 
intellectual property courts in Pakistan, and 
examines the experience of several other countries. 
 
Keywords: Intellectual property rights (IPRs), 
enforcement, infringement, counterfeiting, piracy, 
special courts, and judicial system 
I. INTRODUCTION  
The enforcement of intellectual property rights 
(IPRs) is a controversial issue among developing
1
 and 
developed countries. Intellectual property rights are 
the rights which are given to persons over the 
creation of their minds. They usually give the creator 
an exclusive right over the use of his or her creation 
for a certain period of time.
2
 The Paris Convention 
was the first treaty regarding IPRs and was signed in 
1883
3
. The Convention was revised at Brussels in 
                                               
 Saad Nusrullah (Pakistan). An engineer and a lawyer; he 
earned his Bachelor's degree in chemical engineering from 
the University of the Punjab in 1995 and his LLM in IP 
degree jointly offered by WIPO and University of Turin, Italy 
in 2010. Currently, he is working as a teacher, trainer and 
intellectual property consultant in Lahore, Pakistan.  
 
1 Instead of using the term 'developing countries' and 'least 
developed countries' separately, 'developing countries' will 
be used for both.  
2 
http://www.wto.org./english/tratop_e/trips_e/intel1_e.ht
ml (last visited 15 January 2016). 
3'International agreements concerning IPRs occurred in the 
later part of the 19th Century. In 1873, the Austrian 
Government held an international exhibition of inventions 
at Vienna, many inventors were hesitant to exhibit. They 
feared that in the absence of protection their inventions 
might be copied. In response, several diplomatic 
1900, at Washington in 1911, at Hague in 1925, at 
London in 1934, at Lisbon in 1958 and at Stockholm 
in 1967, and was amended in 1979.
4
 It now applies 
to patents, industrial designs, utility models, trade 
names, marks and geographical indications.
5
 The 
Paris Convention's failure to protect the rights of 
authors and publishers and to safeguard their works 
from being copied led to another multilateral treaty 
protecting copyrights in 1886
6
, the Berne 
Convention.
7
 Later on, with the creation of the 
World Trade Organization (WTO), the most 
comprehensive multilateral agreement on IPRs, 
namely, the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) came into effect 
on 1 January 1995. The TRIPS Agreement 
incorporated obligations from the previous 
conventions concerning IPRs. It established 
minimum standards for the protection of IPRs, 
allowing Members to provide more extensive 
protection if they so wished.
8
 
II. SPECIALIZED IP COURTS 
Since the TRIPS Agreement is an Annex to the 
Marrakesh Agreement Establishing the World Trade 
Organization, all WTO Members are bound by it. 
However different time frames were granted to 
states according to their status as developed and 
developing countries
9
, after which states had to start 
incorporating the standards and laws governing IPRs 
under the TRIPS Agreement.
10
  
 
The agreement generally obliged Member States to 
comply with the standards for the protection of IPRs 
and to prevent infringements by enacting laws by 
providing remedies and taking further steps to 
promote protection.
11
 Under the Agreement, 
Members were obliged to implement a fair, speedy 
and improved system of IPR enforcement, just like 
                                                                
conferences were held. These culminated in 1883, when 11 
States signed the Paris Convention for the protection of 
Industrial Property. The convention established rules 
between the Member States concerning patents, 
trademarks and industrial designs.' Simon Walker, 'The 
TRIPS Agreement, Sustainable Development and the Public 
Interest, Environmental Policy and Law' Paper No. 41, 
IUCN-The World Conservation Union, 2011, pp5-6. 
4<http://www.wipo.int/treaties/en/ip//parish/ 
summaries/_paris.html>(last visited 15 January 2016). 
5 ibid. 
6 Simon Walker, The TRIPS Agreement, Sustainable 
Development and the Public Interest, Environmental Policy 
and Law Paper No. 41, IUCN-The World Conservation 
Union, 2011, pg.6 
7 Berne Convention for the Protection of Literary and 
Artistic works. 
8<https://www.wto.org/english/tratop_e/ 
trips_e/intel2_e.htm>(last visited 15 January 2016). 
9 
<https://www.wto.org/english/tratop_e/trips_e/tripfq_e.h
tm#Who%27sSigned>(ast visited 15 January 2016) 
10 Preamble of the TRIPS Agreement 1995. 
11 Article 41(1) Section 1. General Obligations. Part III. 
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any other legal system.
12
 States were not required to 
create a separate specialized system or courts in 
order to deal with IPR disputes distinct from the 
existing system dealing with the other laws in 
general. However, states have established separate 
IPR courts at their own discretion.
13
 Most of the 
Member States have established separate 
specialized Tribunals or Courts in order to resolve 
IPR-related disputes in order to make the system 
more efficient. These courts are established with 
different names in different states such as the 
Specialized Intellectual Property Court
14
, the 
Intellectual Property Court
15
, the Patents Court, a 
specialist court within the Chancery Division of the 
High Court of Justice of England and Wales
16
, the 
central Intellectual Property and International Trade 
Court (IP&IT Court),
17
 and the Court for Intellectual 
Property Disputes
18
, to name a few. The purpose of 
all these Tribunals is basically to arbitrate on issues 
concerning IPRs. 
 
This establishment of separate systems for the 
protection of IPRs has been highly appreciated by 
forums such as the International Intellectual 
Property Institute (IIPI) and the United States Patent 
and Trademark Office (USPTO) for a variety of 
reasons. Such specialized judicial systems develop a 
better understanding and awareness of IPR-related 
matters, which ultimately reduces litigation and 
judicial errors, and brings coherency and certainty 
making the system effective overall with an 
increased predictability of case outcomes. There are 
different models of courts with different names 
adopted by the various states but having an identical 
purpose. Some states have one kind of court only 
and some have more than one for intellectual 
property-related disputes. These different courts in 
the various countries are as follows: 
 
Specialized IPR Trial Court;
19
 
 
Specialized IPR Appeals Court;
20
 
 
Specialized IPR Trial Division; 
21
 
 
                                               
12 Article 41(2) Section 1.General Obligations. Part III. 
13 Article 41(5) Section 1.General Obligations. Part III. 
14 Malaysia names its court the 'Intellectual Property 
Session Court'.  
15 Singapore's 'Intellectual Property Court' is one of the 
specialist commercial court established under the High 
Court of Singapore. 
16 United Kingdom 
17 Thailand 
18The Intellectual Property Court, Russian Federation.  
19 First instance court that only hears IPR disputes. 
20 Second instance court that only hears IPR disputes.  
21 Specialized division of a first instance court of general 
jurisdiction that only hears IPR disputes. 
Specialized IPR Appeals Division;
22
 
Commercial Trial Court;
23
 
 
Commercial Appeals Court;
24
 
 
Trial Court that exclusively hears IP;
25
 
 
Appeals Court that exclusively hears IPR cases;
26
 
 
Administrative Tribunal;
27
 
 
Specialized Judges on Courts of General 
Jurisdiction;
28
 
 
Considering Specialized IPR Court, Division, or 
Tribunal;
29
 and 
 
Considering Commercial Court.
30
 
 
In the United States there is one specialized IPR 
court, the United States Court of Appeals for the 
Federal Circuit.
31
 It is an appellate court which has 
jurisdiction over matters related to patents, 
trademarks, appeals from the United States Court of 
International Trade, the US Trademark Trial and 
Appeals Board, the US Patent Trial and Appeal Board 
and issues, including issues arising from the US 
International Trade Commission. The court mainly 
provides guidance to the lower courts concerning 
IPR cases.
32
 
 
As regards specialized courts in China, the 
government has established a court of general 
jurisdiction with a specialized division that hears IPR 
disputes. The Chinese judicial system essentially 
consists of Basic People's Courts, Intermediate 
People's Courts, High People's Courts and the 
                                               
22 Specialized division of a second instance court of general 
jurisdiction that only hears IPR disputes. 
23 First instance court that hears IPR matters in addition to 
other commercial, economic, business disputes. 
24 Second instance court that hears IPR matters in addition 
to other commercial, economic, business disputes. 
25 First instance court of general jurisdiction that exclusively 
hears IPR matters. 
26 Second instance court of general jurisdiction that 
exclusively hears IPR matters. 
27 Specialized tribunal that is part of an administrative 
agency and hears IPRs matters. 
28 Judges sitting on courts of general jurisdiction who have 
training or experience in IPR matters. 
29 The state is considering implementing a specialized IPR 
trial or appeals court, a specialized IPR trial or appeals 
division, or a specialized IPR administrative tribunal. 
30 The state is considering implementing a commercial trial 
or appeals court. 
31 The court was established under Article III of the 
Constitution by the Congress on 1 October 1982. 
32 <http://www.cafc.uscourts.gov/the-court/court-
jurisdiction> (last visited 15 January 2016). 
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Supreme People's Court.
33
 All High People's Courts, 
Intermediated People's Courts and Basic People's 
Courts have specialized IPR divisions with civil 
jurisdiction to hear IPR cases. There is also a 
specialized division in the Supreme People's Court to 
hear cases related to IPRs. There are specialized IPR 
judges in these specialized divisions.
34
 A specialized 
IPR tribunal, the Chinese Intellectual Property 
Organization's Re-examination Board, conducts the 
proceedings of annulment. The People's Courts has 
the jurisdiction to hear appeals from the board.
35
 
The victims of infringements can also seek reliefs 
from the administrative organization which enforces 
quickly. 
36
 
 
Similarly, Japan has also established a separate 
system for IPR-related issues, comprising a 
specialized appeals court, specialized divisions of 
district and appeals court to hear cases regarding IP 
disputes. Appeals from district courts on patent 
actions, suits against decisions of the Japan Patent 
Office, and IPR cases of first instance can be filed 
before the Intellectual Property High Court. Further, 
one specialized division of the Osaka High Court, four 
divisions of the Tokyo District Court and two 
divisions of the Osaka District Court have been 
established to hear IPR cases.
37
 
 
India, as a developing country, has established a 
specialized administrative tribunal, which hears 
appeals regarding IPRs. The decisions of the Register 
Trademarks can be appealed to the Indian 
Intellectual Property Appeals Board, established in 
1999. There must be at least one technical and one 
judicial member on the board.
38
 It sits in 
Ahmedabad, Chennai, Delhi, Kolkata and Mumbai. 
Trials regarding infringement are under the 
jurisdiction of the High Court.
39
 
                                               
33 The Supreme People's Court of the People's Republic of 
China, Intellectual Property Protection by Chinese Courts in 
2009,<http://www.court.gov.cn/zscq/znss/201004/t20100
426_4545.html> (Last visited 15 January 2016). 
34 ibid. 
35 Patent Law of the People's Republic of China, Adopted at 
the 4th Session of the Standing Committee of the Sixth 
National People's Congress, 12 March 1984, Amended 27th 
Session of the Standing Committee of the 
Seventh National People's Congress, 4 September 1992. 
36United Kingdom Intellectual Property Office, Intellectual 
Property Rights Primer For China 24 (2008).  
37 The International Intellectual Property Institute (IIPI) and 
the United States Patent and Trademark Office (USPTO), 
Study on Specialized Intellectual Property Courts (2012) 
38 Peter Oller, 'Academics Challenge India's IP Appeals 
Board' Managing Intellectual Property (11 February 2011). 
39 Intellectual Property Appeals Board, 
<http://www.ipab.tn.nic.in/> (last visited 15 January 2016). 
III. ESTABLISHMENT OF SPECIAL IP COURTS IN 
PAKISTAN 
Pakistan, being a member of WTO since 1 January 
1995, is also a developing country and as such the 
provisions of the TRIPS Agreement and all the 
obligations regarding IPR enforcement are 
applicable.
40
 The TRIPS Agreement granted its 
members classified as developing economies like 
Pakistan a period of five years, i.e. until 2000, to 
bring laws governing IPRs in conformity with the 
obligations required by the Agreement.
41
 Formerly, 
the protection of IPRs was not well developed in 
Pakistan. The laws governing IPRs in Pakistan can be 
divided into two regimes: Pre-2000 and Post-2000. 
 
The existence of these two regimes is obvious for the 
reason that after 2000 Pakistan was obliged to 
replace its outdated and archaic IP-related laws, in 
order to comply with the global standards and the 
requirements of the TRIPS Agreement.
42
 The pre-
2000 legislation
43
 included: 
 
 The Patents and Designs Act 1911 and the 
Patent Rules 1933; 
 
 The Patents and Designs Act 1911 and 
Design Rules 1933; 
 
 The Trademarks Act 1940 and the 
Trademark Rules 1963; and 
 
 The Copyright Ordinance 1962 and the 
Copyright Rules 1967. 
 
The foregoing laws were replaced with new laws i.e. 
post-2000 legislation
44
, including: 
 
 The Patent Ordinance 2000 and the Patent 
Rules 2003; 
 
 The Registered Designs Ordinance 2000; 
 
 The Registered Layout-Designs of 
Integrated Circuits Ordinance 2000;  
 
                                               
40 
<https://www.wto.org/english/thewto_e/countries_e/paki
stan_e.htm> (last visited 15 January 2016). 
41 
<https://www.wto.org/english/tratop_e/trips_e/tripfq_e.h
tm#Who%27sSigned>(Last visited 15 January 2016). 
42 Id. 
43 <http://supremecourt.gov.pk/ijc/Articles/19/2.pdf> (last 
visited 15 January 2016). 
44 ibid. 
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 The Trademarks Ordinance 2001 and the 
Trademark Rules 2004; 
 
 The Copyright Ordinance 1962, as 
amended in 2000; and 
 
 The Copyright Rules 1967, as amended in 
2002. 
 
The two aforementioned regimes with different 
legislations highlight the impact of the TRIPS 
Agreement, which resulted in significant changes in 
the laws related to IPRs. The Intellectual Property 
Organization of Pakistan (IPO-Pakistan) established 
on 8 April 2005 under the cabinet division is the 
main institution in Pakistan that deals with the 
management and enforcement of IPRs, creating 
awareness about their great importance in a modern 
and digitalized society. It deals with the 
administration of IPRs, including patents, 
trademarks, designs and copyrights and promotes 
protection by taking various steps and proposes 
legislation.
45
 
 
The concept of specialized courts or tribunals having 
exclusive jurisdiction over particular subject matters 
is not novel or without examples in the context of 
Pakistan.
46
 The constitution of Pakistan allows the 
establishment of such specialized courts.
47
 
Therefore, in order to further strengthen IPR 
enforcement and to increase efficiency, separate IPR 
Tribunals having exclusive jurisdiction regarding IPR-
disputes have been established in Pakistan, based on 
modern IP judicial models. However the number of 
such tribunals is determined by the federal 
government, according to judicial necessity. At 
present three courts have been established: one in 
Punjab, in Sindh and the last in the federal capital 
territory of Islamabad; the courts became functional 
on 1 October 2015 after the appointment of 
presiding officers.
48
 The Tribunals have the exclusive 
jurisdiction to hear cases regarding the infringement 
of IPRs or any other offence related to IP.
49
 Then any 
                                               
45 <http://ipo.gov.pk/Contents/AboutIPO.aspx>(last visited 
15 January 2016). 
46 Anti-Terrorism courts, Accountability Courts, Banking 
Courts, Consumer Courts, Child Protection Court, Drug 
Courts, Environmental Protection Tribunals, Labour Courts 
to name a few are currently working in Pakistan.  
47 Article 175. The Judicature. Part VII. The Courts. Chapter 
1 of the Constitution of the Islamic Republic of Pakistan. 
48 
<http://ipo.gov.pk/Common/NewsDetails.aspx?NewsID=25
3> 
 (last visited 15 January 2106). 
49 Section 18(1) and (2) of the Intellectual Property 
Organization of Pakistan Act, 2012. 
High Court having territorial jurisdiction over the 
tribunal can hear the appeals from the tribunals.
50
 
IV. ADVANTAGES AND DRAWBACKS OF 
SPECIALIZED IP COURTS 
A state stands to gain numerous benefits by 
establishing a specialized IP judicial system as 
exemplified in some of the systems of developed 
countries. The establishment of a specialized IP 
enables governments to legislate according to issues 
and challenges in this particular area of litigation, in 
which legislation may include regulations, 
procedures or laws. Specialized IP courts in Pakistan 
would give judges of the courts an opportunity to 
develop expertise in IP law. Such expertise in this 
area would enable the judges to decide IP cases 
more efficiently and effectively. The impact of such 
expertise would be that the judges and advocates 
would be able to diagnose patterns, intricacies and 
issues arising from cases, rendering the overall 
system more effective.
51
 
Intellectual property-related Issues are becoming 
more complicated than ever as a result of changing 
technologies and the rise in the number of 
innovations. Hence a specialized system with expert 
and competent professionals would contribute to an 
incessant development in this legal arena, required 
to tackle these issues effectively. The establishment 
of a specialized IP system would ensure protection of 
IPRs and encourage business and commercial 
communities to invest. Weak enforcement of IPRs in 
some developing countries like Pakistan might 
discourage multinational companies to invest and 
start business in such countries due to the possibility 
of loss of their valuable rights. The establishment of 
specialized IP courts would improve the protection 
of IPRs and encourage multinational companies to 
invest more in Pakistan; hence its economy would 
grow further. 
Though there can be many benefits of a specialized 
IP system, still the hypothesis may not stand equally 
true and beneficial for every state. There must be a 
contextualized analysis of the particulars of the given 
country, taking into consideration the advantages 
and drawbacks in order to measure the overall 
efficacy. If a specific model is effective in a particular 
country, it does not necessarily mean that such a 
model would be appropriate in any other country. 
Every state should adopt a model for the protection 
of IPRs, customized and tailored to its own 
                                               
50 Section 19 of the Intellectual Property Organization of 
Pakistan Act, 2012. 
51 The International Intellectual Property Institute (IIPI) and 
the United States Patent and Trademark Office (USPTO), 
Study on Specialized Intellectual Property Courts (2012). 
 
 
WIPO-WTO Colloquium Papers, 2015 
_____________________________________________________________________________________ 
 
61 
 
conditions, context, requirements and pattern or 
nature of the issues. These considerations should be 
taken into account by every government and are 
crucial, especially for a developing country with 
quite limited resources like Pakistan. Accordingly, it 
must be evaluated if the cost is justifiable, because a 
great deal would be spent on infrastructure and the 
establishment of such a specialized system. 
Another aspect to take into account is that there 
should be sufficient litigation for a separate system 
in order to justify this cost. Thus the cost must be 
weighed against the benefits, otherwise it would be 
merely the misuse of resources and it would be 
more pragmatic to spend the resources to resolve a 
number of other issues that a country like Pakistan is 
facing such as poverty and terrorism. In a country 
like Pakistan the focus should be on promoting IP 
education by arranging special courses and training 
on IPRs for small and medium-sized enterprises 
(SMEs), lawyers, judges and the business 
communities. This would be a more pragmatic 
approach, as it would not only reduce litigation by 
bringing awareness, but also reduce the need for 
such tribunals and would save resources for other 
issues. 
52
 
The countries having modern IP judicial systems 
models have IP expertise in the specialized courts for 
the IPR matters as exemplified in the 
aforementioned case-studies. The establishment of a 
separate IP court system seems logical and justified 
only if it has the judges who have special knowledge 
in IPRs, otherwise there is no point in creating a 
separate system if it lacks this requirement because 
there will be no novelty, and instead of bringing the 
intended consistency, certainty and efficiency, it will 
inevitably lead to various problems.  
As regards the situation in Pakistan at present, 
separate tribunals have been established, but the 
qualification for presiding officers does not include 
any expertise in IP. A person who has been judge of 
the High Court or has been a District and Sessions 
Judge or an advocate who is qualified to be 
appointed as a Judge of High Court can be a 
presiding officer in the IP tribunal, so technically 
there is no one specialized in the IP tribunals.
53
  
The other issue with the specialized IP tribunals in 
Pakistan is that only three courts have been 
                                               
52 The International Intellectual Property Institute (IIPI) and 
the United States Patent and Trademark Office (USPTO), 
Study on Specialized Intellectual Property Courts (2012) 
53 Section. 16(4) of the Intellectual Property Organization of 
Pakistan Act, 2012. 
established in the province of Sindh, Punjab and in 
the federal capital territory Islamabad but no 
tribunal has been established in Khyber 
Pakhtunkhwa and the province of Baluchistan.
54
 So it 
has become difficult for litigants to access the 
tribunals as there are many commercial centres in 
major cities and this has further worsened the 
situation, because before the establishment of the 
aforementioned tribunals, the proceedings regarding 
IPRs could be initiated in any district court. This is a 
very important factor which must be considered for 
tribunals should be easily accessible to the litigants, 
whether by increasing the number of tribunals or 
analysing the locations of commercial centres, and 
the locations of the tribunals should be decided 
accordingly.
55
  
The other issue concerning the establishment of 
specialized IP tribunals is that, as the judges would 
remain the same and only a limited number of 
judges would preside, there is a probability that 
judges may become prejudiced. As in Pakistan there 
would be one judge in each IP tribunal and this legal 
arena is still developing, only a limited number of 
lawyers are experts on IP-related issues, and they 
would be frequently appearing before the same 
judge with the possibility that the judge may become 
biased, which is detrimental to the essence of the 
independence of the judiciary i.e. impartiality, and 
may lead to corruption.
56
 
Establishing specialized IP courts dealing with 
particular IP matters may narrow the vision and the 
mentality of the judges confined to IP matters and 
may lead to ignorance of other legal causes of action 
and matters involved in a case. This would affect 
cases which involve multiple interlinking issues, need 
to be resolved collectively.
57
 
V. CONCLUSION 
Having specialized intellectual property courts may 
represent both benefits and issues and challenges. 
Pakistan, being a developing country with limited 
resources, should focus on bringing awareness to 
lawyers and judges with special training. Public 
                                               
54 
<http://ipo.gov.pk/Common/NewsDetails.aspx?NewsID=25
3>(last visited 21 February 2016). 
55 The International Intellectual Property Institute (IIPI) and 
the United States Patent and Trademark Office (USPTO), 
Study on Specialized Intellectual Property Courts (2012). 
56 The International Intellectual Property Institute (IIPI) and 
the United States Patent and Trademark Office (USPTO), 
Study on Specialized Intellectual Property Courts (2012). 
57 ibid. 
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awareness of intellectual property compliance also 
needs to enhanced, keeping in view factors such as 
poverty, corruption, nepotism, lack of expertise and 
lack of IP education. Thus instead of establishing 
separate intellectual property tribunals, leading to 
various issues in the context of Pakistan, a more 
pragmatic middle ground would be to improve the 
existing legal system for IP matters by reforming the 
overall judicial system and diagnosing the root 
causes of the issues rendering the overall system 
inefficient. It could be more justifiable in terms of 
cost and benefits. However, as the specialized 
intellectual property tribunals have now been 
established by the Government of Pakistan and are 
now functional, such tribunals would only serve the 
purpose if judges receive suitable training on the 
subject matter and other steps, necessary to 
maximize the benefits and minimize the issues and 
challenges related to specialized IP courts, are 
urgently taken, keeping in view the limited resources 
and other constraints being faced by the country. 
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8 PARALLEL IMPORTS, TRADEMARK LAW, AND 
AGENCY REGULATIONS: LEGAL UNCERTAINTY IN UAE 
JURISPRUDENCE 
 
Dr Bashar Malkawi* 
ABSTRACT 
Parallel importation is one of the most enigmatic issues 
in the laws of the United Arab Emirates (UAE). This 
article addresses the merits and demerits of parallel 
importation from the perspective of the UAE. It reviews 
the relevant provisions in its trademark and agency laws, 
as well as relevant case law. The article also examines 
the options available to the UAE legislature to reform its 
laws and then provides a set of conclusions and 
recommendations.  
Keywords: trademarks law, agency law, parallel imports, 
exhaustion, trade 
I. INTRODUCTION 
Trademarks are among the most precious assets of 
enterprises. The value of a trademark amounts to 
billions of dollars. Each year the Best Global Brands 
Report generates increasing interest from companies 
and practitioners associated with brands and the Report 
lists the top 100 most valuable brands worldwide.
1
 
Emirates Airline, headquartered in the UAE, is the most 
valuable airline brand worldwide valued at 
US$7.5 billion.
2
  
The UAE encounters cases of parallel importation 
because it is a high-priced economy. Parallel imports can 
occur on account of the non-availability of a product in 
the market or of sourcing low-priced products from 
other countries, thus making it possible to make profits 
through price differences.
3
 Generally parallel import 
                                               
1* Dr Bashar H. Malkawi (United Arab Emirates) is Dean and 
Professor of Law at the University of Sharjah, United Arab 
Emirates. He holds an S.J.D in International Trade Law from 
American University, Washington College of Law and a LLM in 
International Trade Law from the University of Arizona. I would 
like to thank Professor David A. Gantz, Professor Mohamed Al-
Shafie, and Ms Martha Chikowore for their review and am 
highly appreciative of their suggestions and comments. 
1 See Best Global Brands Ranking, Interband Ranking (2014). 
available at <http://www.bestglobalbrands.com/2014/ranking/ 
>  
2 Emirates finished 171 out of the 500 evaluated global brands. 
See Emirates Soars as World's Most Valuable Airline, Gulf News 
(2 February 2016). 
3 See Triska Hamid, 'UAE Tech Fans Forced to Dig Deep for 
Microsoft Surface' The National (11 November 2012) (In 
September the iPhone 5 reached Dh6,000 before dropping 
almost Dh2,000 only a few weeks later). The main reason why 
parallel imports have emerged is price differentials between 
the same products sold in different markets. See also 
Christopher Stothers, Parallel trade in Europe: Intellectual 
Property, Competition and Regulatory Law 2 (2008).  
products are cheaper, depending on the nature of the 
product, owing to the absence of customer care and 
warranties.
4
 In exceptional circumstances however, 
prices can soar and fluctuate. Retailers are tempted to 
opt for parallel imports when manufacturers fail to 
launch a product. Low prices for parallel imported 
products may affect the domestic sales of the 
trademarked products, giving rise to the question as to 
whether parallel imports should be restricted or 
prohibited. 
UAE is a party to several treaties and international 
organizations. For example, UAE is a member of the Gulf 
Cooperation Council (GCC).
5
 In addition, UAE is a 
Member of the World Trade Organization (WTO).
6
 
Although UAE has made many efforts to bring its 
intellectual property laws into compliance with the 
international legal standards set forth in the WTO's 
Agreement on Trade-Related Intellectual Property Rights 
(TRIPS) and other international treaties, the UAE has not 
taken a clear stance on many intellectual property issues 
such as trade secrets, and trademark exhaustion and 
parallel imports of trademarked goods. Trademarks 
have been the form of intellectual property most 
familiar to the business community in the UAE. Yet, 
neither trademarks law nor agency law or practice 
addresses clearly parallel importation.
7
 
Parallel imports or grey market goods are genuine goods 
and not counterfeits, whereby trademark is 
misappropriated. Parallel imports involve the 
importation of genuine goods outside the authorized 
distribution channels. In other words, parallel import is 
the importation of these goods from a foreign source by 
bypassing the authorized local distributor and trademark 
licensee, thereby allowing the sale of goods directly to 
                                               
4 For example, grey market pharmaceutical products in the 
United States can be as much as 80 per cent cheaper. See Elin 
Dugan, 'United States of America, Home of the Cheap and the 
Grey: A Comparison of Recent Court Decisions Affecting the US 
and European Grey Markets' (2001) 33 Geo. Wash. 
Int'l L. Rev. 397,410.  
5 The GCC is generally regarded as a success story for economic 
integration in Arab countries. The GCC was established in May 
1981. The GCC consists of six member states: (1) United Arab 
Emirates; (2) Bahrain; (3) Saudi Arabia; (4) Oman; (5) Kuwait; 
and (6) Qatar. See the Cooperation Council Charter, List of 
Member States (1981) available at 
<http://www.gccsg.org/eng/index.php?action=Sec-
Show&ID=1> (last visited 12 February 2016). 
6 UAE has been a Member of the WTO since 10 April 1996. See 
World Trade Organization, Members and Observers, available 
at: 
<https://www.wto.org/english/thewto_e/whatis_e/tif_e/org6_
e.htm> (last visited 11 February 2016).  
7 The paper is concerned mainly with parallel importation 
development in the UAE in the context of trademarks laws and 
agency regulation. However, trademarks law shall not be 
regarded as the only instrument of regulating parallel 
importation. Competition law, which is outside the scope of this 
paper, is an indirect instrument that can be used to address the 
issue of parallel importation. Parallel import restrictions can 
distort competition and thus may breach competition law.  
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retailers or consumers.
8
 In most cases, the manufacturer 
establishes an exclusive territory or conditions of resale 
through some contractual agreement or agreements, by 
which the manufacturer, distributor or trademark 
registrant generally agrees to sell only to particular 
entities and not to other entities that may compete with 
the authorized channel.
9
 
The paper will examine these competing interests in 
further detail, analyse why the courts in UAE have been 
reluctant to adopt a clear position on parallel imports, 
and explain why a legislative amendment to the 
Trademarks Law and Agency regulation is likely to be 
necessary before UAE's position on parallel imports is 
made clear. 
II. THE UAE COMMERCIAL AGENCIES LAW 
The Commercial Agencies Law (Federal Law No. 18 of 
1981, as amended by Federal Law No. 14 of 1988) 
defines a commercial agency as any arrangement, 
whereby a foreign company is represented by an agent 
to distribute, sell, offer, or provide goods or services 
within the UAE for a commission or profit.  
Trading is at the core of the UAE's commercial heritage, 
and consequently the UAE has special laws and practices 
encouraging foreign suppliers to use local sales agents.
10
 
The following conditions highlight this stance: 
 Commercial agents must be UAE nationals or 
companies incorporated in the UAE and 
owned entirely by UAE nationals.
11
 
 Commercial agents must be registered with 
the UAE Ministry of Economy and Commerce 
to engage in commercial agency activities. 
However, if the agency is not registered, no 
action can be taken against parallel 
importation. 
 The agency agreement must be registered in 
order for the agent to avail himself of the 
protections afforded under the law and to 
have the agency relationship recognized under 
UAE law.  
                                               
8 See Keith E Maskus, 'Parallel Imports', (2000).23 World Econ. 
1269. 
9 See Robert J Staaf, 'The Law and Economics of the 
International Grey Market: Quality Assurance, Free-Riding and 
Passing Off' (1988) 4 Intell. Prop. J. 191, 192. 
10 See Alisha Ansari, 'What is the Scope of Competition Law in 
the UAE? A Comparative Study with Developed and Developing 
Nations 131-137 (Master Thesis, University of Western Ontario 
2013). 
11 See Federal Commercial Agencies Law No. 18 of 1981, 
Article 2. 
 Commercial agents are entitled to an exclusive 
territory encompassing at least one emirate 
for the specified products. (Article 5.1 of the 
Commercial Agencies Law). However, an 
exclusivity agreement does not change the 
source of the product.  
 Unless otherwise agreed, commercial agents 
are entitled to receive commissions on sales of 
the products in their designated territory, 
irrespective of whether such sales are made by 
or through the agent. (Article 7 of the 
Commercial Agencies Law) 
 Commercial agents are entitled to prevent 
products subject to their agency from being 
imported into the UAE if the agent is not the 
consignee. A corollary dimension that arises in 
relation to the application of this article is the 
controversial subject of parallel importation. 
For example, the president of Samsung Gulf 
Electronics has called on the UAE Government 
to implement tougher restrictions on the 
parallel importation of branded consumer 
electronics goods. Retailers are selling 
Samsung products outside of regulated 
distribution channels.
12
 The language of the 
commercial agency law effectively acts as a 
ban on parallel imports of that product. 
However, companies operating in free trade 
zones in the UAE can import such products 
and resell them within a free zone.  
 Commercial agents are entitled to receive 
compensation from the principal if the agency 
is terminated without substantial justification 
or if the agency is not renewed by the foreign 
principal and the agent may be able to 
preclude the foreign party from appointing a 
replacement agent in such circumstance. 
On the basis of these conditions, a sales agent is given 
the exclusive right to import the relevant product, to 
receive compensation for any parallel import of the 
product by others and even to block the foreign 
supplier's direct import of the product into the sales 
agent's territory. In other words, the local commercial 
agent is given a monopoly right and serves as the main 
instrumentality for protecting trademarks. 
III. TRADEMARKS LAW: THE GENERAL FRAMEWORK 
Trademarks identify the source from which the goods 
originate and guarantee the quality of the goods bearing 
                                               
12 See Ronan Shields, 'Samsung Warns UAE over Parallel 
Imports' Arabian Business (14 November 2006). 
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that trademark.
13
 The UAE Trademarks Law of 2002 
emphasizes the function a trademark plays in 
distinguishing the goods and protecting the interests of 
consumers.
14
 
The Trademarks Law of 2002 (Trademarks Law) 
describes a trademark in the broadest language as any 
visually perceptible sign. The Trademarks Law defines a 
trademark as any visually perceptible mark used or 
available to any person to distinguish his goods or 
services from the goods or services of others. This is in 
compliance with Article 15 of the TRIPs Agreement 
which states that a Member may require, as a condition 
of registration, that a sign be visually perceptible. For 
instance, a trademark could be a word, logo, numeral, 
letter, slogan, or a colour.
15
 As such, the Trademarks 
Law does not apply to non-traditional trademarks such 
as sound or smell. For example, a fragrance trademark 
can never be registered.
16
 In order to receive protection, 
a trademark does not need to be original, but it must be 
distinctive and be able to represent to consumers the 
source of goods or service identified. The UAE adopts a 
system of first-to-file. When there are two or more 
applications for registration of marks identical with or 
confusingly similar to each other, or for identical or 
similar goods or services, legal protection may only be 
granted to the valid application with the earliest priority 
or filing date amongst all applications.
17
 Article 19 of the 
Trademarks Law grants protection in renewable ten-
year portions. Specifically, Article 19 states, in part, that: 
The period of protection resulting from the 
registration of a trade mark shall be 10 years. 
The mark owner may secure the continuance 
of such protection for successive periods of 10 
years each if he applies for renewal of such 
mark's registration within the last year of the 
                                               
13 See William Cornish and David Llewelyn, Intellectual Property: 
Patents, Copyrights, Trademarks and Allied Rights 620 (6th ed., 
2007). 
14 See Trademarks Law No. 8 of 2002, Article 3. Presumably the 
law does not permit registration through the Madrid System 
Concerning the International Registration of Marks under the 
Madrid Protocol, since UAE is not a party. This is the trademark 
registration system used by the nearly 100 countries. Although 
it is not directly relevant to grey market goods it would 
facilitate trademark protection for global companies operating 
in the UAE and their agents. See World Intellectual Property 
Organization, Madrid – The International Trademark System, 
available at: <http://www.wipo.int/madrid/en/>. 
15 See Article 2 of Trademarks Law No. 8 of 2002, In respect of 
colours, it is to be noted that limitation of a trademark to a 
colour(s) may be a basis for establishment of distinctiveness. As 
to whether colours themselves, such as the colour orange, can 
be treated as trademarks, the answer is not clear. 
16 The registration of fragrances or sounds would present 
complex challenges for trademark examiners in the UAE. It is 
unclear how they would be categorized, catalogued, preserved 
during the registration period, or searched and tested for 
confusing similarity. 
17 ibid. Article 17.  
valid protection period according to the terms 
and conditions provided for in this Law and its 
Executive Regulations.  
The Trademarks Law provides penalties against 
offenders who misrepresent goods or use counterfeit 
trademarks. These penalties include fines and/or 
imprisonment.
18
 Article 37 of the law states: 
Shall be sentenced to imprisonment and a fine 
of at least Dh. 5000 (Five Thousand) or either: 
1. Any person who forges a trade mark 
registered according to law or imitates same in 
a way misleading the public and any person 
who uses with bad faith a forged or imitated 
trade mark. 2. Any person who places with bad 
faith on his products a registered trade mark 
owned by a third party, or uses such mark 
without right. 3. Any person who deliberately 
sells, offers for sale or negotiation or acquires 
for sale products having a forged, imitated or 
illegally placed trade mark, the same applies to 
any person who deliberately provides or offers 
the provision of services under a forged, 
imitated or illegally placed trade mark.  
Moreover, Article 39 states: 
Any person who repeats one of the offenses 
stated in Articles 37 and 38 hereof, shall be 
punished with the same penalty in addition to 
closing the commercial premises or the 
exploitation project for a period of no less 
than 15 days and no more than 6 months and 
publishing the judgment at the cost of the 
party adjudged pursuant to the procedures 
indicated in the Executive Regulations.  
The Law does not state if the owner of an infringed 
trademark may obtain an accounting of profits. 
Moreover, Article 41 of the Law provides for a cease and 
desist order. It also provides for an interlocutory seizure 
of goods. The seizure is to take place at the request of 
the owner of a trademark. The Law provides for the 
destruction or disposal of materials or tools used in 
infringement of trademarks. Article 43 states that: 
The competent court may rule the confiscation 
of the object attached or to be attached later 
and the deduction of its price from the fines or 
compensations or disposition thereof in any 
other way deemed expedient by the court. The 
court may also order to destroy the illegal 
marks or, when necessary, to destroy the 
products, envelopes, packing, tools and any 
such other objects bearing such marks or 
illegal data, as well as, the machines and tools 
                                               
18 ibid. Article 37.  
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used specifically in the forging operation. It 
may likewise order all the foregoing even in 
case of acquittal. The court may further order 
that the judgment be published in the bulletin 
or in an Arabic daily at the cost of the 
judgement debtor.  
An owner of a trademark will have to register the 
trademark for using it.
19
 This is in line with the doctrine 
that trademark rights are territorial.
20
 Registration of a 
trademark gives certain rights which include the 
exclusive right to use the mark, licensing, and 
enforceability.
21
 For example, Article 10 of the 
Trademarks Law provides that: 
Subject to the provisions of Article 26 hereof, 
no trade mark identical or similar to an already 
registered mark may be registered for the 
same categories of products or services, or 
different goods or services, if the use of the 
requested trademark would generate an 
impression that such goods or services are 
linked to the goods or services of the owner of 
the registered mark or prejudicing his 
interests. Should one or more persons apply 
simultaneously for the registration of the same 
mark or close or similar marks for one 
category of products or services, the Ministry 
shall suspend the registration of all 
applications until an attested waiver is 
submitted by the opponents in favour of one 
of them or a final judgment is awarded in 
favour of one of them. 
In addition, Article 17 states:  
Any person who registers a mark shall be 
deemed its sole owner. The ownership of such 
mark may not be disputed if the person who 
registers it, uses it uninterruptedly for at least 
5 years from the date of registration without 
an action being lodged against him ruling for 
its validity. The owner of a registered 
trademark may prevent others from using a 
similar or identical trademark, to distinguish 
products or services that are identical, similar 
                                               
19 ibid. Article 7. 
20 Registered trademark rights extend nationwide within a 
country. For instance, for the purpose of trademarks law, only 
registration -and in some cases use - in UAE is relevant. If a 
company desires to extend its trademark rights outside the 
national borders of a particular country, then that company 
must register its trademark in every country. See Edouard 
Treppoz, 'International Choice of Law in Trademark Disputes 
From a Territorial Approach to a Global Approach' (2014). 37 
Colum. J.L. and Arts 557, 559  
21 See Trademarks Law No. 8 of 2002, Articles 10, 17, 30, 31, 
and 37.  
or correlated for which the mark has been 
registered, in such a way that confuses the 
consumers.  
Article 30 provides that: 
The owner of a trade mark may, by a written 
and attested contract, licence one or more 
persons to use such mark for all or part of the 
products or services for which the mark is 
registered. The mark owner may use it himself 
unless otherwise agreed. The period for 
licensing the use of a mark may not exceed 
that prescribed for its protection. 
Also, Article 31 of the law states: 
A contract licensing the use of a trade mark 
shall be recorded in the Trade Marks Register 
of marks. Such licensing shall have no effect 
vis-à-vis third parties except after being 
recorded in the register and announced in the 
manner determined in the Executive 
Regulations.  
Article 37 provides that: 
Shall be sentenced to imprisonment and a fine 
of at least Dh. 5000 (Five Thousand) or either:  
1. Any person who forges a trade mark 
registered according to law or imitates same in 
a way misleading the public and any person 
who uses with bad faith a forged or imitated 
trade mark; 
2. Any person who places with bad faith on his 
products a registered trade mark owned by a 
third party, or uses such mark without right; 
3. Any person who deliberately sells, offers for 
sale or negotiation or acquires for sale 
products having a forged, imitated or illegally 
placed trade mark, the same applies to any 
person who deliberately provides or offers the 
provision of services under a forged, imitated 
or illegally placed trade mark.  
The Trademarks Law provides for a registry of 
trademarks.
22
 The registry helps inform applicants what 
marks have been registered, and provides a description 
of their goods, products and services, changes, and 
licence of the mark.  
                                               
22 ibid. Article 5. 
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IV. UAE LAW AND EXHAUSTION OF RIGHTS 
The theory of trademark exhaustion is used to justify the 
importation of grey market products. Under this theory, 
once the first sale of a marked product takes place after 
the product has entered the stream of commerce in the 
trademark owner's territory, the trademark owner's 
rights are exhausted, that is to say, the trademark owner 
can no longer control sales of the trademarked 
products.
23
 It has also been argued that the trademark 
owner loses the right to control subsequent sales of 
trademarked products even once these products have 
been sold abroad.
24
 
There is no international agreement that addresses 
national, regional, or international exhaustion. The Paris 
Convention does not regulate this issue and the TRIPS 
Agreement takes a neutral position in dealing with this 
concept.
25
 As negotiators of TRIPS could not agree on 
how to deal with grey market goods, the issue of 
exhaustion and parallel importation is left to national 
legislations and court decisions.  
Whether or not the owner or licensee of the registered 
trademark can block the importation of the grey market 
goods depends on what position the UAE adopts on 
trademark exhaustion and parallel imports. The 
Trademarks Law fails to address clearly whether parallel 
imports infringe trademark rights and whether it adopts 
a national or international exhaustion of rights. 
Additionally, UAE customs authorities, even in 
developed countries such as the United States and the 
European Union, in general can be somewhat lax when 
it comes to checking whether the products are 
authorized for sale by the manufacturer or rights holder 
at the point of entry, unless the lawful trademark holder 
advises customs regarding the likelihood of shipments of 
grey market goods.
26
 It just is not a high priority for most 
customs services. 
The most pertinent legislative provisions provide in 
relevant parts: 
 The trademark owner who registered his mark 
in UAE has the exclusive right to use such 
trademark for the product that it has been 
registered.
27
 However, the Trademarks Law 
                                               
23 See Ryan L Vinelli, 'Bringing Down the Walls: How Technology 
is being Used to Thwart Parallel Importers Amid the 
International Confusion Concerning Exhaustion of Rights' (2009) 
17 Cardozo J. Int'l and Comp. L. 135, 149.  
24 Lazaros G Grigoriadis, Trade Marks and Free Trade: A Global 
Analysis 59-60 (2014).  
25 Article 6 of the TRIPS Agreement provides that nothing in the 
agreement shall be used to address the issue of the exhaustion 
of intellectual property rights. 
26 See James Whymark, Policing Parallel Imports around the 
World, in Anti-Counterfeiting  – A Global Guide (2014) 32  
27 See Trademarks Law No. 8 of 2002, Article 17.  
does not provide examples of 'use' of the 
holder of a trademark right such as 
subsequent sale, displaying or distributing 
trademarked products.  
 It shall not be permissible to cause prejudice 
to the exclusive right of another person to use 
a registered trademark. This language can 
provide protection against parallel imports on 
the basis that such imports can cause 
prejudice to the exclusive right to a trademark.  
 Registration of any trademark which is 
identical or similar to a trademark previously 
registered for the same classes of products or 
services, or non-similar class of goods and 
services, is not permitted if using the 
trademark may generate the impression of a 
connection between the goods and services to 
be registered and those of the owner of the 
registered mark, or if using the trademark to 
be registered may damage his interests.
28
 This 
Article can be used to block import goods that 
bear any marks confusingly similar to 
registered trademarks. 
 The trademark owner may, by a written 
notarized contract, grant to any person a 
licence to use the trademark in accordance 
with the agreed agreement and quality 
guidelines. The trademark licence agreement 
may specify the range of the geographical area 
for marketing products or services bearing the 
trademark; and to prevent all actions, which 
may lead to lower the value of or cause harm 
to the products or services bearing the 
trademark.
29
 Thus, a trademark owner can use 
the licence to restrict the sale or distribution 
of products bearing his mark when these 
products are manufactured abroad. The 
licensee could argue that the imported 
products are manufactured in breach of the 
licence agreement lacking the quality of the 
genuine products.  
 It is an infringement of the exclusive right to 
use a registered trademark to sell goods that 
the owner knows bear a counterfeited 
registered trademark.
30
 
V. UAE CASE LAW 
The influx of grey market goods has generated a few 
court cases that have seen trademark holders and their 
authorized distributors pitted against retail dealers who 
                                               
28 ibid. Article 10.  
29 ibid. Article 34.  
30 ibid. Article 37. 
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have profited from their sales of grey market products. 
The legal theories under which a plaintiff can file a 
trademark infringement suit include the Trademarks 
Law, unfair competition, unjust enrichment, and breach 
of contractual relations in agency agreements.
31
 This is 
explained in the following typical cases. 
A case concerning parallel imports was decided in 
2009.
32
 It is generally considered the most significant 
case because for the first time in the UAE it resulted in 
imprisonment of the defendants.
33
 However, closer 
examination of the case reveals that the court treated 
the case as one involving counterfeit goods and thus 
imposed the jail sentences.
34
 By definition grey market 
goods are genuine, not counterfeit. If the imported 
products are counterfeit, the exclusive importer can 
prevent the sale of these products by filing a trademark 
infringement claim in the court. Moreover, the court 
ruled – in part - that the importation of goods must go 
through approval procedures by government entities 
before importation is allowed. One wonders whether 
the defendant in that case had obtained the necessary 
governmental approval would the products still have 
been permitted to enter the country. The court did not 
provide clear guidance under what circumstances 
parallel imports may be permitted, and what if 
appropriate government permits were obtained. 
Therefore, the jurisprudential value of that case can be 
limited.  
The case concerns a UAE company, UAE Mechanical, 
acting as an agent and distributor of ‘Maggi’ chicken 
stock cubes which is a product of Nestle.
35
 It came to the 
knowledge of UAE Mechanical that some traders 
                                               
31 Courts in other countries considered various theories in their 
analyses of parallel importations. For example, some courts 
focussed on the function of the trademark which serves to 
identify the source of the goods, while in some cases the focus 
was upon deception or consumer confusion. Other courts 
focussed on material differences between the goods. See 
Christine Haight Farley, 'Territorial Exclusivity in US Copyright 
and Trademark Law' (2014) Washington College of Law 
Research Paper No. 2014-30, 51-52.  
32 See Praveen Menon, 'Shopkeeper jailed over illegal DVDs' 
The National (13 October 2009). 
33 ibid. 
34 Trademark laws afford various types of relief to owners of 
registered marks. These include seizure, confiscation or 
destruction of infringing goods. Damages may also be awarded. 
In addition, infringement constitutes a criminal offence 
punishable by imprisonment or fines. Therefore, a criminal case 
may be filed simultaneously with a civil action for damages. See 
Amir H Khoury, 'The Development of Modern Trademark 
Legislation and Protection in Arab Countries of the Middle East' 
(2003) 16 Transnat'l Law 249, 263, 275. See also Bradley J 
Olson, 'The 10 Things Every Practitioner should Know about 
Anti-Counterfeiting and Anti-Piracy Protection' (2007) 7 J. High 
Tech. L. 106, 125  
35 See Journal of Bar Association, Decision No. 10/1418, p 957 
(2010). 
imported boxes of Maggi cubes (product of Egypt). As 
stated by the plaintiff, these products did not conform 
to the required specifications. The High Federal Court 
found that UAE Mechanical was entitled to preserve its 
rights as the authorized agent of the manufacturing 
company for marketing certain goods.
36
 Also, the court 
accepted UAE Mechanical's arguments that it was 
entitled to protect its rights in the trademark that is 
registered for Maggi cubes and that unauthorized 
importation and sale of these goods was an 
infringement of the exclusive rights. 
As the facts of the case show, some parallel importers 
imported genuine goods that are subject to an agency 
agreement with the purpose of circumventing the agent. 
The effect of the Court's decision is that while Nestle 
could not enjoin sales of grey market goods in the UAE, 
its agent/distributor succeeded in obtaining remedies by 
having the goods of the parallel importers impounded, 
destroyed, or re-exported, or by requesting 
compensation. Apparently, the quality of Maggi 
(product of Egypt) differs from Maggi cubes designed for 
the UAE market. Maggi of Egypt cubes may not be 
designed to comply with consumer specifications in 
UAE. By bringing the case, the agent/distributor sought 
to protect regular trade channels. In this context, it 
raised possible violations of the agency law. Trademark 
infringement cases focus on the protection of the rights 
of the commercial agent and the elimination of the 
threat to monopoly rather than the recognition and 
protection of trademark rights.
37
 Unfortunately, the 
court in that case did not address the issue of parallel 
importation in greater detail. 
In another case, the trademark owner entered into a 
licensing agreement with a UAE distributor.
38
 Then a 
third party in the UAE attempted to import the goods. 
That case presented an opportunity for the courts to 
rule directly on the legality of importing parallel imports 
without the prior authorization of the trademarks owner 
or its licensee. In that case, however, the trademark was 
not registered in the UAE, so the plaintiff could not 
proceed under the Trademarks Law which is applicable 
only to national registered trademarks (unless the mark 
is well known), and had to proceed under unfair 
                                               
36 In the UAE, cases decided by courts do not have precedential 
value, as they provide an indication of how courts approach 
issues and are of some value in predicting how future cases 
might be decided. The sole exceptions are decisions by the High 
Federal Court, the highest court in UAE, which is highly 
influential and asserts wide powers. 
37 For example the Brylcreem case in the UAE was lodged under 
the commercial transaction law, but not under the trademarks 
law. See David Price, The Development of Intellectual Property 
Regimes in the Arabian Gulf States: Infidels at the Gates (2009) 
36.  
38 See Journal of Bar Association, Decision No. 13/786, 
(2013).page 147.  
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competition provisions of the Commercial Code.
39
 
Therefore, the court did not address whether the 
licensee or trademark owner's rights were exhausted. 
The court considered the claim based upon the need to 
prevent consumer confusion as to the source of goods. 
The approach taken by courts in the UAE demonstrates 
that the judiciary is not the proper vehicle for a final 
determination of the parallel importation issue. Courts 
were presented with specific facts that differed on a 
case-by-case basis. Those court decisions do not settle 
the matter in a satisfactory matter. Sometimes 
conflicting court cases have definitely muddied the 
waters. Customs authorities may not be able to seize 
grey market goods at the borders as a result of practical 
administrative difficulties. An authorized agent or 
distributor should bring a private action in court against 
the importer of grey market goods, a task that could 
prove difficult as the distributor must identify the 
parallel importer and engage in a time-consuming 
process.
40
 Modification in legislations and holistic policy 
changes are needed. 
VI. THE DEBATE OVER PARALLEL IMPORTS IN THE UAE 
The debate over whether to permit parallel imports of 
trademarked goods in the UAE raises important and 
sensitive political, economic and legal issues. The 
broader policy question concerns a conflict between the 
importance of permitting free competition and the need 
for protecting the rights of the trademark holder. 
Some in the UAE may argue that agents/distributors 
would abuse the market because of the exclusive 
agency.
41
 Parallel imports would not be sold in 
competition with goods subject to an exclusive agency 
agreement. Those agents/distributors are strong 
merchants.
42
 They may desire to protect themselves 
from the interference of small competitors or merchants 
since they do not have to lower their prices to compete 
with parallel imports.
43
 Small merchants may not be 
able to benefit from price discrimination among 
                                               
39 See The Federal Commercial Transactions Law No. 18 of 
1993, Articles 64-66. 
40 To avoid any administrative difficulty, some large companies 
in the UAE, who act as agent or distributor for foreign 
corporations, appoint a parallel import coordinator.   
41 There are six commercial agents who control more than 40 
per cent of the UAE commodity market. See 'Inflation and Price 
Hike in the UAE; Effects and Solutions' available at 
<http://www.albayan.ae/across-the-uae/1186581628317-
2007-08-12-1.781298> (12 August 2002).  
42 See Bernard M Hoekman and Jamel Zarrouk, Catching Up 
with the Competition: Trade Opportunities and Challenges for 
Arab Countries 239 (2000).  
43 See 'MEA Consumables Market Continues to Grow but Faces 
Mounting Pressure from Parallel Imports' available at 
<http://idc-cema.com/eng/about-idc/press-center/58276-mea-
consumables-market-continues-to-grow-but-faces-mounting-
pressure-from-parallel-imports> (27 April 2014). 
different markets. Closed distribution channels would 
impede free trade, competition, and consumer choice in 
terms of product and price.  
Those with opposing views may counter that local 
agents/distributors/wholesalers have built the goodwill 
of imported products through their time consuming and 
expensive marketing plans, promotional efforts, and by 
providing a product warranty through after-sale 
servicing.
44
 The purpose of all these programmes is to 
maintain clients and increase the sale of goods. Agents 
provide services and incur costs that parallel importers 
do not provide or incur.
45
 Thus, parallel importers enjoy 
a free ride at the expense of authorized distributors. In 
addition, parallel imports may damage product quality 
control.
46
 The quality of product frequently varies from 
region to region.
47
 Poor quality in parallel imports could 
cause consumer confusion and diminish the reputation 
of the manufacturer and agent. In analysing the 
language of the Commercial Agency Law, one can find a 
protectionist flavour in protecting domestic interests. 
This is obvious when reading the language in the 
Commercial Agency law which states that commercial 
agents are entitled to prevent products subject to their 
agency from being imported into the UAE if the agent is 
not the consignee. 
VII. CONCLUSION 
Parallel importation represents a thorny issue as it is 
intertwined with the economic, political, and legal 
conditions in a particular country. Many intellectual 
property scholars and experts have studied merits and 
demerits of parallel importation. The UAE faces the 
difficult path of choosing the appropriate path in 
addressing parallel importation.  
There is no definitive solution for the issue of parallel 
importation in the UAE. Nevertheless, the UAE cannot 
maintain the status quo. The Trademarks Law does not 
address clearly whether parallel imports infringe 
trademark rights and whether it adopts a national or 
                                               
44 See Sarmad Hasan Manto, 'The Perils of Grey Market Trade' 
(October 2014), available at <http://www.theoath-
me.com/s/the-perils-of-grey-market-trade> (last visited 
14 February 2016).  
45 The agent/distributor is required to provide spare parts and 
other items which are necessary and sufficient for maintenance 
of the imported goods. See Commercial Agency Law, Article 11. 
46 See Manoj Nair, 'UAE's Auto Market Sees Flare up in Grey 
Imports' Gulf News (24 March 2014). 
47 See International Trademark Association, 'Position Paper on 
Parallel Import' (July 2007) 10 (Goods may have been 
formulated or packaged for a particular jurisdiction, and then 
are imported into a different jurisdiction from that intended by 
the brand owner. Motor lubrication oils are radically different 
for the Middle East and Scandinavia. This is to the detriment of 
the consumer and erodes the brand owner's value in the 
brand).  
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international exhaustion of rights. Further, UAE case law 
does not provide clear guidance under what 
circumstances parallel imports may be permitted, and 
what if appropriate government permits are obtained. 
Trademark owners and their agents use the UAE agency 
law to prevent parallel importation. The UAE agency law 
should not be used as a backdoor – through exclusive 
agreements – to ban parallel importation and replace 
the role of trademarks law. Trademarks law should play 
a central stage in addressing the issue of parallel 
importation in the UAE.  
Although placing a total ban on parallel imports in the 
UAE seems the easiest way, it is unrealistic. This will 
even exacerbate the current situation where the 
authorized agent enjoys monopolistic position. As long 
as there are differences in market conditions among 
countries, parallel imports will exist. A total ban on 
parallel imports will lead to further legal uncertainty and 
may even encourage counterfeit trade. Therefore, the 
question that needs to be answered is how to balance 
the interests of stakeholders i.e. trademark owner and 
commercial agent, and those of the consumers.  
As a first step, the UAE should consider the costs and 
benefits of allowing parallel imports. Parallel 
importation promotes free and healthy competition in 
both price and service. The source of supplying and 
distributing products for UAE's market would be 
diversified. Then, the UAE needs to modify its 
trademarks law and other regulations in a way to 
address parallel importation in an orderly fashion. For 
example, parallel importation could be allowed where 
there is no evidence consumer confusion. The burden of 
proof for consumer confusion – which could be a very 
substantial – falls upon the importer/agent for the 
genuine goods. In most parallel importation cases, there 
are no guarantees and after-sales services. Therefore, 
the UAE may want to require a labelling system to 
inform consumers that parallel products are not subject 
to guarantees and other services. The UAE, through the 
Ministry of Economy, could even require retailers to 
market their products as parallel importation. In 
addition, the UAE should keep the door open for 
trademark owners and their licensees to challenge 
parallel importers. This allows the courts to be proactive 
in addressing the issues not covered by the law and 
create guidelines under which the various parties 
involved can bring an action to protect their interests.  
Now UAE has a good opportunity more than at any 
previous time to learn from the experience of other 
countries that have decided to regulate and not totally 
ban parallel importation, instead of following our own 
restrictive model. It is important for any future 
trademarks law in the UAE to be flexible no matter 
which approach the country decides to adopt.  
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9 WHY SOUTH AFRICA SHOULD INTRODUCE 
PATENT SEARCHES AND SUBSTANTIVE EXAMINATIONS 
TO IMPROVE ACCESS TO ESSENTIAL MEDICINES 
 
Dr Lonias Ndlovu 
ABSTRACT 
This paper provides an overview of South Africa's 
current patent search and substantive examination 
regime and argues that the current legal regime is 
inadequate and requires a serious overhaul. The paper 
further highlights the importance of patent searches and 
substantive examinations, while providing a 
comparative analysis of applicable legal provisions. 
Although South Africa has recently acknowledged that 
the law should be changed to introduce patent searches 
and substantive examinations, this paper nonetheless 
highlights possible impediments to this proposed law 
reform. This paper concludes that patent searches and 
substantive examinations should be introduced 
alongside other patent law reforms such as the 
introduction of pre and post-grant patent opposition.  
Keywords: Patent searches, substantive examination, 
access to medicines, TRIPS flexibilities, essential 
medicines, generics 
I. INTRODUCTION 
At present, South Africa is confronted with several 
epidemics such as 'HIV/AIDS, other infectious diseases, 
violence and injuries, and non-communicable diseases'.
1
 
In the context of public health, the country is faced with 
ongoing health-related challenges such as HIV/AIDS, 
tuberculosis, malaria, heart disease, cancer, hepatitis 
and a host of other ailments. Although state-driven 
treatment programmes have seen HIV/AIDS infection 
rates decline, there has been no such decline in  
                                               
 Dr Lonias Ndlovu (Zimbabwe) is Associate Professor in the 
School of Law, Faculty of Law, University of Venda, South 
Africa. Previously, he worked in the universities of Fort Hare, 
Zululand and North West also in South Africa, as a lecturer, 
senior lecturer and associate professor. He obtained the 
degrees LLB (2003) and LLM (2005) from the University of Fort 
Hare and LLD (2014) from the University of South Africa. His 
doctoral thesis examines the extent to which selected Southern 
African Development Community (SADC) member States have 
incorporated TRIPS flexibilities into their patent laws, in order 
to improve citizens' access to essential medicines. His teaching 
and research interests lie in intellectual property law generally, 
intellectual property and public health, human rights and 
access to medicines, commercial law and international trade 
law. He runs a limited commercial law practice and consults for 
government, international organizations and NGOs on IP and 
public health.  
 
1 Yusuf A Vawda, 'Pharmaceutical Innovation, Incremental 
Patenting and Compulsory Licensing Country Case Study: South 
Africa' IDCR, (Toronto 2011) 2. 
diseases in other areas, especially tuberculosis and 
lifestyle diseases such as heart disease. It has been 
reported that South Africa has the largest antiretroviral 
treatment programme globally and these efforts have 
been largely financed from its own domestic resources.
2
 
The country now invests more than US$ 1 billion 
annually to run its HIV/AIDS programmes.
3
 
South Africa largely depends on imported patented 
medicines to deal with the burgeoning disease burden. 
However these medicines are expensive.
4
 Although 
some Southern African Development Community (SADC) 
members, such as South Africa, Zimbabwe and 
Mozambique, have limited pharmaceutical 
manufacturing capacity, the volumes of locally produced 
drugs are inadequate to deal with the disease burden. 
As members of the World Trade Organization (WTO), 
SADC members can take advantage of the flexibilities 
introduced by the Agreement on Trade-Related Aspects 
of Intellectual Property Rights (TRIPS) and override 
patent rights in some specified instances in order to 
access affordable essential medicines.  
The TRIPS Agreement does not prescribe how patent 
laws should be drafted in Member countries, but 
provides for the basic tenets of patentability. Therefore, 
it is up to individual countries to decide, within the 
confines of their laws, what amounts to patentable 
subject matter and how its patentability may be 
determined. One way of ensuring that only high quality 
patents are registered would be to require that trained 
experts examine all patent applications for technical 
quality, after the existing database has been searched 
for possible conflicting patents. Patent searches and 
substantive examinations are important and this paper 
makes the case for their inclusion or clarity in South 
African patent law in order to improve access to 
essential medicines. Patent searches and substantive 
examinations were recently identified as an important 
area of IP law requiring urgent reform in South Africa.
5
 
II. BASIC CONCEPTS AND DISTINCTIONS 
Essentially, a patent search may be regarded as the 
process by which prior inventions or ideas are examined, 
with a view to finding information that bears close 
                                               
2 John Maurice, 'South Africa's Battle against HIV/AIDS Gains 
Momentum' (The Lancet 2014), 1535-1536. 
3 Maurice above mentioned at 1535. 
4 South Africa's total health budget is estimated to be 
R178 billion in 2017/18 (Former Finance Minister Nhlanhla 
Nene's budget Speech delivered on 25 February 2015 at 
<http://www.mediaclubsouthafrica.com/economy/4165-south-
africa-s-budget-2015-the-full-text>. This figure includes the 
annual cost of procuring medicines for public sector hospitals 
and clinics, a figure which is unsustainable when one factors in 
other demands, such as provisioning for higher education on 
the fiscus.  
5 For these and other IP law reform priority areas, see generally 
South Africa's Draft National Policy on Intellectual Property, 
2013 available at: <http://groundup.org.za/sites/default/ 
files/36816_gen918.pdf (3 December 2014). 
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similarity to a given patent application, in order to 
determine whether the claimed invention is novel and 
inventive. Information relevant to the prior art of a 
pharmaceutical patent application may be widely sought 
by a number of third parties such as the Ministry of 
Health, generic drug producers, research institutions, 
academics and civil society groups interested in health 
matters.
6
 These searches would supplement prior art 
disclosures in patent applications, and patent searches 
undertaken through more traditional databases. Patent 
searches for relevant prior art in patent applications can 
be undertaken via the South African Companies and 
Intellectual Commission (CIPC) online facility, European 
or US Patent Office databases, or the WIPO database. In 
order for deserving patent applications to be registered, 
an up-to-date and reliable patent database is a 
prerequisite.  
In practice, in the South African context, a prior art 
search is ordinarily undertaken by the applicant inventor 
or by his patent attorney/agent. This is undertaken to 
ensure that no existing patents are being infringed and 
that the invention is new/novel. Although this initial 
search is not essential, it is advisable.  
In South Africa, Section 34 of the Patents Act
7
 authorizes 
the examination of patent applications, but at present 
no such examination is conducted.  
On the other hand, where patent applications are 
examined by qualified examiners, the patent 
examination entails an analysis of the patent application 
for technical quality, adequate disclosure, unity of 
claims, and whether the prior art signifies that the 
claimed invention is new and involves an inventive step. 
Such an examination also seeks to establish the 
potential industrial applicability of a patent application. 
As stated above, South African law mandates patent 
examinations although in practice these are not carried 
out.
8
 
In summary, a patent search and substantive 
examination system will essentially involve an 
examination of the quality of the invention.
9
 This will 
                                               
6 MSF, Treatment Action Campaign (TAC) and Section 27 
recommendations to the South African Department of Trade 
and Industry (DTI) on the Draft IP Policy, entitled, 'Joint 
Submission on the Draft National Intellectual Property Policy' 
(2013), 30 (hereafter TAC, MSF and Section 27 
recommendations).  
7 Patents Act 57 of 1978 as amended.  
8 Section 34 of the Patents Act.  
9 Yu-Fang Wen and Thapi Matsaneng 'Patents, Pharmaceuticals 
and Competition: Benefiting from an Effective Patent 
Examination System' (2013) 8 available at: 
<http://www.compcom.co.za/wp-
content/uploads/2014/09/Patents-Pharmaceuticals-and-
entail a consideration of a number of prerequisites, such 
as the subject matter of the invention which must be 
patentable, the industrial applicability aspect of the 
patent, and the novelty and inventive step aspects.
10
 In 
the context of pharmaceuticals, properly stringent 
patentability criteria would therefore examine, among 
other things, the absolute novelty of the invention and a 
significant degree of inventiveness shown, for instance, 
whether there is a significant technological or 
therapeutic advance. This may entail revisiting the new 
use provisions provided for by the Patents Act.
11
 South 
Africa would do well to require the patent office to 
undertake a thorough technical and scientific 
examination of the validity of the claims of every patent 
application filed.
12
 For reasons outlined immediately 
below, patent searches and examinations are important 
for South Africa. 
III. WHY ARE PATENT SEARCHES AND EXAMINATIONS 
IMPORTANT FOR SOUTH AFRICA? 
From the perspective of an applicant, undertaking a 
patent search prior to applying for a patent is crucial, as 
it helps the applicant to
13
: 
 Determine whether the intellectual property 
may be protected as an invention i.e. whether 
the invention meets the various requirements 
for the successful grant of a patent
14
; 
 determine whether or not he or she is 
infringing someone else's intellectual property 
right;
15
 
 learn about competition or to direct research 
and innovation; 
 determine who owns an IPR; and 
                                                                    
Competition-Yu-Fang-Wen-and-Thapi-Matsaneng-Annual-
Competition-Conference-2013.pdf> 
10 Wen and Matsaneng, above, at 9. 
11 Section 25(9) of the Act provides for the patenting of novel 
uses of known substances. 
12 Treatment Action Campaign, 'Why South Africa Should 
Examine Pharmaceutical Patents' (2013), Policy Brief 60, 5. 
13 This information was taken from the website of the South 
African Companies and Intellectual Property Commission 
(CIPC), 'Online Transacting', available at: 
<http://www.cipc.co.za/index.php/trade-marks-patents-
designs-copyright/patents/how-app/> (last accessed 
6 March 2016). 
14 These requirements are set out in TRIPS Article 27 and 
Section 25(1) of the South African Patents Act.  
15 The various grounds for the possible infringement of patents 
and the possible remedies are spelt out in Sections 65 to 71 of 
the South African Patents Act.  
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 check that their IPR in question is not being 
infringed. 
By contrast, as will be further emphasized below, while 
it is advisable for applicants for patents to undertake 
patent searches as advocated above, it is unfortunate 
that South Africa's existing patent database is 
incomplete and not all patent documents are included. 
The applicant will need to resort to the use of the Paper 
Based Patent Disclosure Office (emphasis added) for the 
missing information.
16
  
The importance of a patent search and examination 
system for the South African legal system may further 
be broadly further highlighted as follows: 
 Introducing patent searches and examinations 
will make life-long saving medicines and drugs 
available and accessible to South Africans, 
because pharmaceutical companies will no 
longer be able to file multiple patents for the 
same drug. 
 Since patent searches and examinations will 
be used to determine whether a 'new' drug is 
novel and inventive, the likelihood of granting 
evergreen patents will be reduced if the Act is 
amended to include, for example, enhanced 
efficacy.
17
 
 From the perspective of competition law, 
introducing patent searches and examinations 
will ensure that big pharmaceutical companies 
do not file patents for minor improvements to 
drugs. This will allow more genuine 
pharmaceutical innovators to enter the 
market and drug prices are likely to stabilize 
once there are many pharmaceutical players 
who will compete against each other with 
positive results for consumers. 
 It is common cause that in the absence of a 
patent search and substantive examination 
system, multiple patents filed by large 
pharmaceutical companies defer the expiry of 
patents by extending their lifespans. The entry 
of generic drugs onto the market will be 
delayed since generic manufacturers must 
wait for these multiple patents to expire. A 
patent search and substantive examination 
will therefore allow for the early entry of 
                                               
16 Since South Africa is regarded as one of the most 
technologically advanced nations in Africa, the incomplete 
electronic database is a serious indictment of the country's 
status as a leader and beacon of economic hope in Africa.  
17 On this and other possible solutions, see Yusuf A Vawda, 
'After the Novartis judgment – "Evergreening" Will Never be 
the Same Again!' (2014) 18 Law, Democracy and Development 
3015-316 at 315. 
generic drugs and promote the establishment 
of more generic manufacturers, thus 
improving the availability of essential drugs 
and introducing much needed competition, 
which will, in turn, lead to a lowering of drug 
prices. 
The introduction of patent searches and examinations 
will ensure that South Africa complies with its own 
national law and makes full use of flexibilities allowed 
under the TRIPS Agreement. In the absence of a patent 
search and examination system, South Africa can in no 
way grant patents that are novel, involve an inventive 
step and are useful in industry, trade and agriculture. 
Similarly, in the absence of a functional patent search 
and examination system, South Africa can in no way 
effectively comply with her obligations spelt out in 
Article 27 of the TRIPS Agreement. 
Finally, through the introduction of patent searches and 
examinations, South Africa will able to provide stronger 
protection and achieve enhanced fulfilment of its 
human right to health obligations.
 
 
It is important not to lose sight of the fact that patent 
searches and examinations do not guarantee non-
infringement of existing patents.
 
This observation does 
not, however, diminish the importance of patent 
searches and examinations as highlighted earlier. 
IV. NOTABLE GAPS IN THE RELEVANT LAW  
The main issue relating to patent searches and 
examinations in South Africa is that patent applications 
are accepted and patents are granted as long as 
administrative and financial requirements are met.
18
 
While the South African Patents Act provides for the 
registrar to 'examine', in the prescribed manner, every 
application for a patent and every complete 
specification accompanying such application
19
, in 
practice this examination does not look beyond the 
formal requirements. This is confirmed by the Patent 
Regulations, which clearly spell out that any application 
accompanied by a provisional specification must be 
examined to ensure that the documents lodged are 
legible and capable of reproduction.
20
 For complete 
specifications, it is provided that the registrar shall 
examine them in order to ensure compliance with the 
prescribed formalities.
21
 
                                               
18 TAC 'Why South Africa Should Examine Pharmaceutical 
Patents' (2013), Policy Brief, Treatment Action Campaign, 
Pretoria 60, 2. 
19 Section 34 of the Act. 
20 Regulation 40 of the Patents Act. 
21 Regulation 41 of the Patents Act. 
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A patent is therefore granted once all the required 
documents are accepted without any enquiry into the 
technical and other requirements for patentability spelt 
out in the Patents Act.
22
  
South African Patent law does not expressly provide for 
a compulsory prior art search, and as previously stated, 
where such a search is not compulsory, the satisfaction 
of patentability criteria cannot be achieved.
23
  
It has been reported that the current South African 
Companies and Intellectual Property Commission (CIPC) 
online search facility leaves a lot to be desired, since the 
only functional search fields are the title of the 
invention, the name of the inventor and the South 
African patent number, while a number of other search 
fields return no results.
24
  
This is compounded by the fact that none of the patent 
claims or specifications can be viewed and the status of 
the patent is not always available or up-to-date.
25
 
If the patent search database is improved and access to 
accurate information on patents is made available to 
stakeholders, this will complement the 
recommendations that are made here about the 
introduction of patent searches and examinations.  
                                               
22 The general and specific requirements for patentability and 
exceptions thereto are set out in Section 25 of the Patents Act.  
23 Section 25(1) of the South African Patents Act 57 (1978) sets 
out the patentability criteria: novelty, involvement of an 
inventive step and usefulness in trade, industry and agriculture.  
24 MSF, TAC, Section 27 Recommendations at 30. 
25 MSF, TAC, Section 27 Recommendations at 31.  
The gaps in the legal regime are summarized in the 
following table: 
Legal provision and content: 
Patents Act and Regulations 
(paraphrased or actual) 
Non-legal summary of provision Commentary and suggested improvement 
S34 'The registrar shall examine in the 
prescribed manner every application for 
a patent and every complete 
specification accompanying such 
application or lodged at the patent office 
in pursuance of such application and if it 
complies with the requirements of this 
Act, he shall accept it.' 
The registrar is required to examine in 
the prescribed manner every 
application for a patent and the 
accompanying descriptive account of 
the patent and if the application 
complies with the Act, accept it. 
It should be mandatory for the registrar to examine all patents 'in 
the prescribed manner'. The prescribed manner is usually the one 
prescribed by the Act and clarified by the Regulations, if any. The 
Regulations (see immediately below) should provide that the 
registrar 'must' examine patents and specifications in order to 
ascertain compliance with section 25(1) of the Act. Alternatively, 
there could be a provision mandating examination for priority 
patents (emphasis added), including those related to 
pharmaceutical, biological, and other medical or health 
technologies. 
Regulation 40 of the South African 
Patents Act 'Any application 
accompanied by a provisional 
specification shall be examined to ensure 
that the documents lodged are legible 
and capable of reproduction.' 
For a provisional application 
specification, the examination will aim 
at ensuring that lodged documents are 
legible and capable of being 
reproduced. 
This kind of examination does not aid the one contemplated by 
Section 34 of the Act. Indeed, it takes away the gains made by 
Section 34. This Regulation must be amended to add 
unequivocally an examination of the technical quality of the 
patent in addition to what is expected of the documents. This will 
give Section 34 its implementing teeth. 
Regulation 41 The registrar shall examine 
the application accompanied by a 
complete specification in order to ensure 
that it complies with the prescribed 
formalities. 
Complete specifications must be 
examined by the registrar to check if 
they comply with the prescribed 
formalities. 
This regulation is ambiguous and must be amended to state 
clearly that the examination will look at the quality of the 
documentation and the technical merits of the final specification. 
This will then actualize the provision in Section 34. 
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V. WHAT CAN SOUTH AFRICA LEARN FROM OTHER 
JURISDICTIONS? 
When one looks at both the African and international 
legal contexts of patent searches and examinations, 
South Africa does not compare favourably. South Africa 
can therefore learn a number of useful lessons from 
other jurisdictions in order to improve its current patent 
law through timely legislative reform. The jurisdictions 
outlined below can indeed offer significant lessons for IP 
law reform for South Africa. The selected laws of select 
countries, together with a commentary on the relevance 
of the law in the context of South Africa, are outlined in 
tabular form below. 
 
 
 
 
 
Country and legal provision Content of legal provision Comments in the context of  
South Africa 
Argentina Pharmaceutical Guidelines: Joint 
Regulation Nos. 118/2012, 546/2012 and 
107/2012 issued on 2 May 2012 by the Argentine 
Patent Office, together with the Ministries of 
Industry and of Health. 
The new Guidelines ambitiously restrict the 
patentability of several categories of inventions in 
the pharmaceutical field, in particular polymorphs 
and pseudo polymorphs, enantiomers, Markush 
claims, selection patents, Salts, esters and other 
derivatives of known substances, Active metabolites, 
prodrugs, formulations and compositions, 
combinations, second medical use and dosage 
regimes and manufacturing processes. 
Although these guidelines are conceived as 
general instructions addressed to the patent 
examiners, in practice, they operate as very 
specific legal provisions which must be adhered 
to. South Africa does not need to adopt a 
similar radical approach; after all, South Africa 
has no patent examiners at the moment. 
However, the specific substances excluded from 
patentability are quite informative, notably the 
exclusion of derivatives of known substances. 
Botswana Industrial Property Act of 2012 Section 22 Provides for the examination of patents 
for technical quality 
Such a provision is long overdue for South 
Africa, which provides for such in Section 34 of 
the Patents Act, but negates it through wrong 
regulations and contrary practice at the patents 
office. 
India Patents Act of 1970, as severally amended Section 11B(1) ‘No application for a patent shall be 
examined unless the applicant or any other 
interested person makes a request in the prescribed 
manner for such examination within the prescribed 
period.’ 
Section 12(1) 'the application and specification and 
other documents related thereto shall be referred at 
the earliest by the Controller to an examiner for 
making a report to him in respect of the following 
matters, namely; "—whether the application is in 
accordance with the Act, whether there is a legal 
ground for any objection …". 
While India has generally been lauded as having 
progressive provisions in its legislation, making 
examinations conditional upon requests 
reduces such an important activity to being 
optional. South Africa should not follow this 
route. It must act in accordance with the 
prescriptions of Section 34. 
This provision spells out very clearly the 
targeted outcomes of the examination process. 
This clear language must be adopted by South 
Africa in order to improve Section 34. 
Kenya Industrial Property Act of 2001 Section 27 – Minister may direct that applications for 
patents relating to a specified field or specified 
technical fields shall be the subject of an examination 
as to substance. 
While this provision is worthier than its South 
African counterpart, it is not truly progressive 
because only selected inventions will be subject 
to this 'examination as to substance'. All 
inventions irrespective of the field of 
technology should be subjected to 'an 
examination as to substance'. South Africa may 
be advised to consider the option of prioritizing 
certain fields or important technologies, like 
medicines and other medical products to 
examination first while examination capacity is 
expanded in other areas. 
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VI. CONCLUSION 
It is heartening to report that, on 9 February 2015, the 
South African Department of Trade and Industry (DTI) 
and the South African Companies and Intellectual 
Property Commission (CIPC) hosted an important 
meeting with relevant stakeholders and announced that 
patent searches and substantive examinations would be 
introduced in the country, perhaps as early as 2017.
26
 
The idea is to fully examine domestic applications in 
selected fields and to partially recognize the substantive 
examination outcomes of other jurisdictions
27
 in respect 
of foreign applicants.
28
 This is welcome news, although 
at the time of writing South African Patent Law practice 
did not cater for patent searches and substantive 
examination. 
 
                                               
26 This information was taken from the website of the South 
African premier IP law firm, Adams and Adams, going by the 
title 'Roundtable Discussion: Substantive Search and 
Examination' 
<http://www.adamsadams.com/index.php/media_centre/news
/roundtable_discussion_substantive_search_and_examination/
>(accessed 6 March 2016). The report is dated 25 February 
2015.  
27 For a comparative note on other jurisdictions in the patent 
examination context of South Africa specifically, see Caroline B 
Ncube, 'The Draft National Intellectual Property Policy 
Proposals for Improving South Africa's Patent Registration 
System: a Review' (2014) 9 Journal of Intellectual Property Law 
and Practice, 822-829. 
28 Adams and Adams, note 26 above. The selected fields are not 
mentioned, the only hint given being, 'the selection of 
technology sectors to be made on the basis of the South African 
economic priorities'. 
 
 
 
 
 
 
 
 
 
 
 
It is worth reiterating that the current lack of 
substantive examination and the absence of opposition 
proceedings has resulted in 'invalid' patents being 
granted, including patents for inventions with only 
'marginal inventive steps', thereby permitting the 
'blocking' of further innovation and development in 
certain market sectors by powerful companies.
29
 
The drug that was involved in the dispute between 
Novartis and the Republic of India
30
, Imatinib Mesylate, 
starkly illustrates the need for patent search and 
examination in South Africa.
31
  
Imatinib Mesylate was patented in South Africa with no 
litigation ensuing.
32
 The most likely reason why this drug 
and its new-use variants have been patented in South 
Africa since 1993 is the fact that South African patent 
law does not provide for mandatory patent searches and 
examinations.
33
 The Mesylate version of Imatinib was 
                                               
29 ibid 28.  
30 See Novartis AG v. Union Of India and Ors, Supreme Court of 
India, Civil Appellate Division, 1 April, 2013, available at 
<http://indiankanoon.org/doc/165776436/> (last accessed 
5 March 2016). 
31 See generally Emmanuel K Oke, 'Exploring the Flexibilities in 
TRIPS: Lessons from India's Pharmaceutical Patent Law' (2015) 
41 Commonwealth Law Bulletin, 82-106; specifically Lonias 
Ndlovu, 'Lessons for the SADC from the Indian Case of Novartis 
AG v. Union of India' 18 Potchefstroom Electronic Law Journal, 
2015, 783-815. 
32 See Companies and Intellectual Property Commission of 
South Africa (CIPC), 'Patent Search Results for Imatinib', at 
<http://patentsearch.cipc.co.za/patents/patentresult.aspx> 
(last accessed 6/03/2016). 
33 See Section 34 of the Patents Act 57 of 1978 and Regulations 
40 and 41 to the same Act. 
Country and legal provision Content of legal provision 
Comments in the context of  
South Africa 
Japan Patent Act (Act No. 121 of 1959) as 
amended in 2006 
Article 47 – The Commissioner of the Patent Office 
shall direct the examination of patent applications by 
an examiner and the qualifications of examiners shall 
be as prescribed by Cabinet Order. 
This self-explanatory provision goes a step 
further and directs how examiners' 
qualifications shall be determined. South Africa 
must consider adopting something similar. 
Thailand Thai Patent Act BE 2522 (1979) as 
amended by Patent Act (No 2) BE 2535 (1992) 
and Patent Act (No 3) BE 2542 (1999) 
Section 24 – 'Before granting a patent to the 
applicant, the competent officer shall: examine the 
application as to its conformity with Section 5, in 
accordance with the rules, procedures and 
conditions prescribed in the Ministerial Regulations.' 
[section 5 deals with requirements for patentability, 
namely novelty, inventive step and utility] 
This is another very clear provision dealing with 
what must be examined. This should illuminate 
South Africa's law reform path in the 
appropriate context. 
Zimbabwe Patents Act (Chapter 26:03, as 
amended by Act No. 14/2002) 
Section 11(1)(a) – 11(2) Provides for the formal 
examination of patent applications by an examiner in 
order to establish compliance with the provisions of 
the Act and to check if there is congruence between 
the final specification, the provisional specification 
and the Patent Cooperation Treaty specification. 
Again, like the similar provisions commented 
on above, this provision also clearly points out 
what will be examined. South Africa must 
expressly provide for patent examination in 
order to effectively use exemptions and 
stringent standards of patentability allowed 
under the TRIPS Agreement and the Patents 
Act of 1978 as amended. 
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patented in South Africa in 1997 and is due to expire in 
2017, while in 2002, a new use patent for the same drug 
was granted, and the patent is due to expire in 2022.
34
 
In 2013 and 2014, Novartis applied and was granted a 
process patent for the Process for the Preparation of 
Alpha Form Imatinib Mesylate
35
 and a product patent 
for the Pharmaceutical Granulate Comprising Imatinib 
Mesylate.
36
  
It is doubtful if such minor additions to Imatinib would 
have been patented in a legal system with a robust 
patent examination model. A patent search and 
substantive examination system will essentially involve 
an examination of the quality of the invention.
37
 This will 
entail a consideration of a number of prerequisites such 
as the subject matter of the invention which must be 
patentable; the industrial applicability aspect of the 
patent; and the novelty and inventive step aspects.
38
  
In the SADC region, Botswana's Industrial Property Act 
of 2010 may be regarded as model legislation for patent 
examinations.
39
 The relevant law provides for an 
examination of a patent application in order to comply 
with the requirements of the Act
40
, and also grants the 
Minister responsible for patents the discretion to 
designate certain patent applications as exempt from an 
examination covering the requirements for novelty and 
inventive step.
41
 Although Botswana's law in the specific 
context could have been better drafted, it is a good 
example of a deliberate step that will limit the abuse of 
the patent system and curb patent evergreening.  
That South Africa has taken a bold step to introduce 
patent searches and substantive examinations is a 
welcome step in the right direction of relevant law 
reform. Some controversies may arise when one factors 
in the state of the economy and some geopolitical 
realities on the ground. For instance, although South 
Africa has now affirmed that the law will change to 
                                               
34 According to Baccarrani et al, 'Chronic Myeloid Leukemia: An 
Update of Concepts and Management Recommendations of 
European Leukemia Net' Journal of Clinical Oncology, 2009, at 
6044, there are no major therapeutic differences between 
Imatinib Mesylate and its new use counterpart.  
35 South African Patent number 2013/00872, granted on 
30 April 2013. 
36 South African patent number 2014/06139, granted on 
27 May 2015. 
37 Wen and Matsaneng (2013) 'Patents, Pharmaceuticals and 
Competition: Benefiting from an effective patent examination 
system' available at: <http://www.compcom.co.za/wp-
content/uploads/2014/09/Patents-Pharmaceuticals-and-
Competition-Yu-Fang-Wen-and-Thapi-Matsaneng-Annual-
Competition-Conference-2013.pdf> at 8 (last accessed 
6 July 2016).  
38 Wen and Matsaneng, above 9. 
39 See specifically Section 22 of the Industrial Property Act 
(Botswana Act).  
40 Section 22(1) of the Botswana Act legislation. 
41 Section 22 (2) of the Botswana Act legislation.  
accommodate patent examiners, the reality is that local 
patent examiners will have to be trained and an 
appropriate jurisdiction or entity to conduct the training 
needs to be identified. Argentina, Brazil and India would 
appear to be attractive candidate countries for such 
training from a developing country perspective. 
However, it is also possible that some developed 
countries, such as Japan or even the United States, may 
be willing to offer the training gratuitously. The choice of 
the appropriate institution to offer the training will in all 
likelihood depend on the ideological congruence 
between the chosen country/institution and South 
Africa. Developed country jurisdictions, which 
traditionally favour patent rights, are likely to fashion 
the examination regime in such a manner that the 
valuable TRIPS exceptions may be seriously 
circumscribed. The choice of the patent examination 
training provider really faces the danger of becoming a 
politically value-laden exercise.  
The other important consideration will be the cost of 
training patent examiners and overhauling the current 
database in order to modernize it for the contemporary 
IP landscape. South Africa indeed faces economic 
challenges at this moment including the prospect of a 
sovereign downgrade from rating agencies like Moody 
and Standard & Poor's.
42
 These economic challenges 
imply two possible occurrences:   
 The postponement of the implementation of 
patent searches and substantive examination; 
and 
 examination or the implementation of a 
compromised regime for same.  
While the nation waits for the process to unfold fully 
until 2017, life has to be lived in the interim and it is 
suggested that the Patent Regulations be amended to 
cater for substantive examination, while the law is being 
amended.
43
 The introduction of patent searches and 
substantive examination without anything further will 
be inadequate. To improve access to essential 
medicines, other aspects of South African patent law, 
such as the cumbersome regime for compulsory 
licences, the absence of pre and post-grant opposition 
and the reluctance of the government to fully 
implement its regime for parallel imports, must also be 
revisited.  
 
 
                                               
42 See for instance, Mail and Guardian 'SA Placed on Review for 
Downgrade' (10 March 2016), available at: 
<http://mg.co.za/article/2016-03-09-sa-placed-on-review-for-
downgrade>  
43 It is common cause that the Patents Act provides for 
substantive examination of patents in Section 34 thereof. 
However, the regulations negate the good effect of the law by 
requiring only formal examinations.  
Dr Lonias Ndlovu, Why South Africa Should Introduce Patent Searches and Examinations to Improve Access to 
Essential Medicines 
________________________________________________________________________________________ 
 
80 
 
BIBLIOGRAPHY 
Adams and Adams, 'Roundtable Discussion: 
Substantive Search and Examination' 
<http://www.adamsadams.com/index.php/media_centr
e/news/roundtable_discussion_substantive_search_and
_examination/> (last accessed on 6 March 2016) 
 
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, 
Apperley J, Cervantes F, Deininger M, Gratwohl A, 
Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian 
H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, 
Hehlmann R, 'Chronic Myeloid Leukemia: An Update of 
Concepts and Management Recommendations of 
European LeukemiaNet' Journal of Clinical Oncology, 
2009 
Correa MC, Intellectual Property Rights, the WTO and 
Developing Countries: The TRIPS Agreement and Policy 
Options (ZED Books London 2000) 
Companies and Intellectual Property Commission of 
South Africa (CIPC), 'Online Transacting' at 
<http://www.cipc.co.za/index.php/trade-marks-patents-
designs-copyright/patents/how-app/> (last accessed 6 
March 2016) 
Government of South Africa, South African Patents Act 
57 of 1978. 
Government of the Republic of South (2013) 'Draft 
National Policy on Intellectual Property' 2013 
available at: 
<http://groundup.org.za/sites/default/files/36816_gen9
18.pdf>  (last accessed 3 December 2014) 
Mail and Guardian 'SA Placed on Review for Downgrade' 
(10 March 2016) 
available at: <http://mg.co.za/article/2016-03-09-sa-
placed-on-review-for-downgrade> (last accessed 
10 March 2016) 
 
Maurice J, 'South Africa's Battle against HIV/AIDS Gains 
Momentum' The Lancet 383, 2014 
 
MSF, Treatment Action Campaign (TAC) and Section 27 
Recommendations to the South African Department of 
Trade and Industry (DTI) (2013) Joint Submission on the 
Draft National Intellectual Property Policy 2013 
Ncube CB, 'The Draft National Intellectual Property 
Policy Proposals for Improving South Africa's Patent 
Registration System: a Review' 9 Journal of Intellectual 
Property Law and Practice 2014 
Ndlovu L, 'Lessons for the SADC from the Indian Case of 
Novartis AG v. Union of India 18 Potchefstroom 
Electronic Law Journal 2015 
Ndlovu L, 'Report on South African Laws Requiring 
Amendment in order to Realise the Fix the Patent Laws' 
(FTPL) Campaign recommendations on the Draft 
National Policy on Intellectual Property Together with 
Examples of Model Legislation from Other Jurisdictions 
2015 
Nene N., Budget Speech delivered on 25 February 2015 
at: 
<http://www.mediaclubsouthafrica.com/economy/4165
-south-africa-s-budget-2015-the-full-text> (last accessed 
3 March 2016)  
Novartis AG v. Union Of India and Ors, Supreme Court of 
India, Civil Appellate Division, 1 April, 2013, available at 
<http://indiankanoon.org/doc/165776436/> (last 
accessed 4 March 2016)  
Oke EK, 'Exploring the Flexibilities in TRIPS: Lessons from 
India's Pharmaceutical Patent law' 41 Commonwealth 
Law Bulletin, 2015 
TAC 'Why South Africa Should Examine Pharmaceutical 
Patents' Policy Brief 60 2013 
Vawda YA, 'Pharmaceutical Innovation, Incremental 
Patenting and Compulsory Licensing Country Case Study: 
South Africa' Toronto: IDRC 2011 
Wen Y and Matsaneng T, 'Patents, Pharmaceuticals and 
Competition: Benefiting from an Effective Patent 
Examination System' available at: 
<http://www.compcom.co.za/wp-
content/uploads/2014/09/Patents-Pharmaceuticals-
and-Competition-Yu-Fang-Wen-and-Thapi-Matsaneng-
Annual-Competition-Conference-2013.pdf> 
(last accessed 6 July 2015) 
_______________ 
 81 
 
CONTACT PERSONS 
 
 
 
 
 
Ms Martha Chikowore 
Training Officer 
WIPO Academy 
World Intellectual Property Organization (WIPO) 
Tel:  +41 (0)22 338 8585 
Fax:  +41 (0)22 740 1417 
Email:   martha.chikowore@wipo.int 
 
 
 
Ms Karla Brepsant 
Publications Assistant 
Intellectual Property, Government Procurement and 
Competition Division 
World Trade Organization (WTO) 
Tel:  +41 (0)22 739 5256  
Fax:  +41 (0)22 739 5790  
Email:   ipd@wto.org   
 
 
 
 
__________ 
 
WIPO-WTO COLLOQUIUM PAPERS
RESEARCH PAPERS FROM THE WIPO-WTO COLLOQUIUM 
FOR TEACHERS OF INTELLECTUAL PROPERTY LAW  2014 
World Intellectual Property Organization (WIPO)
34, chemin des Colombettes
P.O. Box 18
CH-1211 Geneva 20
Switzerland
Telephone:
+4122 338 91 11
Fax:
+4122 733 54 28
www.wipo.int 
World Trade Organization (WTO)
Rue de Lausanne 154
CH-1211 Geneva 21
Switzerland
Telephone:  
+4122 739 51 14
Fax:  
+4122 739 57 90
Email:  
ipd@wto.org
www.wto.org
W
IP
O-
W
TO
 C
OL
LO
Q
UI
UM
 P
A
PE
RS
 
20
14
WIPO-WTO COLLOQUIUM PAPERS
RESEARCH PAPERS FROM THE WIPO-WTO COLLOQUIUM 
FOR TEACHERS OF INTELLECTUAL ROPERTY LAW  2014 
World Intellectual Property Organization (WIPO)
34, chemin des Colombettes
P.O. Box 18
CH-1211 Geneva 20
Switzerland
Telephone:
+4122 338 91 11
Fax:
+4122 733 54 28
www.wipo.int 
World Trade Organization (WTO)
Rue de Lausanne 154
CH-1211 Geneva 21
Switzerland
Telephone:  
+4122 739 51 14
Fax:  
+4122 739 57 90
Email:  
ipd@wto.org
www.wto.org
W
IP
O-
W
TO
 C
OL
LO
Q
UI
UM
 P
A
PE
RS
 
20
14
ISBN: 978-92-870-4259-0
9 789287 042590
WIPO-WTO COL OQUIUM PAPERS
RESEARCH PAPERS FROM THE WIPO-WTO COL OQUIUM 
FOR TEACHERS OF INTEL ECTUAL PROPERTY LAW  2014 
World Intell ctual Property Organization (WIPO)
34, chemin des Col mbettes
P.O  Box 18
CH-12 1 Geneva 20
Switzerland
Tel phone:
+4122 338 91 1
Fax:
+4122 733 54 28
w . ipo.int 
World Trade Organization (WTO)
Rue de Lausanne 154
CH-12 1 Geneva 21
Switzerland
Tel phone:  
+4122 739 51 4
Fax:  
+4122 739 57 90
Email:  
ipd@wto. rg
w . to. rg
W
IP
O-
W
TO
 C
OL
LO
Q
UI
UM
 P
A
PE
RS
 
20
14
2015
